Final Program in it's entirety - MyGirlsBlood

Hemophilia
Saturday, July 10 - Wednesday, July 14
FINAL PROGRAM
XXIX INTERNATIONAL CONGRESS
OF THE WORLD FEDERATION
OF HEMOPHILIA
Organized by:
Hosted by:

Saturday, July 10, 2010
Pre-Congress Sessions
Saturday, July 10, 2010
NURSES WORKSHOP≤
08:30 – 15:30 Sponsored by Baxter
Room: Puerto Madera
Chair: Elizabeth Paradis, Canada
08:30
Fundamentals of Hemophilia
James Munn, U.S.A., and Penny McCarthy, Australia
10:00
BREAK
10:30
Welcome Remarks
Elizabeth Paradis, Canada
10:45 – 12:30
Life Stages
Anu Saag, Estonia
n Circumcision in Hemophilia
Emna Gouider Belhadjali, Tunisia
n A Nursing Perspective of Pediatric Pain
Rhonda Fritz, U.S.A.
n Social Inclusion of Young and Adult Young Men
with Hemophilia
Raúl Bordone, Argentina
n A Nursing Care Plan for Patients with Bleeding
Disorders
Carmen Egan, Ireland
n Ageing and Hemophilia
Lucie Lacasse, Canada
12:30
LUNCH
14:00
Nursing Educational Activities in Summer
School of Hemophilia: Turkish Experience
Selmin Senol, Turkey
16
14:30
WFH Activities – Part I
IHTC Fellowship Experience, Malaysia and China
Elizabeth Paradis, Canada, and Kuixing Li, China
15:30
BREAK
16:00
WFH Activities – Part II
Twinning…What a Successful Twinning Is All About
(Peru/U.S.A.)
Susan Zappa, U.S.A.
17:00
Evaluation and close
PSYCHOSOCIAL WORKSHOP
08:30 - 15:30
Room: Belgrano
Co-Chairs: Susan Cutter, U.S.A., and Ed Kuebler, U.S.A.
08:30
Welcome and Introduction of the WFH
Psychosocial Committee
Sylvia von Mackensen, Germany
08:45
Session I: Fostering Psychosocial
Involvement in Hemophilia Care Around the
World: Recent Trainings in Minsk, Georgia,
and Jordan
Anne Duffy, Ireland, Richa Mohan, India, and Frederica
Cassis, Brazil
09:30
Icebreaker Session
Irene Fuchs, Argentina, and Silvina Grana, Argentina
10:15
BREAK

Pre-Congress Sessions cont’d
10:30
Session II: Sexuality Issues for PWH through
the Life Cycle
Ed Kuebler, U.S.A., and Frederica Cassis, Brazil
11:15
Session III: Case Studies
Silvina Grana, Argentina, Tony Roberts, South Africa,
and Ruud Bos, the Netherlands
12:15
LUNCH
13:15
Session IV: Spirituality/Cultural Issues in
Comprehensive Care Model for PWH: A
Personalized Account
Noorallah Taheri, Iran
13:45
Session V: Psychosocial Issues for Hemophilia
Patients with Inhibitors
Susan Cutter, U.S.A.
14:15
Session VI: How to Help Children with
Hemophilia Cope with Feeling Different from
their Peers
Dawn von Mayrhauser, U.S.A.
14:45
Session VII: Impact of Hemophilia on
Partners and Spouses
Anne Duffy, Ireland
15:15
Closing Remarks and Evaluations
MSK - ORTHO WORKSHOP
08:30 - 15:30 Sponsored by Novo Nordisk
Room: Montserrat
Chair: Adolfo Llinas, Colombia
Live Surgeries
Horacio Caviglia, Argentina
Zero-contact Argentinean Soccer in Persons
with Hemophilia
Fundación de la Hemofilia, Argentina
Follow up on Guidelines
Gianluigi Pasta, Italy
Follow up on Registries
Nick Goddard, U.K., and Pier Luigi Solimeno, Italy
Creating a Photograph Library for Teaching
the Musculoskeletal Care of Hemophilia
Adolfo Llinás, Colombia
MSK – PHYSIOTHERAPY &
REHABILITATION WORKSHOP
08:30 - 15:30
Room: Palermo
Chair: Angela Forsyth, U.S.A.
08:30
Welcome and Opening Remarks
Angela Forsyth, U.S.A.
08:45
Evidence Based Practice
Rachel Tiktinsky, Israel
n Rehabilitation Medicine
Maria Matilde Rosas, Venezuela
n Physiotherapy
Sébastien Lobet, Belgium
17
Saturday, July 10, 2010

Saturday, July 10, 2010
Pre-Congress Sessions cont’d
10:00
Developing a Research Question
Lily Heijnen, the Netherlands, and Karen Beeton, U.K.
11:30
LUNCH
13:00
Hot Topics Debate: The Use of Ice
Chair: Pamela Narayan, India
Kathy Mulder, Canada, and Nichan Zourikian, Canada
14:15
Physiotherapy/Rehabilitation around the
World and/or Special Projects Update
Chair: Angela Forsyth, U.S.A.
n IHTC
Natasha Jankovic, Serbia
n International Standards
Kathy Mulder, Canada
Report from the “floor”
Workshops report
Lixia Chen, China
15:15
Closing Remarks/Brainstorming
Angela Forsyth, U.S.A.
LABORATORY SCIENCES
WORKSHOP: DIAGNOSIS OF
HEMOPHILIA AND ALLIED
BLEEDING DISORDERS
10:00 - 12:30
Room: Ceibo
Chair: Steve Kitchen, U.K.
10:00
Selection, Use, and Limitations of PT & APTT
for Detection of Bleeding Disorders with
Case Studies
Andreas Hillarp, Sweden
18
10:40
Improving the Performance of Factor Assays
Steve Kitchen, U.K.
11:10
Bedside Kit for Diagnosis of Hemophilia A
and B
Ampaiwan Chuansumrit, Thailand
11:30
Improving the Detection of Inhibitors with
Case Studies
Angus McCraw, U.K.
12:00
Internal Quality Control and External Quality
Assessment in Hemostasis with Examples of
Problem Solving
Steve Kitchen, U.K.
12:30
Laboratory Diagnosis Question and Answer
Session with Panel
VWD AND RARE BLEEDING
DISORDERS
14:30- 17:30
Room: Ceibo
Co-Chairs: Rezan Kadir, U.K., and Flora Peyvandi, Italy
14:30
QOL of Women with Bleeding Disorders
Sylvia von Mackensen, Germany
14:45
Psychological Aspects and Long-Term
Management of Women with Bleeding
Disorders
Nicola Dunn, U.K.

Pre-Congress Sessions cont’d
15:00
How to Prepare & Support Affected Women
to Deal with the Medical & the Social
Aspects
Shirin Ravanbod, Iran, and Mehran Karimi, Iran
15:15
Inherited Bleeding Disorders - Experience as
a Patient and a Treating Doctor
Susan Halemi, Germany
15:30
Management of Pregnancy and Delivery
Rezan Kadir, U.K.
16:30
Prenatal Diagnosis & PGD: Novel
Technologies/State of Art of PGD in Different
Regions of the World
Flora Peyvandi, Italy, and Carol Kasper, U.S.A.
17:00
Women with Bleeding Disorders
Andra James, U.S.A., and Roshni Kulkarni, U.S.A.
n Consensus from an International Expert Panel on
Diagnosis and Management
n Preliminary Report from U.S. CDC data
PUBLISHING WORKSHOP (WILEY-
BLACKWELL)
14:00- 15:30
Room: Recoleta
Chair: Christine Lee, U.K.
Welcome/Introductions
The Publishing Process
n What happens to your paper step by step from
submission to publication and beyond
Editor’s Perspective
n Different types of articles
n Components of an article and structuring your
article
Peer-reviewer’s Perspective
n What a reviewer is looking for in a manuscript
submission
Author’s Perspective
n The process of writing an article: from research
to submission
Special Topics Regarding Publication
n Ethical issues including plagiarism and duplicate
publication
n Copyright issues
n Impact factor
n Open access
Question and Answer Session
GENE THERAPY
16:00- 17:30
Room: Recoleta
Chair: David Lillicrap, Canada
16:00
Gene Therapy - Basic Information
David Lillicrap, Canada
16:30
Testing in Animal Models of Hemophilia
Margaret Ozelo, Brazil
17:00
Testing in Human Clinical Trials
Margaret Ragni, U.S.A
19
Saturday, July 10, 2010

Sunday, July 11, 2010
Congress Sessions
Sunday, July 11, 2010
PLENARY SESSIONS 08:45 – 10:15
PLENARY – 01≤
Room: Buenos Aires
Chair: Alison Street, Australia
President’s Address: Our Global Family –
Achieving Our Vision
Mark Skinner, U.S.A.
Plenary 02≤
Room: Buenos Aires
Chair: Adolfo Llinás, Colombia
MSK: Imaging Modalities in Hemophilia
Andrea Doria, Canada
10:15 - 10:45
REFRESHMENT BREAK
10:45 – 12:15
CONCURRENT SESSIONS
S1.1 – MEDICAL≤
Neonatal Bleeding Disorders
Room: Buenos Aires
Chair: Gili Kenet, Israel
n Evaluation of Neonatal Hemostasis
Anthony Chan, Canada
n Natural History of Neonatal Hemophilia
(UDC Study)
Roshni Kulkarni, U.S.A.
n Other Bleeding Disorders in the Neonate
Gili Kenet, Israel
S1.2 – MEDICAL≤
Viral Pathogens
Room: Puerto Madero
Chair: Margaret Ragni, U.S.A.
n Impact of HIV on Hepatitis C
Margaret Ragni, U.S.A.
n HCV Update: Clinical and Treatment
Kenneth Sherman, U.S.A.
20
n Clinical Impact of Parvovirus B19 Infection
Jeanne A. Jordan, U.S.A.
S1.3 – MULTIDISCIPLINARY≤
Helping Children Cope with Bleeding
Disorders
Room: Belgrano
Chair: Silvina Grana, Argentina
n Strategies for a Normal Life
César Garrido, Venezuela
n Mother's Perspective
Gordana Stevanovic, Serbia
n Building Acceptance and Adaptability in
Children Managing Hemophilia: The National
Member Organization’s Role
Christine Keilback, Canada
n Psychologist Perspective
Ed Kuebler, U.S.A.
S1.4 – LABORATORY SCIENCES
Laboratory Assessment of Hemostasis
Room: Ceibo (1st Floor)
Chair: Angus McCraw, U.K.
n Pre Analytical Variables in Hemostasis
Angus McCraw, U.K.
n Use & Limitations of APTT as a Screening Test
for Mild Bleeding Disorders
Andreas Hillarp, Sweden
n Evaluation and Selection of Coagulation
Analysers
Marion Enchenagucia, Venezuela
S1.5 – MUSCULOSKELETAL≤
Electrotherapy Practical Review
Room: Montserrat
Co-Chairs: Rachel Tiktinsky, Israel, and Noemi Moretti,
Argentina
n Overview
Rachel Tiktinsky, Israel
n The Application of Surface Emg in
Physiotherapy for Hemophilia
Pamela Narayan, India
n Low Level Laser Therapy in Treating
Musculoskeletal Disorders
Adley Sabbour, Egypt
n Educational Review and Evidence
Lixia Chen, China
* Only the names of the presenters are listed. For a complete list of co-authors who have contributed to the work, please
refer to the Book of Abstracts.

Congress Sessions cont’d
S1.6 – MULTIDISCIPLINARY
Integrating Outreach to Women with VWD &
Rare Bleeding Disorders into NMO
Strategies
Room: Palermo
Chair: Clare Cecchini, Canada
n Canadian Experience
Clare Cecchini, Canada
n Lebanese Experience
Claudia Djambas-Khayat, Lebanon
n Georgian Experience
Marina Mdivnishvili, Georgia
n Venezuelan Experience
Arlette Ruiz-Saez, Venezuela
12:15 – 14:00
LUNCH BREAK AND INDUSTRY SYMPSOSIA
14:00 – 15:30
CONCURRENT SESSIONS
S2.1 – MEDICAL≤
Animal Models of Inhibitors
Room: Buenos Aires
Chair: David Lillicrap, Canada
n Transgenic Mouse Models for Deciphering
Inhibitor Mechanisms
Brigit Reipert, Austria
n Tolerance Mechanisms in Animal Models
David Lillicrap, Canada
n Inhibitors Associated with Gene Transfer
Valder Arruda, U.S.A.
S2.2 – MEDICAL≤
Platelet Disorders
Room: Puerto Madero
Chair: Sara Israels, Canada
n Structure Function Relationships of Platelet
Disorders
Sara Israels, Canada
n Glanzmann's Thrombasthenia
Magdy El-Ekiaby, Egypt
n High Prevalence of Bleeding among Patients
with Mucocutaneous Bleeding
Teresa Quiroga, Chile
S2.3 – MUSCULOSKELETAL
Free Paper I
Room: Ceibo (1st floor)
Chairs: Ginaluigi Pasta, Italy and Naomi Morretti,
Argentina
n The Swedish Haemophiliac’s Self Reported
Activity and Function in Daily Life: Reported
with HAL, AIMS 2, and IPA
Brodin E1 , Baghaei F2 , Stibrannt Sunnerhagen K3 1 Physiotherapy Department, Sahlgrenska
University Hospital, Institute of Neuroscience and
Physiology/Rehabilitation Medicine, Sahlgrenska
Academy at Göteborg University, Göteborg,
2Department of Haematology and Coagulation,
Coagulation Centre, Sahlgrenska University
Hospital, Göteborg, 3Institute of Neuroscience
and Physiology/Rehabilitation Medicine,
Sahlgrenska Academy at Göteborg University,
Göteborg, Sweden
n Physiotherapy Training Workshop in South
Africa – Unchartered Territory
Rahim S1 , Remmers E2 , Cruickshank A-L3 1Red Cross War Memorial Children’s Hospital,
Cape Town, South Africa, 2Steve Biko Hospital
University of Pretoria, South Africa, 3Groote Schuur Hospital University of Cape Town, South
Africa
n Hemophilia Joint Health Score (HJHS)
Reliability Study in China
Sun J1 , Hilliard P2 , Zourikian N3 , Chen L4 , Luke
KH5 , Feldman BM2 , Blanchette V2 , Poon MC6 1 2 Nanfang Hospital, Guangzhou, China, Hospital
for Sick Children, Toronto, ON, Canada, 3Hôpital Ste Justine, Montreal, QC, Canada, 4Peking Union Medical College Hospital, Beijing, China,
5Children’s Hospital of Eastern Ontario, Ottawa,
ON, Canada, 6University of Calgary Foothills
Medical Centre, Calgary, AB, Canada
n Musculoskeletal Health in Patients with
Hemophilia in Colombia
Marmolejo C2 , Pantoja S2 , Pardo-Díaz E1 1 2 Universidad Del Valle, Center of Treatment IPS
Medex, Cali, Colombia
21
Sunday, July 11, 2010

Sunday, July 11, 2010
Congress Sessions cont’d
n Surgical Management of Chronic Large
Pseudotumour in Hemophilia Patients Who
Presented Late at Kuala Lumpur Hospital,
Malaysia
Osman Z, Abd K, Faraizah MR
Orthopaedic Department, Hospital Kuala
Lumpur, Malaysia
n Integral Physiotherapeutic Guidelines for
Hemophilia Patients from Spanish Foundation
Victoria Eugenia
López-Cabarcos C1 , Querol F2 , Villar A1 , Liras A1 ,
Mingot ME1 1Scientific Commission of Royal Foundation
Victoria Eugenia, Malaga, Spain
2Department of Physiotherapy of University of
Valencia and Thrombosis and Hemostasis Unit,
Department of Hematology, La Fe University
Hospital, Valencia, Spain
S2.4 – MEDICAL
Free Paper I
Room: Palermo
Chair: Amy Shapiro, U.S.A., and Rolf Ljung, Sweden
n Safety and Prolonged Biological Activity
following a Single Administration of a
Recombinant Molecular Fusion of Native
Human Coagulation Factor IX and the Fc
Region of Immunoglobulin G (IgG) (rFIXFc) to
Subjects with Hemophilia B
Shapiro AD1 , Ragni M2 , Valentino L3 , Key N4 ,
Josephson N5 , Powell J6 , Cheng G7 , Tubridy KL8 ,
Peters R8 , Dumont J8 , Luk A8 , Hallen B9 , Gozzi P9 ,
Bitonti A8 , Pierce GF8 1Indiana Hemostasis and Thrombosis Center,
Indianapolis, IN, U.S.A., 2University of Pittsburgh,
Pittsburgh, PA, U.S.A., 3Rush University, Chicago,
IL, U.S.A., 4University of
North Carolina, Chapel Hill, NC, 5Puget Sound
Blood Center, Seattle, WA, U.S.A., 6University of
California, Davis, CA, U.S.A., 7Chinese University
of Hong Kong, Hong Kong, PRC, 8Biogen Idec,
Waltham, MA, U.S.A., 9Biovitrum AB (publ),
Stockholm, Sweden
n A Randomized Clinical Trial on Prophylaxis vs.
Episodic Treatment in Children with
Haemophilia A: the ESPRIT Study
Gringeri A1 , Lundin B2 , von Mackensen S3 ,
Mantovani L4, Mannucci P1 1Angelo Bianchi Bonomi Hemophilia and
Thrombosis Centre, Fondazione Ospedale
Maggiore Policlinico and University of Milan,
22
Italy, 2Department of Radiology, University
Hospital of Lund, Sweden, 3Institute of Medical
Psychology, University of Hamburg, Germany,
4Centre of Pharmacoeconomics, University
Federico II of Naples, Italy
n Hemophilic Shoulder Arthropathy: Clinical,
Radiological and Ultrasonographic
Characteristics of 70 Patients Analysis
Li T-Y 1 , Chen Y2 , Cheng S3 , Pan R4 , Chang S1 1Haemophilic Care and Research Center,
Department of Physical Medicine and
Rehabilitation, Tri-Service General Hospital,
National Defense Medical Center, Taipei, Taiwan,
2Department of Hematology, Tri-Service General
Hospital, National Defense Medical Center,
Taipei, Taiwan, 3Department of Pediatrics, Tri-
Service General Hospital, National Defense
Medical Center, Taipei, Taiwan, 4Department of
Orthopedics, Tri-Service General Hospital,
National Defense Medical Center, Taipei, Taiwan
n Hemophilia A Patients without Detectable
Mutations – Investigation of Disease-
Associated Factors
Ljung R, Knobe K, Sjörin E, Nilsson D, Halldén C
Lund University, Departments of Paediatrics and
Malmö Centre for Thrombosis and Haemostasis,
University Hospital, Malmö, Sweden
n Management of Surgery in Congenital Factor
VII Deficiency
Batorova A1 , Jankovicova D1 , Prigancova T1 ,
Horvathova D1 , Steno B2 , Borovsky M3 1National Hemophilia Center and Dept. of
Hematology, 2Dept. of Dept. of Orthopaedics
and Traumatology, 3Dpt. of Gynecology and
Obstetrics, University Hospital, Bratislava,
Slovakia
n A Single Center Experience in Circumcision of
Hemophilia Patients: Izmir Protocol
Yilmaz Karapinar D1 , Akýn M1 , Ay Y1 , Balkan C1 ,
Celik A2, Kavakli K1 1Pediatric Hematology Department and
2Pediatric Surgery Department, Faculty of
Medicine,
Ege University, Izmir, Turkey
n Can the Haemophilia Joint Health Score (HJHS)
Identify Differences in Joint Status in Boys with
Severe Haemophilia Receiving Prophylaxis?
Bladen M1 , Main E2 , Hubert N1 , Mathias M1 ,
Khair K1 , Liesner R1 1Great Ormond St Hospital for Sick Children and
2Institute of Child Health, London, United
Kingdom

Congress Sessions cont’d
S2.5 – MULTIDISCIPLINARY≤
Living with a Rare Bleeding Disorder
Room: Belgrano
Chair: Paula Bolton-Maggs, U.K.
n FV and FVIII
Latifa Lamhene, Algeria
n Glanzmann
Evelyn Grimberg, the Netherlands
n FI
Gabriel Lottaz, Switzerland
n Comprehensive Care for Persons with RBD
Mahmoud Ibrahim Abu-Riash, Jordon
S2.5 – MULTIDISCIPLINARY≤
Development Steps to Establishing a
National Hemophilia Care Program
Room: Montserrat
Chair: Gordon Clarke, U.K.
n Health Care Delivery
Parttraporn Isarangkura, Thailand
n Medical Expertise
Mehpara Kazimova, Azerbaijan
n Treatment Products
Arafat Awajan, Jordan
n Patient Organizations
Marta Monteros, Mexico
23
Sunday, July 11, 2010

Monday, July 12, 2010
Congress Sessions cont’d
Monday, July 12, 2010
PLENARY SESSIONS 08:45 – 10:15
Plenary 03≤
Room: Buenos Aires
Chair: Raúl Pérez-Bianco, Argentina
Novel Therapies
Claude Negrier, France
Plenary 04≤
Room: Buenos Aires
Chair: Robert Montgomery, U.S.A.
Factor VIII & VWF: Too Sweet for Their Own Good
Peter Lenting, France
10:15 - 10:45
REFRESHMENT BREAK
10:45 – 12: 15
CONCURRENT SESSIONS
M1.1 – MEDICAL≤
Late Breaking Topics
Room: Buenos Aires
Chair: Alison Street, Australia
n Current Trial Updates
Victor Blanchette, Canada
n Asymptomatic vCJD Infection
James W. Ironside, U.K.
n International Prospective Randomized Immune
Tolerance (ITI) Study: Preliminary Results of
Therapeutic Efficacy and Safety
Donna DiMichele, U.S.A.
M1.2 - MEDICAL≤
VWD Diagnosis and Laboratory Issues
Room: Puerto Madero
Chair: Giancarlo Castaman, Italy
n Accelerated Clearance of VWF
Robert Montgomery, U.S.A.
n Functional Tests for VWF (GP1B/Collagen Binding)
Giancarlo Castaman, Italy
n Laboratory Markers Predicting VWD
Associated Bleeding in Surgery
Susana Meschengieser, Argentina
24
M1.3 - MULTIDISCIPLINARY≤
Sports: Dangerous, Beneficial, or Luxury
Room: Belgrano
Chair: Nichan Zourikian, Canada
n Sport in Hemophilia: What is Appropriate?
Gustavo Galatro, Argentina
n Personal Experiences/Examples: Scuba Diving
Martial de Haro, France
n Psychosocial Impact of Sports
Sylvia von Mackensen, Germany
n Youth’s Perspective
Elie Khairo, Lebanon
M1.4 – LABORATORY SCIENCES
Free Paper II
Room: Ceibo Room (1st floor)
Chairs: Piet de Kleijn, the Netherlands, and Marvin
Gilbert, U.S.A.
n The Effect of Neutral-Cushioned Running
Shoes on the Intra-Articular Force in the
Hemophilic Ankle
McLaughlin P
Royal Free Hospital NHS Trust, London, United
Kingdom
n Total Ankle Replacement for the Treatment of
Severe Hemophilic Ankle Arthropathy: A 1-12
Year Follow-Up
Brand B1 , Klammer G2 , Vienne P3 , Espinosa N2 ,
Jankauskas L2 1 2 Hematology University Hospital Zurich, Klinik
St. Anna, Luzern, 3University Hospital Balgrist
Zurich, Germany
n Assessment of Bone Density and Strength
Using Peripheral Quantitative Computed
Tomography (pQCT) in Children with
Hemophilia; Preliminary Report
Xafaki P1 , Balanika A2 , Pergantou H1 ,
Papakonstantinou O2 , Platokouki H1 1Hemophilia Centre- Haemostasis Unit, "Aghia
Sophia" Children's Hospital of Athens, 22nd Radiology Department, University General
Hospital of Athens "Attikon", Greece
n Hemophilic Chronic Knee Synovitis: Preventive
Therapy of Hemarthrosis Using Endovascular
Embolization
Galli E1 , Caviglia H1 , Perez Bianco R2 , 3 , Candela
M2 , Moreti N3 , Baques A2 1 2 Hospital Fernandez, Academia Nacional de
Medicina and 3Fundacion de la Hemofilia,
Buenos Aires, Argentina

Congress Sessions cont’d
n Long Term Follow-Up for Total Knee
Replacement at Castelfranco Veneto
Hemophilia Centre
Tagariello G1 , Petris U2 , Sartori R1 , Tassinari C1 ,
Risato R1 , Radossi P1 1Haemophilia Center Transfusion and Haemat -
ology, Castelfranco Veneto, Italy 2Ortopaedic Department, Castelfranco Veneto, Italy
n Above Knee Amputation, Liver Transplant,
and Total Knee Replacement in 18 Months in a
Patient with Severe FIX Deficiency - A Case
Study
Sherlock E, O'Donnell J
National Centre For Hereditary Coagulation
Disorders, Dublin, Ireland
M1.5 – MULTIDISCIPLINARY
Free Papers I
Room: Palermo
Chair: Magdy El-Ekiaby, Egypt
n Therapeutic Training for Hemophilic Children
Followed by Necker-Enfants Malades Hospital
in Paris, France, and a Specialized Children’s
Health Care Center at OSSEJA (France), from
1990 to 2009
Torchet M-F, Dirat G, Makhloufi M, Aouba A,
Rothschild C, Lapeyre M
Necker-Enfants Malades Hospital, Paris, France
n How Do Patients Undergoing Prophylaxis
Treatment Live Hemophilia?
Tarrida C, Cabré P, Grases S
Catalan Association of Haemophilia, Barcelona,
Spain
n The Development of an Innovative Internet-
Based Educational Program to Promote Self-
Management for Teens with Hemophilia
Breakey V1 , Ignas D2 , Blanchette V1 , 2 , Stinson J2 1 2 Division of Hematology/Oncology, and Child
Health Evaluative Sciences, The Hospital for Sick
Children, Toronto, Canada
n Self Management for Individuals with
Hemophilia
Dargan A, O Sullivan A, O Donnell J, Jamieson S
National Centre for Hereditary Coagulation
Disorders, St. James Hospital, Dublin, Ireland
n Understanding Adolescents with Hemophilia
and Their Relationship to Treatment
Antunes S, Vrabic A
Universidade Federal de São Paulo, Depto
Oncologia Clinica e Experimental, Brazil
n Sportsman with Hemophilia
Ahmad F
Pakistan Hemophilia Patient Welfare Society
Lahore Chapter, Lahore, Pakistan
M1.6 – MULTIDISCIPLINARY≤
Patient Outreach: Catch Them Early
Room: Montserrat
Chair: David Page, Canada
n Canadian Experience (VWD)
David Page, Canada
n Russian Experience
Yuri Zhulyov, Russia
n Mexican Experience
Ricardo Carlos Gaitan Fitch, Mexico
n Tunisian Experience
Emna Goudier Belhadjali, Tunisia
12:15 – 14:15
LUNCH BREAK AND INDUSTRY SYMPSOSIA
14:15 – 15:45
CONCURRENT SESSIONS
M2.1 – MEDICAL≤
Special Lectures in Hemophilia Management
Room: Buenos Aires
Chair: Angelika Batorova, Slovakia
n Arosenius Lecture: Gene Therapy and Inhibitor
Development: The Final Solution?
Katherine A. High, U.S.A.
n Plasma Derived vs. Recombinant Concentrates
Safety
Alessandro Gringeri, Italy
M2.2 – MEDICAL
Free Papers II
Room: Palermo
Chair: Jenny Goudemand, France, and Flora Peyvandi,
Italy
n Incidence of Liver-Related Morbidity in a
Cohort of Hemophilia Patients: The Impact of
HAART on HCV Progression
Katsarou O1 , Ioannidou P1 , Bakoyannis G2 ,
Kouramba A1 , Touloumi G2 , Karafoulidou A1 1Blood Centre – National Reference Centre for
Bleeding Disorders “Laiko” General Hospital,
Athens Greece, 2Dept of Hygiene, Epidemiology
and Medical Statistics, Athens University Medical
School, Greece
25
Monday, July 12, 2010

Monday, July 12, 2010
Congress Sessions cont’d
n Examination of Differential T Regulatory
Lymphocyte Responses Following Human FIX
Gene Therapy in a Novel Mouse Model
Expressing Defective Human Factor IX
Compared to Factor IX Knockout Mice
Hu G1 , Monahan P1 , Gui T1 , Velander W2 ,
Stafford D1 1University of North Carolina at Chapel Hill,
U.S.A., 2University of Nebraska-Lincoln, U.S.A.
n Distribution of von Willebrand Disease (VWD)
Types in 197 Families from the French National
Reference Center for VWD (CRMW): Type 1 is
not the most Frequent within “True” VWD
Fressinaud E1 , Goudemand J2 , Boisseau P3 ,
Ternisien C3 , Itzhar N1 , Dreyfus M4 1 2 Hopital Antoine Beclere, University Hospital of
Lille, 3University Hospital of Nantes, 4University
Hospital of Bicêtre, France
n The European Network of Rare Bleeding
Disorders (EN-RBD) Project: Results of 3-Years
Analysis
Peyvandi F1 , Menegatti M1 , Palla R1 , Siboni SM1 ,
Halimeh S2 , Pergantou H3 , Celkan T4, Gilmore R5 ,
Mikovic D6 , Benedik-Dolnicar M7 , Giangrande P8 1A. Bianchi Bonomi Hemophilia and Thrombosis
Center, Fondazione IRCCS Ca’ Granda, Ospedale
Maggiore Policlinico, Università degli Studi di
Milano and Luigi Villa Foundation, Milan, Italy,
2MVZ Labor Duisburg GmbH - Duisburg,
Germany, 3Haemophillia Center, Haemostasis
Unit, Agia Sofia Children’s Hospital, Athens,
Greece, 4Department of Pediatric Hematology-
Oncology, Cerrahpasa Medical Faculty of
Istanbul University, Istanbul, Turkey, 5National Centre for Hereditary Coagulation Disorders, St
James's Hospital, Dublin, Ireland, 6Haemostasis Department and Haemophilia Center, Blood
Transfusion Institute of Serbia, Belgrade, Serbia,
7National Haemophilia Center, University
Children’s Hospital, Ljubljana, Slovenia, 8Oxford Haemophilia & Thrombosis Centre, Nuffield
Department of Clinical Medicine, University of
Oxford, U.K.
n Electronic Bleeding Questionnaire: A Novel
Approach in the Diagnosis of Mild Bleeding
Disorders
Hamilton A1 , Scovil S2 , Elbatarny H1 , Othman M1 1Laurentian University- St Lawrence College,
2Biomotion Laboratory, Queen's University,
Kingston, ON, Canada
26
n Thrombin Generation in Patients with a
Bleeding Tendency of Unknown Origin
Ay C, Haselböck J, Laczkovics C, Koder S,
Pabinger I
Clinical Division of Haematology and
Haemostaseology, Department of Medicine I,
Medical University of Vienna, Austria
n Clinical Bleeding Episodes in Women with Rare
Bleeding Disorders: Results from the
European Network of Rare Bleeding Disorders
(EN-RBD) Project
Mikovic D1 , Siboni SM2 , Benedik-Dolnicar M3 ,
Bidlingmaier C4 , Celkan T5 , Gilmore R6 , Pergantou
H7 , Giangrande P8 , Peyvandi F2 1Haemostasis Department and Haemophilia
Center, Blood Transfusion Institute of Serbia,
Belgrade, Serbia, 2A Bianchi Bonomi Hemophilia
and Thrombosis Center, Fondazione IRCCS Ca’
Granda, Ospedale Maggiore Policlinico, Università
degli Studi di Milano and Luigi Villa Foundation,
Milan, Italy, 3National Haemophilia Center,
University Children’s Hospital, Ljubljana, Slovenia,
4Pediatric Hemophilia and Thrombosis Centre, Dr.
von Hauner‘s Children‘s University Hospital,
Munich, Germany, 5Department of Pediatric
Hematology-Oncology, Cerrahpasa Medical
Faculty of Istanbul University, Istanbul, Turkey,
6National Centre for Hereditary Coagulation
Disorders, St James's Hospital, Dublin, Ireland,
7Haemophillia Center, Haemostasis Unit, Agia
Sofia Children’s Hospital, Athens, Greece,
8Oxford Haemophilia & Thrombosis Centre,
Nuffield Department of Clinical Medicine,
University of Oxford, Oxford, United Kingdom
M2.3 – MULTIDISCIPLINARY≤
Importance of Psychosocial Support in the
Treatment of People with Bleeding Disorders
and Their Families
Room: Puerto Madero
Chair: Frederica Cassis, Brazil
n How NMO Leaders Can Promote Psychosocial
Services for Their Patients
Ed Kuebler, U.S.A.
n Psychosocial Needs of an Inhibitor Patient
Alison Inder, New Zealand
n Methods of Support for Children & Their
Families
Silvina Grana, Argentina
n Importance of Integrating Psychosocial
Discipline into Comprehensive Care
Frederica Cassis, Brazil

Congress Sessions cont’d
M2.4 – MUSCULOSKELETAL
Hemophilia A and VWD
Room: Ceibo (1st floor)
Chair: David Lillicrap, Canada
n Lessons Learnt from Type 1 VWD Studies
David Lillicrap, Canada
n Assay Design and Use of Chromogenic Factor
VIII Assays
Steffen Rosen, Sweden
n Laboratory Detection of Inhibitors to FVIII and
Other Clotting Factors
Bert Verbruggen, the Netherlands
M2.5 - MULTIDISCIPLINARY≤
Home Treatments and Self Infusion:
Strategies of Delivery
Room: Belgrano
Chair: Bongi Mbele, South Africa
n How to Prepare for Home Infusion
Bongi Mbele, South Africa
n Teaching Techniques
James Munn, U.S.A.
n Port and Infusion
Karin Lindvall, Sweden
n Challenges in Developing Countries
Carmen Cunho Mello Rodrigues, Brazil
M2.6 - MULTIDISCIPLINARY≤
Personal and Social Development of People
with Bleeding Disorders
Room: Montserrat
Chair: Susan Cutter, U.S.A.
n Prospects and Job Opportunities of Persons
with Bleeding Disorders
Antonio F. Gómez Cavallini, Argentina
n Role of NMO Defending Peoples Rights
David Silva, Spain
n Psychosocial Care & Education for the Patient
with Bleeding Disorders
Susan Cutter, U.S.A.
15:45 – 16:30
POSTER PRESENTATIONS
(see poster index for titles and authors)
16:30 – 18:00
CONCURRENT SESSIONS
M3.1 – MEDICAL≤
Applications of Genetics
Room: Buenos Aires
Chair: Paula James, Canada
n Genetic Testing in Hemophilia A: Clinical
Relevance
Johannes Oldenburg, Germany
n Role of Genetic Diagnosis of VWD
Paula James, Canada
n New Genetic Strategies in Bleeding Disorders
(GWAS)
Jorge DiPaola, U.S.A.
M3.2 – MEDICAL≤
New Developments in Lab Diagnosis and
Monitoring
Room: Puerto Madero
Chair: Steve Kitchen, U.K.
n Update in Bleeding Disorders (Including 1
Stage and 2 Stage FVIII Assays)
Steve Kitchen, U.K.
n Standardization of Platelet Function Testing in
Bleeding Disorders
Catherine Hayward, Canada
n Potential Utility of Thrombin Generation
Testing in Bleeding Disorders
Claude Negrier, France
M3.3 - MULTIDISCIPLINARY≤
Making the Case for Effective Clotting Factor
Therapy in an Era of Health Technology
Assessment
Room: Belgrano
Chair: David Page, Canada
n An Introduction to Health Technology
Assessment
David Page, Canada
n From Cryo to Concentrates
Triroj Krutvecho, Thailand
27
Monday, July 12, 2010

Monday, July 12, 2010
Congress Sessions cont’d
n Prophylaxis in Children in the Developing
World
Alok Srivastava, India
n Prophylaxis in Children & Adults in the
Developed World
Marilyn Manco-Johnson, U.S.A.
M3.4 – DENTAL
Oral Surgery
Room: Ceibo (1st floor)
Chair: Eduardo Rey, Argentina
n Pseudo-Tumours and Other Soft Tissue Lesions
Antonio Valiente, Spain
n Dental Surgery with Minimal Factor Support in
the Inherited Bleeding Disorder Population at
the Alfred Hospital
Hewson I, Street A, McCarthy P, Walsh M
Alfred Hospital, Melbourne, Australia
n Extensive Bleeding After Tooth Extraction in
Patient with Inhibitors to Factor VIII: A Case
Report
Brkovic B1 , Jurisic M1 , Suvajdzic N2 , Rakic L3 ,
Mikovic D3 1Clinic of Oral Surgery, Faculty of Dentistry and
2Institute of Hematology, Faculty of Medicine,
University of Belgrade, Serbia, 3Blood Transfusion
Institute, Belgrade, Serbia
n 10-Year Experience with Protocol for the Care
of Hemophilia Patients
Parreira M, Puia S, Rey E, Candela M, Perez
Bianco R, Tezanos Pinto M
1Foundation of Hemophilia, Buenos Aires,
Argentina
n Periodontal Treatment in Hemophilia:
Hemostatic Solutions
Vassallo M, Venturino J, Rey E, Perez Bianco R,
Tezanos Pintos M
National Academy of Medicine, Buenos Aires,
Argentina
M3.5 - MULTIDISCIPLINARY
MEET THE EXPERTS – Orthopedic Issues
Room: Montserrat
Chair: Horacio Caviglia, Argentina
n Panel: Mauricio Silva, MD, and Kathy Mulder,
BPT
28
M3.6 – MULTIDISCIPLINARY
Free Paper II
Room: Palermo
Chair: Gordana Stevanovic, Serbia
n Charity vs. Compensation
Harvey M
The Macfarlane Trust, London, U.K.
n The Role of Social Networking in Hemophilia
Management
Khair K1 , Collier C1 , Holland M2 , Smith S2 1Great Ormond Street Hospital for Children NHS
Trust, London, U.K., 2hiFive, Chislehurst, Kent,
U.K.
n Educating Mothers of Young Children with
Hemophilia in Jordan
Sayyadeh A
Jordan Hemophilia and Thalassemia Society,
Amman, Jordon
n Long Term Survival of Hemophilia Patients
with HIV and HCV Infection
Schneider MM, Shows A, Giebl A, Schramm W
Dept. of Hemostasis and Transfusion Medicine,
University of Munich, Germany
n Improving Motivation to Self-Manage Joint
Pain: 1) Evaluation of a Low-Intensity
Intervention, 2) Tests of the Influence of
Changes in Readiness to Self-Manage
Elander J1 , Robinson G
1 2 University of Derbyshire, Derbyshire, U.K., The
Haemophilia Society, London, U.K.
n Day and Half Outdoor Programs with
Teenagers with Hemophilia A and B Without
Prophylaxis
Cassis F, Santos V, Carneiro J, Soares-Jr L,
Sandoval E, Villaca P
Hospital Das Clinicas - Universidade De Sao
Paulo, Brazil

Congress Sessions cont’d
Tuesday, July 13, 2010
PLENARY SESSIONS 08:45 – 10: 15
Plenary 05≤
Room: Buenos Aires
Chair: Alison Street
Aspects of Aging
Gerry Dolan, U.K.
Plenary 06≤
Room: Buenos Aires
Chair: Paula Bolton-Maggs, U.K.
Mild Hemophilia
Kathelijne Peerlink, Belgium
10:15 – 10:45
REFRESHMENT BREAK
10:45 – 12: 15
CONCURRENT SESSIONS
T1.1 - MEDICAL≤
Therapeutic Gene Transfer
Room: Buenos Aires
Chair: Robert Montgomery, U.S.A.
n Intraarticular Gene Transfer
Paul Monahan, U.S.A.
n Stem Cell-Based Gene Delivery
Margareth Ozelo, Brazil
n Platelet-Based Gene Therapy
Robert Montgomery, U.S.A.
T1.2 - MULTIDISCIPLINARY≤
Ageing and Hemophilia
Room: Puerto Madero
Chair: Anne Duffy, Ireland
n Overview
Anne Duffy, Ireland
n New Challenges Facing the Ageing PWH
Population
Zygmunt Gruszka, Sweden
n Medical Aspects of Ageing and Wellness in
People with Bleeding Disorders
Alison Street, Australia
n Healthy Techniques
Angela Forsyth, U.S.A.
n Personal Experience in a Developing Country
Anil Lalwani, India
n Personal Experience in a Developed Country
Mike Carnahan, New Zealand
T1.3 - MSK
Free Papers III
Room: Belgrano
Chairs: Mauricio Silva, U.S.A., and Karen Beeton, U.K.
n Hemophilic Pseudotumour: Guidelines for a
Classification System and Its Outcome
Mohanty S
Department of Orthopaedic Surgery, King
Edward VII Memorial Hospital, Bombay, India
n Integrated Postural Analysis in Children with
Haemophilia: A Comparative Study
Boccalandro E, Gringeri A
Angelo Bianchi Bonomi Haemophilia and
Thrombosis Centre, Fondazione Ospedale
Maggiore Policlinico and University of Milan,
Milan, Italy
n Evaluation of Bone Mineral Density and Bone
Turnover in Patients with Haemophilia
Steno B1 , Batorova A2 , Stenova E3 , Badidova J2 ,
Jankovicova D2 1The 2nd Dept. of Orthopaedics and
Traumatology National Hemophilia Center,
2 3 Dept. of Hematology, The 1st Dept. of Internal
Medicine, University Hospital, Comenius Medical
School, Bratislava, Slovakia
n Scoring Systems for MRI Evaluations of
Hemophilic Joints
Manco-Johnson M1 , Lundin B2 , Manco-Johnson M1 1University of Colorado Denver, U.S.A.,
2University Hospital of Lund, Lund, Sweden
n Natural Evolution of Blood Induced Joint
Damage in Patients with Haemophilia: Clinical
Relevance of Three-Dimensional Gait Analysis
Lobet S1 , Detrembleur C2 , Hermans C1,
Lambert C1 1 2 Haemostasis and Thrombosis Unit, and Physical
Medicine and Rehabilitation Unit, Cliniques
Universitaires Saint-Luc, Brussels, Belgium
29
Tuesday, July 13, 2010

Tuesday, July 13, 2010
Congress Sessions cont’d
n The Combination of IL-4 and IL-10 Protects
Against Blood-Induced Cartilage Damage
Van Meegeren M 1 , 2 , Jansen N 1 , 2 , Roosendaal G 2 ,
Lafeber F 1
1 Dept. of Rheumatology & Clinical Immunology
and 2 Dept. Hematology and Van Creveld Clinic,
UMC Utrecht, the Netherlands
T1.4 – MEDICAL
Free Papers III
Room: Ceibo (1st floor)
Chair: Annarita Tagiaferri, Italy, and Antonio Coppola,
Italy
n Ischemic Heart Disease: A New Challenge in
the Management of Hemophilia: Patients
Between Bleeding and Thrombotic Risk
Coppola A1 , Santoro R2 , Rivolta G3 , Schinco P4 ,
Radossi P5 , Di Capua M6 1Regional Reference Centre For Coagulation
Disoreders, Federico II University Hospital,
Naples, 2Haemophilia Centre, Pugliese-Ciaccio
Hospital, Catanzaro, 3Regional Reference Centre
for Haemophilia, University Hospital, Parma,
4Regional Reference Centre for Thrombotic and
Haemorragic Disorders, Dep. of Haematology,
University of Turin, 5Transfusion and Haemophilia
Centre, Hospital of Castelfranco Veneto, Italy
n Cardiovascular Assessment in Adult
Hemophilia Patients – A Pan-European Survey:
The Advance Study Group
Dolan G, on behalf of the ADVANCE Working
Group
Nottingham University Hospitals, United
Kingdom
n Prophylaxis vs. On-Demand Therapy Through
Economic Report (P.O.T.T.E.R.) Study: Results
at 3-Year Follow-Up
Tagliaferri A1 , Rivolta G1 , Feola G2 , Mancuso M3,
Zanon E4 , Santoro C5 1Haemophilia Centre of Parma, Parma. Italy,
2Haemophilia Centre of Vallo della Lucania, Vallo
della Lucania, Italy, 3Haemophilia Centre of
Milano, Milano, Italy, 4Haemophilia Centre of
Padova. Padova, Italy, 5Haemophilia Centre of
Roma, Roma, Italy
n Prophylaxis Usage Among Different Age
Groups with Hemophilia in Japan: Results from
the ADVATE Post-Authorization Safety
Surveillance (PASS) Studies
Fukutake K1 , Taki M2 , Hanabusa H3 , Shima M4 ,
Shirahata A5 and the Advate PASS study group6 1 2 Tokyo Medical University Hospital, Tokyo, St.
30
Marianna University School of Medicine
Yokohama City Seibu Hospital, Kanagawa,
3 Ogikubo Hospital, Tokyo, 4 Nara Medical
University, Nara, 5University of Environmental
and Occupational Health Japan, Fukuoka, and
6 Baxter BioScience Japan Medical Affairs Clinical
Trial, Tokyo, Japan
n LA-N8, a New Long-Acting Recombinant FVIII,
is Equipotent with Advate® in an Acute Tail
Bleeding Model in FVIII Knockout Mice
Johansen PB, Tranholm M, Olsen EHN, Kjalke M,
Jespersgaard C, Thim L, Andersen S, Bjørn SE,
Stennicke HR
Biopharmaceuticals Research Unit, Novo Nordisk
A/S, Maaloev, Denmark
n Development of Plasma Suppliers for the Indus -
trial Production of Antihemophilic Factor VIII
Zucchi A, Varela G, Massa C
Laboratorio e Hemoderivados, Cordoba,
Argentina
n Using New Technology Tools to Raise
Awareness: World Hemophilia Day Case Study
Ford S, Myles E
World Federation of Hemophilia, Montreal, QC,
Canada
T1.5 – MULTIDISCIPLINARY
MEET THE EXPERTS – Hepatitis C
Room: Palermo
Chair: Jorge Daruich, Argentina
n Panel: Kenneth Sherman, MD and Elizabeth
Paradis, RN
T1.6 – MULTIDISCIPLINARY≤
Twinning: Overcoming the Barriers
Rooms: Montserrat
Chairs: Aris Hashim, Malaysia, and Nigel Key, U.S.A.
n Concept of Twinning
Aris Hashim, Malaysia
n Medical Twins
Nigel Key, U.S.A.
n Hot Twins
Anthony Roberts, South Africa
n South/South Twinning
Alok Srivastava, India
12:15 – 14:15
LUNCH BREAK AND INDUSTRY SYMPOSIA

Congress Sessions cont’d
14:15 – 15:45
CONCURRENT SESSIONS
T2.1 - MEDICAL
Pharmacovigilance/Surveillance
Room: Buenos Aires
Chair: Chris Ludlam, U.K.
n Overview
Chris Ludlam, U.K.
n Clinical Data (Adverse Event)
Mike Makris, U.K.
n Why Do We Need Pharmacovigilance?
Mark Weinstein, U.S.A.
T2.2 - MUSCULOSKELETAL≤
Controversial Subjects in Musculoskeletal
Care of Hemophilia: Cross Fire
Room: Puerto Madero
Chair: Adolfo Llinás, Colombia
Crossfire 1: Should All Acute Hemarthrosis Be
Aspirated?
Moderator: Shubhranshu Mohanty, India
n All Acute Hemarthrosis Should Be Aspirated
Mauricio Silva, U.S.A.
n Only Painful Hemarthrosis Should Be Aspirated
Gianluigi Pasta, Italy
Crossfire 2: Arthrodesis of the Ankle versus Total
Ankle Replacement for the Treatment of Hemophilic
Arthrosis
Moderator: Adolfo Llinás, Colombia
n Arthrodesis Is the Best Choice
James Luck, U.S.A.
n Total Ankle Replacement Is the Best Choice
AG Asencio, France
Crossfire 3: Treatment of the Acute Compartment
Syndrome
Moderator: Nick Goddard, U.K.
n Compartment Syndromes Should Be Treated
Non Surgically
Federico Fernández-Palazzi, Venezuela
n Compartment Syndromes Should Be Treated
Surgically
Horacio Caviglia, Argentina
Crossfire 4: The Direct Effect of Exercise on Persons
with Hemophilia
Moderator: Thomas Wallny, Germany
n From the Point of View of Coagulation
Marilyn Manco-Johnson, U.S.A.
n From the Point of View of the Physiatrist
Axel Seuser, Germany
T2.3 - MULTIDISCIPLINARY≤
HIV and HCV Infection: Present and Future -
Psychological and Medical Aspects
Room: Belgrano
Chair: Lene Jensen, Denmark
n Medical Breakthroughs
Jorge Daruich, Argentina
n Innovations in Treatment
Marcelo Corti, Argentina
n Compensation (Global Overview)
Brian O’Mahony, Ireland
n Psychological Aspect
Anthony Roberts, South Africa
T2.4 - MULTIDISCIPLINARY ≤
Young Voices
Room: Montserrat
Chair: Antonio F. Gómez Cavallini, Argentina
n How to Recruit Young Leaders in Hemophilia
Deon York, New Zealand
n Youth Member on NMO Board
Eduard Grigoryan, Armenia
n Closed and Open Electronic Forums
Jacob Bech Andersen, Denmark
n How to Form a Youth Group and What
Activities Create Success
Tor V Bjermert & Markia Jacobsson, Sweden
T2.5 - MULTIDISCIPLINARY
Free Paper III- Ultimate Multidisciplinary
Clinic: What We Learn from Each Other
Room: Palermo
Chair: Raúl Pérez-Bianco, Argentina
n Laboratory Sciences: Significant Improvement
of the Between-Laboratory Variation of FVIII
Inhibitor Testing: Results of a Workshop
Meijer P1 and Verbruggen HW 2
1ECAT Foundation, Leiden, the Netherlands,
2Radboud University Nijmegen Medical Center,
Nijmegen, the Netherlands
n Nursing: A Visual Tool to Help Parents of New
Hemophilia Patients Identify Bleeds that
Require Treatment
Amesse C1 , Mulder C2 , Zourikian N1 , Rivard G1 1Montreal Sainte-Justine Hospital, Montreal, QC,
Canada, 2Health Sciences Center, Winnipeg, MB,
Canada
31
Tuesday, July 13, 2010

Tuesday, July 13, 2010
Congress Sessions cont’d
n Psychosocial: Assessment of Needs and
Expectations in the Psychological
Management of Hemophilia Patients: A French
Survey
Torchet M, Stieltjes N, Magli-Barioz D, Bella C
CH Necker Enfants Malades, Paris, France
n Musculoskeletal: Bone Mineral Density in
Hemophilia Patients: A Meta-Analysis
Marcucci M1 , Fabbriciani G2 , Brozzetti M3 , Luciani
M4 , Iorio A1 1Hemophilia Centre, University Of Perugia,
2Emergency Medicine, ASL 1, Città di Castello,
Italy, 3Ospedale di Norcia, Azienda A.S.L. n. 2
dell’Umbria, Perugia, 4Ospedale del Bambino
Gesù, Roma, Italy
n Dental: Evaluation of a Collaborative Model of
Shared Care Designed to Increase Access to
Preventive and Restorative Dentistry for
Patients with Hemophilia
Dougall A1 , O'Mahony B2 1National Centre for Hereditary Coagulation
Defects and 2Irish Haemophilia Society, Dublin,
Ireland
T2.6 – LABORATORY SCIENCES
Tests of Global Hemostasis and their
Applications
Room: Ceibo (1st floor)
Chair: Alok Srivastava, India
n Clinical Utility of Thromboelastography in
Bleeding Disorders
Meera Chitlur, U.S.A.
n Pre Analytical Variables in Thrombin
Generation Testing
Yesim Dargaud, France
n Waveform Analysis on Coagulation Analyser
Sukesh Nair, India
15:45 – 16:30
POSTER PRESENTATIONS
(see poster index for titles and authors)
32
16:30 – 18:00
CONCURRENT SESSIONS
T3.1 - MEDICAL≤
Late Breaking Topics II: From Research to
"Personalized Care"
Room: Buenos Aires
Chair: David Lillicrap, Canada
n Role and Proposed Activities of the MAB
Research Sub-Committee
David Lillicrap, Canada
n Tailored Treatment including Prophylaxis
Katheijn Fischer, the Netherlands
n FVIII and Haplotype Differences
Tom Howard, U.S.A.
n Patients' Viewpoints on Research Trial
Enrolment and Necessary Safeguards
Mark Skinner, U.S.A.
n Prophylaxis in Developing Countries
Alok Srivastava, India
T3.2 - MEDICAL≤
Hemophilic Arthropathy
Room: Puerto Madero
Chair: Adolfo Llinás, Colombia
n Update on Pathogenesis of the Bleeding Joint
Monique Van Meegeren, the Netherlands
n Update from MSK Committee
Pier Luigi Solimeno, Italy
n The Ankle Joint
Adolfo Llinás, Colombia
T3.3 - MULTIDISCIPLINARY≤
Pain Management and Coping
Room: Belgrano
Chair: Alessandro Gringeri, Italy
n Physician's Perspective
Alessandro Gringeri, Italy
n Psychologist’s Perspective
Irene Fuchs, Argentina
n Patient’s Perspective
(TBC)
n Nurse’s Perspective
Penny McCarthy, Australia

Congress Sessions cont’d
T3.4 - MUSCULOSKELETAL
Free Papers IV
Room: Ceibo (1st floor)
Chairs: Axel Seuser, Germany, and Maria Matilde
Rosas, Venezuela
n Effects of Modified Tai-Chi Exercise Program
(MTCEP) in Post Operative Periods in Hemophilic
Arthritis
Park Y1 , Bak W1 , Yang H1 , Yoo M1 , Choi Y2 , Yoo K2 1Hemophilia center, East-West Neo Medical
Center, Kyunghee University, Seoul, Korea,
2Korea Hemophilia Foundation, Seoul, Korea
n Influence of a Water Activities Programme on
Hemophilic Children’s Physical Condition and
Quality of Life
Perez- Alenda S1 , Querol F1 , Tembl M2 , Laguna
S3 , Vañó L3 , Aznar J1 1Universidad De Valencia, Unidad Hemostasia Y
Trombosis, Hospital La Fe, 2Federación de
Deportes Adaptados CV, and 3Ashecova, Valencia, Spain
n Influence of an Aquatic Training Protocol on
the Reduced Risk of Cardiovascular Morbidity
and Mortality in a Hemophiliac
Perez- Alenda S1,2 , Querol F1,2 , González L1 ,
Gallach J2 , Abad-Franch L1,2 , Mañez I3 1 2 Universidad de Valencia, Unidad Hemostasia Y
Trombosis, Hospital La Fe, Valencia, 3Servicio de
Rehabilitación, Hospital La Fe, Valencia, Spain
n Evaluation of ‘Sports for Haemophilia 2009’ in
Hong Kong
Lam H-W
Hong Kong Haemophilia Society, Hong Kong,
China
n Postural Alterations in Patients with
Hemophilia Who Received Total Knee
Replacement (TKR)
Daffunchio C, Moretti N, Thomas A, Caviglia H,
Perez Bianco R
Fundacion de la Hemofilia, Buenos Aires,
Argentina
n Bleed or Something Else? Recurrent Shoulder
Pain in an Adolescent with Moderate
Hemophilia A: The Cost Benefit of
Physiotherapy
McLaughlin P
Royal Free Hospital NHS Trust, London, U.K.
T3.5 - MULTIDISCIPLINARY≤
Overcoming Obstacles in Building
Comprehensive Care in Developing Countries
Room: Montserrat
Chair: Carlos Safadi Márquez, Argentina
n Role of New Technologies (Genetic Diagnosis
and Therapies)
Giridhara R. Jayandharan, India
n Strategies for Patient Identification
Flerida Hernandez, Philippines
n Implementation of Guidelines for Treatment
Magdy El Ekiaby, Egypt
n Strategies for NMOs
Carlos Safadi Márquez, Argentina
T3.6 - DENTAL
Restorative Dentistry & Audit
Room: Palermo
Chair: Andrew Brewer, U.K.
n Minimally Invasive Dentistry
Soraya Leal, Brazil
n A Retrospective Audit of the Dental Health
Status and Treatment Needs of Referred
Hematology Patients Attending a U.K. Dental
Hospital
Manton S, Martin A, Bhuta B
Special Care Dentistry, Dundee University Dental
Hospital, U.K.
n Physical and Perceptional Oral Health Status
of Children with Hemophilia A
Dogan C, Sasmaz I, Antmen B, Seydaoglu G,
Yazicioglu I
Çukurova University, Department of
Paedodontics, Istanbul, Turkey
n To Audit the Success Rate of Using 4%
Articaine as Buccal Infiltration in Order to
Anaesthetize Mandibular Molars for
Restorative Dental Treatment in Patients with
a Hereditary Coagulation Disorder
Smith G1 and Dougall A2 1 2 Dublin Dental School and Hospital National
Centre for Coagulation Disorders, Dublin, Ireland
33
Tuesday, July 13, 2010

Wednesday, July 14. 2010
Congress Sessions cont’d
Wednesday, July 14, 2010
PLENARY SESSIONS 08:45 – 10: 15
Plenary 07≤
Room: Buenos Aires
Chair: Susana Meschengieser, Argentina
Women & Bleeding Disorders
Andra James, U.S.A.
Plenary 08≤
Room: Buenos Aires
Chair: Raúl Pérez-Bianco, Argentina
Prophylaxis
Victor Blanchette, Canada
10:15 – 10:45
REFRESHMENT BREAK
10:45 – 12:15
CONCURRENT SESSIONS
W1.1 - MEDICAL≤
Clinical Issues in Inhibitors
Room: Buenos Aires
Chair: Keith Hoots, U.S.A.
n A Role for Prophylaxis in Inhibitor Patients?
Keith Hoots, U.S.A.
n Update on Immune Tolerance
Elena Santagostino, Italy
n Differential Responses to Bypassing Agents
Jan Astermark, Sweden
W1.2 - MUSCULOSKELETAL
Therapeutic Exercise Tool Box
Room: Palermo
Co-Chairs: Greig Blamey, Canada, and Thuvia
Flannery, U.K.
n Function
Piet de Kleijn, the Netherlands
n Strength
Nick Zourikian, Canada
34
n Flexibility
Angela Forsyth, U.S.A.
n Proprioception
Lee Short, U.K.
n Balance
Natasha Jankovic, Serbia
W1.3 - MULTIDISCIPLINARY ≤
Meet the Real Experts: Life Stages
Room: Belgrano
Chair: Belinda Burnett, New Zealand
n Youth Perspective from a Developing Country
Vaibhav Nehra, India
n Youth Perspective from a Developed Country
Paul Wilton, Canada
n Middle-Age Perspective from a Developed
Country
Gabriele Callizani, Italy
n Middle-Age Perspective from a Developing
Country
Yuri Zhulyov, Russia
n Older Perspective from a Developed Country
Gordon Clarke, U.K.
n Older Perspective from a Developing Country
Said Ul-Islam, Pakistan
W1.4 - MEDICAL
Free Papers IV
Room: Ceibo (1st floor)
Co-Chairs: Angelika Batorova, Slovakia, and Wolfhart
Kreuz, Germany
n Platelet Binding of NN1731, a Factor VIIa
Variant with Enhanced Tissue Factor-
Independent Activity
Hoffman M1 , Persson E2 , Ezban M2 , Monroe DM3 1Duke University & Durham Veterans Affairs
Medical Center, Durham, North Carolina U.S.A.;
2 3 Novo Nordisk A/S, Måløv, Denmark; University
of North Carolina, Chapel Hill, North Carolina,
U.S.A.

Congress Sessions cont’d
n Inhibitor Incidence in Hemophilia A Patients
Intensively Treated with Continuous Infusion
of Factor VIII
Batorova A1 , Holme P2 , Gringeri A3 , Fijnvandraat
K4 , Richards M5 , Hermans C6 , Altisent C7 , Lopez-
Fernández M8 on behalf of the European
Hemophilia Treatment Standardization Board
(EHTSB)
1National Hemophilia Center, Dept. of
Hematology and Transfusion Medicine, University
Hospital, Bratislava, Slovakia, 2Haematology Medical Department, Rikshospitalet, University
Hospital, Oslo, Norway, 3Centro Emofilia A.
Bianchi Bonomi, University Hospital, Milan, Italy,
4Department of Pediatric Hematology, Academic
Medical Center, Amsterdam, the Netherlands,
5Paediatric Haematology Department, Children’s
Day Hospital, St. James University Hospital,
Leeds, United Kingdom, 6Haemostasis Department, Cliniques Universitaires St Luc,
Bruxelles, Belgium, 7Servicio de Hematologia –
Unidad de Hemofilia, Hospital Val d’ Hebron,
Barcelona, 8Thrombosis and Haemostasis Unit.
Servicio de Hematología y Hemoterapia,
Complexo Hospitalario Universitario de A
Coruña, Coruña, Spain
n Factor VIII Light Chain Mutations and Cysteine
Substitutions Predispose for Inhibitor
Development in Mild and Moderate
Hemophilia A: First Results From the
INSIGHT Study
Eckhardt CL1 , 2 , Peters M1 , Kamphuisen PW2 ,
Astermark J3 , Oldenburg J4 , Hay CRM5 ,
Santagostino E6 , Ingerslev J7 , D’Oiron R8 , van der
Bom JG9 and Fijnvandraat K1 for the INSIGHT
investigators
1Paediatric Haematology, Emma Children’s
Hospital, Amsterdam, the Netherlands, 2Vascular Medicine, Academic Medical Center,
Amsterdam, the Netherlands, 3Centre for
Thrombosis and Haemostasis, Malmö University
Hospital, Lund University, Malmö, Sweden,
4Institute of Experimental Haematology and
Transfusion Medicine, University Hospital Bonn,
Bonn, Germany, 5Hemophilia Center, Manchester
Royal Infirmary, Manchester, U.K., 6Angelo Bianchi Bonomi Hemophilia and Thrombosis
Center, IRCCS Maggiore Hospital, Mangiagalli &
Regina Elena Foundation, University of Milan,
Milan, Italy, 7University Hospital Skejby, Aarhus,
Denmark, 8Haemophilia Centre, Hôpital Bicêtre,
Paris, France, 9Clinical Epidemiology, Leiden
University Medical Center, Leiden, the
Netherlands
n Inhibitor Incidence in Previously Untreated
Patients (PUPs) with Hemophilia A and B -
Final Evaluation of the Prospective PUP Study
Conducted by the Paediatric Committee of
the GTH (German, Swiss, and Austrian Society
of Thrombosis and Haemostasis Research)
Kreuz W1 , Auerswald G2 , Budde U3 , Lenk H4 ,
Escuriola Ettingshausen C1, on behalf of GTH-
PUP-Study-Group
1JW Goethe University Hospital, Dept. Pediatrics
III, Frankfurt, 2ZKH St.Jürgen-Straße, Prof. Hess
Childrens Hospital, Bremen, 3AescuLaboratory, Hamburg, 4University Hospital Leipzig, Dept.
Pediatrics, Germany
n First Human Dose Trial of Subcutaneously
Administered Recombinant Activated Factor
VII (rFVIIa) to Hemophilia A and B Patients
Shows Prolonged FVIIa Half-Life, and Provides
Evidence of Safety and Tolerability
Tiede A1 , Lethagen S2 , Friedrich U3 , Stenmo C3 ,
Allen G4 , Giangrande P5 , Goudemand J6 , Hay C7 ,
Holmström M8 , Klamroth R9 , McKenzie S10 ,
Miesbach W11 , Negrier C12 , Jimenez Yuste V13 and
Berntorp E14 1Hannover Medical School, Hannover, Germany,
2 3 Rigshospitalet, Copenhagen, Denmark, Novo
Nordisk A/S, Bagsvaerd, Denmark, 4Children’s Memorial Hospital, Chicago, U.S.A., 5Churchill Hospital, Oxford, U.K., 6Hôpital Cardiologique,
Lille Cedex, France, 7Manchester Royal Infirmary,
Manchester, U.K., 8Karolinska Universitetssjukhuset, Stockholm, Sweden,
9Vivantes Klinikum im Friedrichshain, Berlin,
Germany, 10Thomas Jefferson University,
Philadelphia, U.S.A., 11Institut für
Transfusionsmedizin Universitätsklinikum
Frankfurt, Germany, 12Hôpital Edouard Herriot,
Lyon, France, 13Hospital Universitario La Paz,
Madrid, Spain, 14Universitetssjukhuset MAS,
Malmö, Sweden
n Why Is the Frequency of Inhibitors Increasing
Among Swedish Children with Severe
Hemophilia A?
Ljung R1 , Petrini P2 , Holmberg F1 1Lund University, Departments of Paediatrics and
Malmö Centre for Thrombosis and Haemostasis,
University Hospital, Malmö, Sweden and
2Paediatric Department of Coagulation
Disorders, Karolinska University Hospital,
Stockholm, Sweden
35
Wednesday, July 14. 2010

Wednesday, July 14. 2010
Congress Sessions cont’d
n Validation of a Predictive Model for
Identifying an Increased Risk for Clinical
Meaningful Inhibitor Development in Children
with Hemophilia A – Results of a Multicenter
Cohort Study
Halimeh S1 , Kenet G2 , Bidlingmaier C3 , Escuriola
C4 , Pautard B5 , Nowak-Göttl U6 1MVZ Laboratory Duisburg GmbH, Germany,
2The Israel National Hemophilia Center, Sheba
Medical Center, Tel-Hashomer, Israel, 3University Hospital Munich, Dept. of Pediatrics, Germany,
4University Hospital Frankfurt, Dept. of Pediatric,
Hematology/Oncology, Germany, 5Centre D'Activite D'Hematologie Oncologie, Centre
Hospitalier Universitaire D'Amien, France,
6University Hospital Muenster, Dept. of
Pediatrics, Germany
W1.5 - MULTIDISCIPLINARY≤
Carriers
Room: Puerto Madero
Chair: Ulf Tedgard, Sweden
n Impact of Diagnosis
Richa Mohan, India
n Female Relatives of People with Hemophilia:
Factors Influencing Uptake
Anne Gillham, South Africa
n Women and the Hemophilia Gene
Claire McLintock, New Zealand
n Management of Bleeding
Ulf Tedgard, Sweden
W1.6 - MULTIDISCIPLINARY≤
Measuring Impairments in Patients with
Hemophilia in Everyday Life
Room: Montserrat
Chair: Elizabeth Paradis, Canada
n Nurse’s Viewpoint
Kate Khair, U.K.
n Physiotherapist’s Viewpoint
Piet de Kleijn, the Netherlands
n Orthopedist’s Viewpoint
Horacio Caviglia, Argentina
n Psychologist’s Viewpoint
Sylvia von Mackensen, Germany
36
12:15 – 14:15
LUNCH BREAK AND INDUSTRY SYMPSOSIA
14:15 – 15:45
CONCURRENT SESSIONS
W2.1 - MEDICAL≤
The Role of Prophylaxis in Bleeding
Disorders
Room: Buenos Aires
Chair: Erik Berntorp, Sweden
n Prophylaxis in VWD
Erik Berntorp, Sweden
n Prophylaxis in Rare Bleeding Disorders
Philippe de Moerloose, Switzerland
n Prophylaxis in Hemophilia
Rolf Ljung, Sweden
W2.2 - MEDICAL ≤
Vascular Bleeding Disorders
Room: Puerto Madero
Chair: Nigel Key, U.S.A.
n Basics of Vascular Hemostasis
Nigel Key, U.S.A.
n Bleeding in Collagen Disorders
Anne De Paepe, Belgium
n Clinical Spectrum and Management of HHT
Claire Shovlin, U.K.
W2.3 - MULTIDISCIPLINARY≤
Sexuality and Bleeding Disorders
Room: Belgrano
Chair: Greig Blamey, Canada
n Circumcision
Bulent Zulfikar, Turkey
n Prevention and Treatment of STDs and
Menorrhagia
Carolyn Francis, U.S.A.
n Psoas and MSK Problems
Greig Blamey, Canada
n Hemophilia, Ageing, and Sexuality
Evelien Mauser Bunschoten, the Netherlands

Congress Sessions cont’d
W2.4 – LABORATORY SCIENCES
Quality Issues in Laboratory Hemostasis
Room: Ceibo (1st floor)
Chair: Eric Preston, U.K.
n Causes of Errors in Medical Laboratories
Giuseppi Lippi, Italy
n Role of External Quality Assessment in the
Identification & Resolution of Assay Problems
Eric Preston, U.K.
n Quality Assurance in Genetic Testing Giridhara
Giridhara R. Jayandharan, India
W2.5 - MUSCULOSKELETAL≤
Management of Arthrofibrosis in Hemophilic
Arthropathy
Room: Montserrat
Chair: Pier Luigi Solimeno, Italy
n Prevention, Diagnosis, Surgical Correction and
Avoidance of Recurrence of Arthrofibrosis
James Luck, U.S.A.
n Posterior Release of the Knee in
Arthrofibrosis: Surgical Approaches,
Precautions and Outcomes
Tariq Sohail, Pakistan
n Achieving Extension After Posterior Release in
Arthrofibrosis
Shubhranshu Mohanty, India
n Femoral Supracondilar Extensor Osteotomy
for the Correction of Flexion Contracture of
the Knee
Javad Mortazavi, Iran
n Ircular External Fixators and Hybrid Frames:
Role in Achieving Extension of the
Arthrofibrotic Knee
Michael Heim, Israel
n Does Preoperative Range of Motion Predict
Postoperative Range of Motion? Tips to
Achieve Greater Motion
Nick Goddard, U.K.
n Bilateral Simultaneous Total Knee
Arthroplasty: How to Correct the Flexion
Contractures and Prevent their Recurrence
Luciano Pacheco, Brazil
n Complete Ligamentous Resectious in Primary
Total Knee Arthroplasty
Sacha Bittelman, Chile
W2.6 - DENTAL
MEET THE EXPERTS: Dental Issues
Room: Palermo
Chair: Alison Dougall, Ireland
n Overview of Local Hemostatic Measures
Andrew Brewer, U.K.
n Panel: Eduardo Rey, DDS, Maria Elvira Pizzigatti
Correa, DDS, Wellington Cavalcanti, DDS
37
Wednesday, July 14. 2010

Index of Speakers
A
Abad Franch, Lydia T3.4
Ahmad, Farooq M1.5
Amesse, Claudine T2.5
Antunes, Sandra Vallin M1.5
Arruda, Valder R. S2.1
Asencio, Joseph Guy T2.2
Astermark, Jan W1.1
Awajan, Arafat S2.6
Ay, Cihan M2.2
B
Bak, Won Sook T3.4
Batorova, Angelika S2.4, M2.1, W1.4
Bech Andersen, Jacob T2.4
Beeton, Karen Pre-PHYSIO, T1.3
Berntorp, Erik W2.1
Bittelman, Sacha W2.5
Bjermert, Tor Voest T2.4
Blamey, Greig W1.2, W2.3
Blanchette, Victor M1.1, W-PL08
Bolton-Maggs, Paula H. B. S2.5
Bordone, Raúl Pre-NURSE
Bos, Ruud Pre-PSYSOC
Brand, Brigitte M1.4
Breakey, Vicky M1.5
Brewer, Andrew T3.6, W2.6
Brodin, Elisabeth S2.3
Burnett, Belinda W1.3
C
Calizzani, Gabriele W1.3
Carnahan, Mike T1.2
Cassis, Frederica Pre-PSYSOC, M2.3
Castaman, Giancarlo M1.2
Cavalcanti, Wellington W2.6
Caviglia, Horacio Pre-ORTHO, M3.5, T2.2, W1.6
Cecchini, Clare S1.6
Chan, Anthony K. C. S1.1
Chen, Lixia Pre-PHYSIO, S1.5
Chitlur, Meera T2.6
Chuansumrit, Ampaiwan Pre-LAB
Clarke, Gordon S2.6, W1.3
Coppola, Antonio T1.4
Corti, Marcelo T2.3
Cunha Mello Rodrigues, Carmen M2.5
Cutter, Susan Pre-PSYSOC, M2.6
D
Daffunchio, Carla T3.4
Dargan, Alison M1.5
38
Dargaud, Yesim T2.6
Daruich, Jorge T1.5, T2.3
De Haro, Martial M1.3
De Kleijn, Piet M1.4, W1.2, W1.6
de Moerloose, Philippe W2.1
De Paepe, Anne W2.2
DiMichele, Donna M1.1
DiPaola, Jorge M3.1
Djambas Khayat, Claudia S1.6
Dogan, Cem T3.6
Dolan, Gerard T-PL05, T1.4
Doria, Andrea S-PL02
Dougall, Alison T2.5, W2.6
Duffy, Anne Pre-PSYSOC, T1.2
Dunn, Nicola Pre-WBD
E
Echenagucia, Marion S1.4
Eckhardt, Corien W1.4
Egan, Carmel Pre-NURSE
El-Ekiaby, Magdy S2.2, M1.5, T3.5
F
Fernández-Palazzi, Federico T2.2
Fischer, Kathelijn T3.1
Flannery, Thuvia W1.2
Ford, Sarah T1.4
Forsyth, Angela Pre-PHYSIO, T1.2, W1.2
Francis, Carolyn W2.3
Fritz, Rhonda Pre-NURSE
Fuchs, Irene Pre-PSYSOC, T3.3
Fukutake, Katsuyuki T1.4
G
Gaitan Fitch, Ricardo Carlos M1.6
Galatro, Gustavo M1.3
Galli, Eduardo Miguel M1.4
Garrido, César S1.3
Gilbert, Marvin M1.4
Gillham, Anne W1.5
Goddard, Nicholas Pre-ORTHO, T2.2, W2.5
Gómez Cavallini, Antonio F. M2.6, T2.4
Goudemand, Jenny M2.2
Gouider Belhadjali, Emna Pre-NURSE, M1.6
Grana, Silvina Pre-PSYSOC, S1.3, M2.3
Grigoryan, Eduard T2.4
Grimberg, Evelyn S2.5
Gringeri, Alessandro S2.4, M2.1, T1.3, T3.3
Gruszka, Zygmunt T1.2
H

Index of Speakers cont’d
Halimeh, Susan W1.4
Harvey, Martin M3.6
Hashim Mohamed, Aris Pre-WBD, T1.6
Hayward, Catherine M3.2
Heijnen, Lily Pre-PHYSIO
Heim, Michael W2.5
Hernandez, Flerida T3.5
Hewson, Ian M3.4
High, Katherine M2.1
Hillarp, Andreas Pre-LAB, S1.4
Hoffman, Maureane W1.4
Hoots, W. Keith W1.1
Howard, Tom T3.1
Hubert, Nicola S2.4
I
Ibrahim Abu-Riash, Mahmoud S2.5
Inder, Alison M2.3
Iorio, Alfonso T2.5
Ironside, James W. M1.1
Isarangkura, Parttraporn S2.6
Israels, Sara S2.2
J
Jakobsson, Marika T2.4
James, Paula M3.1
James, Andra H. Pre-WBD, W-PL07
Jankovic, Natasa Pre-PHYSIO, W1.2
Jayandharan, Giridhara R. T3.5, W2.4
Jensen, Lene T2.3
Jordan, Jeanne A S1.2
Jurisic, Milan M3.4
K
Kadir, Rezan Pre-WBD
Karimi, Mehran Pre-WBD
Kasper, Carol K. Pre-WBD
Katsarou, Olga M2.2
Kavakli, Kaan S2.4
Kazimova, Mehpara S2.6
Keilback, Christine S1.3
Kenet, Gili S1.1
Key, Nigel T1.6, W2.2
Khair, Kate M3.6, W1.6
Khairo, Elie M1.3
Kitchen, Steven Pre-LAB, M3.2
Kreuz, Wolfhart W1.4
Krutvecho, Triroj M3.3
Kuebler, Edward Pre-PSYSOC, S1.3, M2.3
Kulkarni, Roshni Pre-WBD, S1.1
L
Lacasse, Lucie Pre-NURSE
Lalwani, Anil T1.2
Lam, Hon-Wai T3.4
Lamhene, Latifa S2.5
Leal, Soraya T3.6
Lee, Christine Pre-PUB
Lenting, Peter J. M-PL04
Li, Kuixing Pre-NURSE
Li, Tsung-Ying S2.4
Lillicrap, David Pre-GENE THERAPY, S2.1, T3.1
Lindvall, Karin M2.5
Lippi, Giuseppe W2.4
Ljung, Rolf S2.4 , W1.4, W2.1
Llinás, Adolfo Pre-ORTHO, S-PL02, T2.2, T3.2
Lobet, Sébastien Pre-PHYSIO, T1.3
Lottaz, Gabriel S2.5
Luck, James T2.2, W2.5
Ludlam, Christopher T2.1
M
Manco-Johnson, Marilyn M3.3, T2.2
Manco-Johnson, Michael T1.3
Markis, Michael T2.1
Martin, Amy T3.6
Mauser-Bunschoten, Evelien P. W2.3
Mbele, Bongi M2.5
McCarthy, Penny Pre-NURSE, T3.3
McCraw, Angus Pre-LAB, S1.4
McLaughlin, Paul M1.4, T3.4
McLintock, Claire W1.5
Mdivnishvili, Marina S1.6
Meijer, Piet T2.5
Meschengieser, Susana M1.2
Mingot, Maria Eva W-PL07, S2.3
Mohan, Richa Pre-PSYSOC, W1.5
Mohanty, Shubhranshu T1.3, T2.2, W2.5
Monahan, Paul M2.2, T1.1
Monteros, Martha S2.6
Montgomery, Robert R. M1.2, T1.1
Moretti, Noemi M-PL04, S1.5, S2.3
Mortazavi, SM Javad W2.5
Mulder, Kathy Pre-PHYSIO, M3.5
Munn, James Pre-NURSE, M2.5
N
Nehra, Vaibhav W1.3
Nair, Sukesh Chandran T2.6
Narayan, Pamela Pre-PHYSIO, S1.5
Negrier, Claude M-PL03, M3.2
39

Index of Speakers cont’d
O
O'Mahony, Brian T2.3
Oldenburg, Johannes M3.1
Osman, Zulkiflee S2.3
Othman, Maha M2.2
Ozelo, Margareth Castro Pre-GENE THERAPY, T1.1
P
Pacheco, Luciano Da Rocha Loures W2.5
Page, David M1.6, M3.3
Paradis, Elizabeth Pre-NURSE, T1.5, W1.6
Pardo-Díaz, Edwin S2.3
Parreira, Miryam M3.4
Pasta, Gianluigi Pre-ORTHO, S2.3, T2.2
Peerlinck, Kathelijne T-PL06
Pérez-Bianco, Raúl M-PL03
Peyvandi, Flora Pre-WBD, M2.2
Pizzigatti Correa, Maria Elvira W2.6
Preston, F. Eric W2.4
Q
Querol Fuentes, Felipe T3.4
Quiroga, Teresa S2.2
R
Radossi, Poalo M1.4
Ragni, Margaret Pre-GENE THERAPY, S1.2
Rahim, Sameer S2.3
Ravanbod, Shirin Pre-WBD
Reipert, Birgit M. S2.1
Rey, Eduardo M3.4, W2.6
Roberts, Anthony Pre-PSYSOC, T1.6, T2.3
Robinson, Georgina M3.6
Rosas, Maria Matilde Pre-PHYSIO, T3.4
Rosen, Steffen M2.4
Ruiz-Sáez, Arlette S1.6
S
Saag, Anu Pre-NURSE
Sabbour, Adley S1.5
Safadi Márquez, Carlos T3.5
Santagostino, Elena W1.1
Sayyadeh, Asia M3.6
Schneider, Manfred Michael M3.6
Senol, Selmin Pre-NURSE
Seuser, Axel T2.2 , T3.4
Shapiro, Amy S2.4
Sherlock, Emma M1.4
Sherman, Kenneth E. S1.2, T1.5
Short, Lee W1.2
Shovlin, Claire W2.2
40
Silva, Mauricio M3.5, T1.3, T2.2
Silva Gomez, David M2.6
Skinner, Mark W. S-PL01, T3.1
Smith, Gillian T3.6
Sohail, Muhammad Tariq W2.5
Solimeno, Pier Luigi Pre-ORTHO, T3.2, W2.5
Srivastava, Alok M3.3, T1.6, T2.6, T3.1
Stennicke, Henning T1.4
Steno, Boris T1.3
Stevanovic, Gordana S1.3, M3.6
Street, Alison M. S-PL01, T-PL04, M1.1, T1.
Sun, Jing S2.3
T
Tagliaferri, Annarita T1.4
Taheri, Noorallah Pre-PSYSOC
Tarrida, Carolina M1.5
Tedgard, Ulf W1.5
Tiede, Andreas W1.4
Tiktinsky, Rachel Pre-PHYSIO, S1.5
Torchet, Marie Françoise M1.5, T2.5
U
Ul-Islam, Saif W1.3
V
Valiente, Antonio M3.4
Van Meegeren, Monique T1.3, T3.2
Vassallo, Mariano M3.4
Verbruggen, Bert M2.4
Villaca, Paula Ribeiro M3.6
von Mackensen, Sylvia Pre-PSYSOC,
Pre-WBD, M1.3, W1.6
von Mayrhauser, Dawn Pre-PSYSOC
W
Wallny, Thomas T2.2
Weinstein, Mark T2.1
Wilton, Paul W1.3
X
Xafaki, Panagiota M1.4
Y
York, Deon T2.4
Z
Zappa, Susan Pre-NURSE
Zhulyov, Yuri M1.6, W1.3
Zourikian, Nichan Pre-PHYSIO, M1.3, W1.2
Zucchi, Andrea Corina T1.4
Zulfikar, Bulent W2.3

Index of Poster Presenters
Sunday and Monday
Posters are on display during exhibit hours. Authors will be
present at their posters for a question and answer period
on Monday, July 12 from 15:45-16:30. Presenting authors
are in bold.
ACQUIRED HEMOPHILIA
01P01
Acquired Hemophilia A Associated with Pancreatic Ductal
Carcinoma
Andrade Caldeira Ferreira M1 , Luís E2 , Aveiro F2 , Caldeira
Ferreira A1 , Freitas B3 , Chediak J4 1 2 Serviço de Medicina Interna, Serviço de Hemato-Oncologia,
3Serviço de Imunohemoterapia, Hospital Central do Funchal,
Santa Cruz, Portugal, 4Advocate Illinois Masonic Medical
Center, Chicago, IL, U.S.A.
01P02
A Case of Acquired Hemophilia Associated with Bullous
Pemphigoid
Antic D1 , Elezovic I1 , Djunic I1 , Miljic P1 , Dugalic V2 1 2 Clinic for Hematology, Clinical Center Serbia, Clinic for
Digestive Surgery, Clinical Center Serbia, Belgrade, Serbia
01P03
Successful Treatment with Rituximab in a Patient with
Acquired FVIII Inhibitor
Begue G, Campregher G, Baduel C
Academia Nacional de Medicina, Buenos Aires, Argentina
01P04
Acquired Hemophilia in Patient Previously Diseased from
Myasthenia Gravis: Case Report
Bilic E, Bilic E, Zagar M
Clinical Hospital Centre Zagreb, Hungary
01P05
Rituximab in the Treatment of Acquired Hemophilia A in a
Patient with Polymyalgia Rheumatica
Braunert L1 , Brügel M2 , Pfrepper C1 , Niederwieser D1 1Department of Internal Medicine, Division of Hematology/
Oncology/ Hemostasis, University of Leipzig, 2Institute of
Laboratory Medicine, Clinical Chemistry and Molecular
Diagnostics, University of Leipzig, Germany
01P06
Acquired Hemophilia A: A More Benign Chronic Disease?
Morais S, Cruz E, Pereira M, Campos M
Hematology Unit, Santo António Hospital, Porto, Portugal
01P07
Efficacy and Safety of Factor VIII Inhibitor by Passing Activity
(FEIBA) in High Thrombotic Risk Patients with Acquired
Hemophilia (AH)
Gamba G, Montani N, Trinchero A, Pecci A, Bertolino GP,
Lodo F
Department of Internal Medicine, Haemophilia Center,
Fondazione IRCCS Policlinico San Matteo, University of Pavia,
Pavia, Italy
01P08
International Recommendations on the Diagnosis and
Treatment of Patients with Acquired Hemophilia A
Huth-Kuehne A1 , St.Louis J2 1SRH Kurpfalzkrankenhaus and Hemophilia Center
Heidelberg Germany, 2Hopital Maisonneuve-Rosemont,
Montreal, Canada
01P09
Acquired Hemophilia A and Primary Biliary Cirrhosis: About
One Case and Review of the Literature
Ajmi N1 , Hdijji S1 , Kassar O1 , Medhaffar M3 , Jdidi I2 , Kallel
C2 , Tahri N3 , Elloumi M1 1 2 Service of haematology, CHU Hédi Chaker Sfax, Laboratory
of Haematology CHU Habib Bourguiba Sfax, 3Service of
Gastro-Enterology, CHU Hédi Chaker Sfax, Tunisia
01P10
Acquired Hemophilia B: About One Case
Ajmi N1 , Hdijji S1 , Kassar O1 , Jdidi I2 , Kallel C2 , Elloumi M1 1 2 Service of Haematology, CHU Hédi Chaker Sfax, Laboratory
of Haematology CHU Habib Bourguiba Sfax, Tunisia
01P11
Acquired Hemophilia A (AHA): Management Profiles in
Argentina
Luis A1 , Alejandro A2 , Pierdominicci M3 , Azzaro S4 , Cermelj
M5 , Bernard H6 1Hospital General de Niños Dr. Ricardo Gutierrez - CABA,
Buenos Aires, Argentina, 2Sanatorio Güemes - CABA, Buenos
Aires, Argentina, 3Hospital General de Agudos J.M. Ramos
Mejia - CABA, Buenos Aires, Argentina, 4Hospital Interzonal
Gral. San Martin - La Plata, Buenos Aires, Argentina, 5Instituto William Osler - CABA, Buenos Aires, Argentina, 6Hospital Central Ramon Madariaga - Posadas, Misiones, Argentina
01P12
Acquired Factor VIII Inhibitor: Report of 19 Cases
Smejkal P1 , Bulikova A1 , Matyskova M1 , Doubek M2 , Mayer
J2 , Penka M1 1Department of Clinical Haematology, University Hospital
and Medical Faculty Masaryk University Brno, Czech
Republic, 2Department of Internal Medicine-Haemato -
oncology, University Hospital and Medical Faculty Masaryk
University Brno, Czech Republic
41
Posters, Sunday and Monday

Posters, Sunday and Monday
Index of Poster Presenters cont’d
01P13
Efficacy and Safety of Repeated Doses of aPCC (FEIBA) in
Elderly Patients with Acquired Hemophilia A and Severe
Bleeding
St-Louis J1 , Meilleur C1 , Demers C2 , Lepine-Martin M3 , Warner
M4 , Rivard G1 1 2 Quebec Reference Centre for Coagulation Inhibitor, Hôpital
Enfant-Jésus, 3CHU Sherbrooke, 4Royal-Victoria Hospital,
Montreal, Canada
01P14
Acquired Hemophilia Following Pegylated-Interferon Therapy
Spanavello M, Rowell J, Zeissink B
Queensland Haemophilia Centre, Herston, QLD, Australia
01P15
Acquired Hemophilia A in a Single Center: Clinical Experience
of 17 Cases
Zheng C, Wu J, Ding K
Department of Hematology, Anhui Provincial Hospital, China
AGEING
02P09
Cardiovascular Disease in Hemophilia
Mauser-Bunschoten E, Fransen van de Putte D, Fischer K,
Roosendaal G, Schutgens R
Van Creveldkliniek, University Medical Center Utrecht, the
Netherlands
02P10
Cardiac Catheterization and Stent Implantation in a Severe
Hemophilia A Patient – A Case Report
Lubetsky A, Schapiro J, Bashari D, Luboshitz J, Kenet G,
Martinowitz U
National Hemophilia Center, Sheba Health, Israel
02P11
Prostatectomy in Hemophilia
Solano M, Casas C, Abello V, Peña A, Aponte H, Caceres A
Hospital de San Jose – FUCS, Colombia
02P12
Cardiovascular Risk is Similar in Hemophilia A Patients and
the General Population
Zwiers M, Lefrandt J, Smit A, Meijer K
University Medical Center Groningen, the Netherlands
42
CAPACITY BUILDING
03P19
A Step Forward for Hemophilia Care in India
Ajmani R, Saraf R
Celestial Biologicals Ltd, Ahmadabad, India
03P20
Patient Advocacy in the Asia Pacific Region: A Report from
the Third Asia Pacific Haemophilia Advisory Board Meeting
Barnes C1 , Zhulyev Y2 , O’Mahony B3 , Gu C4 1Royal Children’s Hospital, Melbourne, Australia,
2 3 Haemophilia Society of Russia, Moscow, Russia, Irish
Haemophilia Society, Dublin, Ireland, 4Baxter Bioscience,
Guangzhou, China
03P21
Collaboration and Learning through Twinning
Caris S1 , Suwannuraks M2 , Finkelstein G1 , Isarangkura P3 1 2 Haemophilia Foundation Australia, Glen Iris, Australia, Thai
Patient’s Club, 3National Hemophilia Foundation of Thailand,
Bangkok, Thailand
03P22
The Importance of Participation of Patient and Family on
Warranty Prophylactic Treatment
Marques R
Ajude-C, Rio de Janeiro, Brazil
03P23
A Training Course in Factor Replacement Therapy Concepts
for Hemophilia Organisation Leaders
O’Mahony B
Irish Haemophilia Society, Dublin, Ireland
03P24
Camping with People with Hemophilia: Important for Young
Health Care Professionals
Okazaki E, Valim A, Junqueira P, Mello M, Villaca P,
D’Amico E
Hospital Das Clinicas, Universidade de São Paulo, Brazil
CARE DELIVERY
04S01
Session M2.5
Home Treatment – Challenges in Developing Countries
Rodrigues C C M
Centro Infantil Boldrini, Campinas São Paulo, Brazil

Index of Poster Presenters cont’d
04S02
Session M3.3
Making the Case for Effective Clotting Factor Therapy in an
Era of Health Technology Assessment: From Cryoprecipitate
to Concentrate, Thailand Experience
Krutvecho T
National Health Security Office, National Hemophilia
Foundation of Thailand, Bangkok, Thailand
04S03
Session M3.3
Prophylaxis for Children and Adults with Hemophilia in the
Developed World
Manco-Johnson M
Mountain States Regional Hemophilia & Thrombosis Center,
University of Colorado Health Sciences Center and The
Children’s Hospital, Denver, CO, U.S.A.
04S04
Session T3.5
Implementation of Guidelines for Treatment
El Ekiaby M
Shabrawishi Hospital Hemophilia Centre, Cairo, Egypt
04S05
SessionT3.5
The Role of New Technologies (Genetic Diagnosis and
Therapies)
Jayandharan GR 1,2 , Srivastava A1 1Christian Medical College, Department of Haematology,
Vellore, India, 2University of Florida College of Medicine,
Department of Paediatrics, Gainesville, FL, U.S.A.
04S06
Session W2.6
Circumcision of People with Hemorrhagic Diathesis
Zulfikar B1 , Karamani2 , Bezgal F3 , Ovalif
1Istanbul University, Pediatric Hematology Oncology, Istanbul,
Turkey 2Urology, Haydarpasa State Hospital, 3The Hemophilia
Society of Turkey, 4Pediatrics, Zeynep Kamil Maternity and
Children’s Hospital, Istanbul, Turkey
04S07
Session W2.3
Prevention and Treatment of STD’s and Menorrhagia
Francis C
Lombardi Cancer Center, Georgetown University,
Washington, DC, U.S.A.
04P08
Session Pre-Congress-Nurses
Circumcision in Hemophilia
Gouider E 1 , Fitouri F 2 , Guesmi M 2 , FkihHassen A 2 , Meddeb
B 1 , Hamzaoui M 2
1 Hemophilia Treatment Centre, Aziza, Othmana Hospital
Tunisia, 2 Pediatric Surgery Department- Children’s Hospital,
Tunis, Tunisia
04P09
Comprehensive Care Team Approach to Bleeding Disorder
Patient Care: Benefits of Team Meeting
Almonte T 1
, Chan AK1,2 , Decker K1 , Walker I1,2 , Goldsmith
R1 , Bos C1 , Waterhouse L1 1 2 Hamilton Health Science-McMaster Hospital, and McMaster
University, Hamilton, ON, Canada
04P10
Evolution of Hemophiliac Patients Taking Care Modalities in
Algeria
BenSadok M1 , Belhani M2 1 2 Isaad Hassani (Beni Messous) UH, Isaad Hassani (Beni
Messous) UH, Algers, Algeria
04P11
Outcomes on a 5-Year Home-Delivery Program for
Hemophilia Patients in Mexico
Blackburn J1 , Epstein J2 , Aguilar L3 , Rivera M1 , Berges A4 ,
Garcia-Chavez J4 1 2 Baxter Export Corporation, Baxter Bioscience, Westlake
Village, CA, 3Baxter, Mexico, 4Centro Medico Nacional La
Raza, Mexico
04P12
Adherence with Hemophilia Treatments in Canada: A Survey
of Hemophilia Healthcare Professionals
Chan A1 , Decker K2 , Warner M3 1 2 McMaster University, Hamilton, ON, Canada, Hamilton
Health Sciences, Hamilton, ON, Canada, 3Royal Victoria
Hospital, Montreal, QC, Canada
04P13
Epidemiology and Diagnosis Aspects of Hemophilia in
Senegal
Diop S, Sy Bah D, Seck M, Bamar Guèye Y, Dièye T, Sall A,
Touré AO, Thiam D, Diakhaté L
Service d’Hématologie, Université Cheikh Anta Diop, Dakar,
Sénégal
43
Posters, Sunday and Monday

Posters, Sunday and Monday
Index of Poster Presenters cont’d
04P14
The Principles of Hemophilia Care in Clinical Practice: A
European Survey
Fischer K1, 2 , on behalf of EHTSB3 1Van Creveldkliniek, Dept of Hematology, Utrecht, the
Netherlands, 2Julius Center for Health Sciences and Primary
3 Care, UMCU, Utrecht, the Netherlands, European
Haemophilia Treatment Standardisation Board
04P15
Survey of the Federally Funded Hemophilia Treatment
Centers in the United States: Analysis of Staffing Patterns
Forsberg A1 , Drake J2 , Voutsis M3 , Cutter S4 , Riske B5 ,
Wicklund B6 1New England Hemophilia Center, UMass Memorial Medical
Center, 2Gulf States Hemophilia and Thrombophilia Center,
3Mount Sinai School of Medicine, Regional Comprehensive
Treatment Center, Penn Comprehensive Hemophilia Center,
University of Pennsylvania Medical Center, Presbyterian,
4Penn Comprehensive Hemophilia Program, University of
Pennsylvania Medical Center - Presbyterian, 5Mountain States
Regional Hemophilia & Thrombosis Center, 6Kansas City
Regional Hemophilia Center, The Children’s Mercy Hospital,
U.S.A.
04P16
Capacity Building of Hemophilia Health Care in Macedonia
Glamocanin S1 , Trajkova-Antevska Z1 , Coneska-Jovanova B1 ,
Dejanova V2 1 2 University Children’s Hospital, Institute of Transfusion
Medicine, Skopje, Macedonia
04P17
How to Treat Acute Lymphoblastic Leukaemia in Hemophilic
Children in Tunisia?
Aissaoui L2 , Gouider E1 , BenSalah N1 , BenAbdennebi Y2 ,
Hafsia R1 , Meddeb B1,2 1Hemophilia Treatment Centre Aziza Othmana Hospital
Tunisia, 2Clinical Hematology Department Aziza Othmana
Hospital, Tunisia
04P18
Benefits of Home Treatment in Tunisia
Gouider E, Zahra K, Zorgan M, Meddeb B
Hemophilia Treatment Centre Aziza Othmana Hospital,
Tunisian Association of Hemophilia, Tunis, Tunisia
04P19
Patient Involvement Programme – An Innovative Way to
Enhance Service Delivery
Graham V, Cahill M, Grogan A
St. James’s Hospital, Dublin, Ireland
44
04P20
Surgery in Patients with Inherited Coagulopathy –
Experiences in Uruguayan Reference Centers
Lemos F 1 , Mezzano R 2 , Insagray J 1 , Boggia B 2 , Rodriguez I 1 ,
Menyou A 1
1 Hospital De Clinicas and 2 Centro Hospitalario Pereira Rossell,
Montevideo, Uruguay
04P21
Delivery of Care in Hemophilia: Patients’ Point of View
Miljic P, Elezovic I, Gotic M
Institute of Haematology, Clinical Center of Serbia, Belgrade
04P22
Hemophilia Care at the National Institute of Hematology
and Blood Transfusion, 2009
Nguyen TM, Nguyen AT, Pham QV, Luu TH
National Institute of Hematology and Blood Transfusion,
Hanoi, Vietnam
04P23
Management of Hemophilia in Madagascar
Olivat RA
Diagnosis and Research Unit, University Hospital HJRA,
Antananarivo, Madagascar
04P24
Disease Management in Hemophilia: First Year of Experience
in Colombian Health System
Pardo-Díaz E 1 , Pantoja S 2 , Marmolejo C 2 , Ramirez O 3
1 Universidad Del Valle, 2 Center of Treatment IPS Medex,
3 Fundación Clinica Valle del Lili, Colombia
04P25
A Romanian Survey of Treated and Untreated Bleeds in
Patients with Hemophilia: Preliminary Analysis
Rusen L 2 , Lambert C 3 , Hermans C 3 , Podeanu M 1 , Podeanu D 1 ,
Oniga N 1
1 National Association of Haemophiliacs in Romania, Ploiesti,
Romania, 2 National Institute for Transfusional Hematology
Bucharest, Romania, 3 Cliniques Universitaires Saint-Luc,
Belguim
04P26
Implementation of a Woman and Bleeding Disorders Clinic:
Enhancing the Comprehensive Care Model
Purcell S 1
, Sanders S2 , Silva M2 , Palerme S2 , James P2 1Southeast Ontario Regional Inherited Bleeding Disorders
Program, 2Queen’s University, Kingston, ON, Canada
04P27
Home Therapy of Hemophilia in a Brazilian Blood Center
Rodrigues D 1 , Ferreira A 1 , Teixeira M 2 , Ferreira M 3 , Pereira P 3
1 Hemominas, 2 Universidade Federal de Juiz de Fora,
3 FAPEMIG, 4 Unipac, Brazil

Index of Poster Presenters cont’d
04P28
Status of Hemophilia Services in India - A Survey
Sachdeva A1 , Kahlon D1 , Dinand V1 , Yadav S1 , Gadhave B2 ,
Venkataraman I3 1Pediatric Hematology Oncology, Sir Ganga Ram Hospital,
2 3 Hemophilia Society, Mumbai, Hemophilia Society, Delhi,
India
04P29
Devising an Accreditation Process for Comprehensive
Hemophilia Care Centers in Iran
Tabatabaey A1 , Ghodousi Moghadam S2 , Mousavi Bazaz S2 1 2 Iranian Hemophilia Society, Mashhad University of Medical
Sciences, Iran
CARRIER ISSUES
05P07
Severe Hemophilia A in Five Females: An Experience of a
Single Centre
Baduel C1 , Baques A1 ,Radic P1 De Brasi C1 , Neme D2 , Tezanos
Pinto M1-2 , Perez Bianco R1-2 , Candela M1 1Academia Nacional de Medicina de Buenos Aires, Argentina,
2 Fundación de la Hemofilia de Buenos Aires, Argentina
05P08
Hemophilia Carriers: Levels of FVIII or FIX
Christiansen K, Ingerslev J, Hvitfeldt Poulsen L
Centre for Haemophilia and Thrombosis, Dept. of Clinical
Biochemistry, Aarhus University Hospital, Skejby, Denmark
05P09
Accidental Diagnosis of Reduced FVIII Levels in Females:
What Does It Mean?
Dardik R, Zivelin A, Kenet G, Lalezari S, Martinowitz U
National Hemophilia Center, Sheba Medical Center, Tel
Hashomer, Israel
05P10
Carrier Diagnosis of Hemophilia A by Fluorescent Multiplex
PCR
González Ramos I1 , Mundo Ayala J1 , Jaloma Cruz A2 , López
Jiménez J1 , Luna Záizar H1 , Esparza Flores M3 1Genética Humana, CUCS, Universidad de Guadalajara,
2Centro de Investigación Biomédica de Occidente, IMSS,
3Federación de Hemofilia de la República Mexicana, A.C.,
Guadalajara, Mexico
05P11
Clinical and Biological Features of Carriers of Hemophilia
Gouider E, Fadhlaoui A, Borgi W, BenSalah N, Zahra K,
Meddeb B
Hemophilia Treatment Centre Aziza Othmana Hospital Tunisia
05P12
Development of a New Diagnostics Method for Hemophilia
A Carrier
Hwang S 1 , Kim H 2 , Kim H 1 , Lim J 1 , Ryu C 3 , Lee K 4
1 Department of Biological Sciences, Ajou University,
2 Department of Hematology-Oncology, School of Medicine,
Ajou University, 3 Department of Pediatrics, Hospital of EulJi
University, 4 Department of Pediatrics, Kyungpook National
University Hospital, Korea
05P13
Personality Factor Identification in Hemophilia Carriers of
Costa Rica: A Proposal for Psychological Support
Jensen-Villalobos E1 , Boza-Calvo C1 , Sandoval M2 , Jiménez-
Cruz G2 1CIHATA-Universidad de Costa Rica, San Jose, Costa Rica
2Departamento Hematología, Hospital Mexico, Mexico City,
Mexico
05P14
Pregnancy and Delivery in Dutch Carriers of Hemophilia A
and B
Knol M1, 2 , Voskuilen M1 , Holterman F1 , Kluin-Nelemans H1 ,
Meijer K1 1Division of Haemostasis and Thrombosis, Department of
2 Haematology, and Department of Obstetrics and
Gynaecology, University Medical Centre Groningen,
Groningen, the Netherlands
05P15
XIST Promoter Mutations in Symptomatic Carriers of
Hemophilia A and B
Mundo Ayala JN1 ,Domínguez Quezada MG1 ,Jaloma Cruz
AR1 ,Bergés A2 ,Pompa Garza MT3 , Esparza Flores MA4 1Centro De Investigación Biomédica De Occidente, IMSS,
2Hospital de Pediatría, Centro Médico Nacional, La Raza,
IMSS, 3Unidad Médica de Alta Especialidad 25, IMSS,
4Federación de Hemofilia de la República Mexicana, A.C.,
Guadalajara, Mexico
05P16
Use of FVIII:C and VWF:Ag in Detection of Hemophilia A
Carriers
Nguyen, TM, Pham, QV, Nguyen AT, Nguyen TN
1National Institute of Hematology and Blood Transfusion,
Hanoi, Vietnam
05P17
X Inactivation Patterns and FVIII:C Activity Levels in Female
Carriers and Non-Carriers of Severe Factor VIII Gene
Mutations
Radic P1 , Tetzlaff T2 , Boduel C1 , Candela M1 , Rossetti L1 , De
Brasi C1 1 2 IIHema, National Academy of Medicine, FCEyN, UBA,
Buenos Aires, Argentina
45
Posters, Sunday and Monday

Posters, Sunday and Monday
Index of Poster Presenters cont’d
05P18
Integral Assessment of Hemophilia Carriers: New Guideline
from Spanish Foundation Victoria Eugenia
Rodriguez-Martorell FJ 1,2
, Mingot ME1,2 , Villar A1 , Palomo-
Bravo A2 , Núñez R2 , Pérez-Garrido R2 , Tizzano E1 , Liras A1 On behalf of RFVE (Royal Foundation Victoria Eugenia1 ) and
GACC (Andalusian Coagulopathies Congenital Group2 ),
Malaga, Spain
05P19
Hemophilia B Carrier Diagnosis and No Family History of
Hemophilia
Tagariello G, Belvini D, Salviato R, Pierobon F, Sartori R,
Radossi P
Haemophilia Center Transfusion and Haematology,
Castefranco Veneto, Italy
CLINICAL ISSUES
06P06
The Effectiveness of Radioisotope Synovectomy for Chronic
Synovitis in Turkish Pediatric Hemophiliacs: Ankara
Experience
Alioglu B1 , Ozsoy H2 , Koca G3 , Sakaogullari A2 , Ozdemir M2 ,
Dallar Y4 1The Ministry of Health of Turkey, Ankara Training and
Research Hospital, Department of Pediatric Hematology,
2 3 Department of Orthopedics, Department of Nuclear
Medicine, 4Department of Pediatrics Ankara Training and
Research Hospital Ankara, Turkey
06P07
Gastrointestinal Bleeding Due to Meckel’s Diverticulum in
Severe Hemophilia A
Arami S, Talks K, Biss T, Hanley J
Department of Haematology, Royal Victoria Infirmary,
Newcastle-upon-Tyne, U.K.
06P08
Intensive Treatment of Hemarthroses in Hemophilia: Clinical
and Ultrasound Management
Aznar J1 , Pérez-Alenda S1-2 , Abad-Franch L1 , Cid A1 , Haya
S1 , Querol F1-2 1Unidad De Hemostasia Y Trombosis, Hospital Universitario
La Fe, 2Universidad de Valencia, Spain
06P09
Excellent Long-Term Results in Living Donor Liver
Transplantation for Hepatitis C Related Hepatocellular
Carcinoma Complicating Hemophilia A: Two Cases from
Hong Kong
Au W1 , Chan S2 1 2 Department of Medicine and Department of Surgery,
Queen Mary Hospital, Hong Kong
46
06P10
Spontaneous Intramural Hematoma of the Intestine in
Patients with Severe Hemophilia A
Perez Bianco R1-2 ; Baduel C 1
; Baques A1 ; Neme D2 ; Tezanos
Pinto M1,2, , Candela M1 1 2 Academia Nacional de Medicina, and Fundación de la
Hemofilia, Buenos Aires, Argentina
06P11
Successful Major and Minor Surgery in Patients with
Hemophilia and High Titer Inhibitor
Balkan C 1 , Yilmaz D 1 , Kavakli K 1 , Aydogdu S 2 , Ozcan C 3 ,
Ay Y 1
1 Dept. of Pediatric Hematology, Ege University Children’s
Hospital, 2 Dept. of Orthopaedics, 3 Dept. of Pediatric Surgery,
Ege University Medical Faculty, Turkey
06P12
Frequency of High-Response Inhibitors in a Cohort of Young
Hemophilia A Patients
Boadas A, Mijares M, Ruiz-Saez A
National Hemophilia Center (NHC), Banco Metropolitano
de Sangre, Caracas, Venezuela
06P13
Change in Bone Mineral Density in Patients with Severe
Hemophilia A and B between the ages of 20 and 50: A Pilot
Study
Bos C, Walker I, Chan A, Almonte T, Decker K, Goldsmith R
McMaster Hemophilia Clinic, Hamilton ON, Canada
06P14
Radiosynovectomy with Phosphorus 32 in Hemophilic
Patients
Buceta A, Torres O, Paoloski G, Pollola J, Cermelj M
Servicio de Hemofilia. Instituto de Patologías Especiales,
William Osler, Buenos Aires, Argentina
06P15
Age at Diagnosis of Hemophilia: Update from the French
registry “FranceCoag Network”
Jousselme C1 , Demiguel V2 , Rafowicz A3 , Torchet M4 , Wibaut
B5 , Chambost H1 1 2 Hemophilia Center Marseille, French Institute for Public
Health Surveillance, 3Hemophilia Center Paris-Bicêtre,
4 5 Hemophilia Center Paris-Necker, Hemophilia Center Lille,
France
06P16
Bone Mineral Density among Adults with Hemophilia: The
Preliminary Report in Taiwan
Chang C-Y 1 , Tseng I 2 , Hsieh M 3 , Shih Y 3
Graduate Institute of Clinical Medicine and 2 College of
Nursing, Taipei Medical University Hospital, 3 Department of
Orthopaedics, Hemophilia Center, Taipei Medical University
Hospital, Taipei, Tiawan

Index of Poster Presenters cont’d
06P17
Continuous Infusion of Clotting Factor Concentrates during
Total Knee Replacement: A 17-Year Experience from a Single
Center
Negrier C, Chevalier Y, Chamouard V, Lienhart A, Meunier S
Hopital Edouard Herriot, CHU, Lyon, France
06P18
Intracranial Hemorrhages in Hemophilic Patients: Two Years
Observational Period at Brigadeiro Hospital San Paulo, Brazil
(2008-2009)
Foschi NM, Teixeira EC, Ferrari S, Garcia E
Hospital Brigadeiro, San Paulo, Brazil
06P19
Anticoagulation in a Patient with Hemophilia B and Mechanic
Heart Valve Replacement
Giersdorf G, Huth-Kühne A, Zimmermann R
Hemophilia Center of Kurpfalz Krankenhaus, Heidelberg,
Germany
06P20
Inflammation Does Not Predispose to Bleeding in a Mouse
Model of Hemophilia
Hoffman M1 , Monroe D2 1 2 Duke University, Durham, NC, University of North Carolina,
Raleigh, NC, U.S.A.
06P21
Variations in International Practices for the Peri-Operative
Management of Major Surgery for Persons with Severe
Hemophilia
Holme P1 , James P2 , Gomez K3 , Fogarty P4 1Oslo University Hospital, Rikshospitalet, Oslo, Norway,
2 3 Queen’s University, Kingston, ON, Canada, Royal Free
Hospital, London, U.K., 4University of California, San
Francisco, U.S.A., on behalf of Global Emerging Hemophilia
Experts Panel (GEHEP)
06P22
European Survey on Pain Management in Patients with
Hemophilia
Holstein K1 , Klamroth R2 , Perez R3 , Richards M4 , Gringeri A5 1Universitätsklinikum Hamburg-Eppendorf, Hamburg,
Germany, 2Vivantes Klinikum im Friedrichshain, Berlin,
Germany, 3Hospital Virgen del Rocio, Seville, Spain, 4Leeds Teaching Hospital NHS Trust, Leeds, United Kingdom, 5A. Bianchi Bonomi Hemophilia and Thrombosis Centre, Milan,
Italy
06P23
Screening and Interventional Colonoscopy in Hemophilia
Patients: 5 Year Experience in a Hemophilia Centre
Ioannidou P, Kouramba A, Kelaidis E, Kotsi P, Markakis K,
Katsarou O
Blood Center, National Reference Centre for Bleeding
Disorders, “Laiko” General Hospital, Athens, Greece
06P24
Recombinant Factor VIIa Concentrate versus Plasma Derived
Concentrates For the Treatment of Acute Bleeding Episodes
in People with Hemophilia and Inhibitors
Matino D 1 , Makris M 2 , D’Amico R 3 , Iorio A 1
1 Department of Internal Medicine, University of Perugia,
Perugia, Italy, 2 Academic Unit of Haematology, University of
Sheffield, Sheffield, U.K., 3 Department of Oncology,
Hematology and Respiratory Diseases, University of Modena
and Reggio Emilia, Modena, Italy
06P25
Bone Mineral Density in Iranian Hemophilic Patients: The
First Experience in the South of Iran
Karimi M, Rezaeifard M
Hematology Research Center, Shiraz University of Medical
Sciences, Shiraz, Iran
06P26
Use of Glubran 2 and Glubran Tissue Skin Adhesive in
Patients with Hereditary Bleeding Disorders Undergoing
Circumcision and Dental Extraction
Haghpanah S, Vafafar A, Golzadeh M, Ardeshiri R,
Karimi M
Hematology Research Center, Shiraz University Of Medical
Sciences, Shiraz, Iran
06P27
Long-Term Follow-Up of People with Hemophilia Successfully
Treated with Liver Transplant from Living Donors
Kim H 1 , Lee H, Jung S, Park J, Kim B, Wang H
Ajou University Hospital, Suwon, Korea
06P28
Pain in the Bleeding Disorders Community: A National Pain
Study
Lambing A 1 , Witkop M 2 , Kachalsky E 1 , Rushlow D 2
1 Henry Ford Health System, Detroit, 2 Munson Medical Center,
Traverse City, MI, U.S.A.
06P29
Could Epitope Profile of Anti-FVIII Autoantibodies Help Us
to Manage Acquired Hemophilia?
Lapalud P 1 , André S 2 , Lacroix-Desmazes S 2 , Schved J 3 , Granier
C 1 , Lavigne-Lissalde G 1
1 UMR3145 SysDiag CNRS/ BioRad Montpellier, 2 INSERM
UMRS 872 Paris, 3 Treatment Hemophilia Centre Montpellier,
France
47
Posters, Sunday and Monday

Posters, Sunday and Monday
Index of Poster Presenters cont’d
06P30
A Case of a 3-Year-Old Boy with Severe Hemophilia A on
Prophylaxis Identified with Chronic Subdural Hematoma Two
Years after the First Episode of Acute Subdural Hematoma
Matsumoto T, Sakata K, Wada H, Kumamoto T, Katayama
N, Komada Y
Mie University Hospital, Division of Blood Transfusion, Tsu
City, Japan
06P31
Pharmacologic Venous Thromboembolism Prophylaxis in
Hemophilic Patients under Major Orthopaedic Surgery:
Experience and Safety Profile
Mingot M 1 , Prieto-Bonilla M 1 , Palomo-Bravo A 1 , Heiniger A 1 ,
Villanueva F 2
1 Hematology Oncology Department, and 2 Orthopedic
Department, Regional University, Hospital Carlos Haya,
Málaga, Spain
06P32
Arthrocentesis in Acute Hemarthrosis in Hemophilia without
Inhibitor
Pérez R 1 , Nuñez R 1 , Povedano J 2
1 Hemophilia Unit, and 2 Deparment of Rheumatology, Hospital
Virgen del Rocío, Sevilla, Spain
06P33
A High-Dose Model of Hemophilia A Prophylactic Treatment
Plyushch O, Kopylov K, Kumskova M, Kudryavtseva L,
Zozulya N
National Research Hematology Center, Moscow, Russia
06P34
Conditions of Birth of Severe Hemophilia Patients in Paris
Area: A Series of 86 Patients
Peynet J 2 , Rafowicz A 1 , Lambert T 3 , d’Oiron R 4
1 CRTH du CHU du Kremlin-Bicêtre, 2 CTH du CH André
Mignot de Versailles, 3 CRTH du CHU du Kremlin-Bicêtre,
4 CRTH du CHU du Kremlin-Bicêtre, France
06P35
Experiences of Activated Prothrombin Complex Concentrate
for Prophylaxis in Three Hemophilia Patients with Inhibitors
Salcioglu Z, Akcay A, Sayilan Sen H, Aydogan G, Akici F,
Tugcu D
Clinics of Pediatric Hematology-Oncology, Ministry of Health,
Istanbul, Turkey
06P36
A More Effective Treatment Algorithm for Hemophilia
Patients in Countries with Less Access to Factor Concentrates
Seuser A 1 , Navarrete Duran M 2 , Auerswald G 3 , Wendel M 4 ,
Chaverri P 5
1 Kaiser-Karl-Klinik Bonn, Germany, 2 Childrens Hospital San
José, Costa Rica, 3 Prof.-Hess Childrens Hospital Bremen,
Germany, 4 Institut für Bewegungsanalyse Bonn, Germany,
5 Hospital Mexico San José, Costa Rica
48
06P37
Surgery for Malignant Neoplasms in Hemophilia Patients
Szczepanik A, Windyga J, Misiak A, Stefanska-Windyga E,
Meissner A
Institute of Hematology and Transfusion Medicine, Warsaw,
Poland
06P38
Type of F8 Gene Mutation in Patients with Hemophilia A
Undergoing Prosthetic Surgery
Tagariello G, Sartori R, Tassinari C, Belvini D, Salviato R,
Radossi P
Haemophilia Center Transfusion and Haematology,
Castelfranco Veneto Haemophilia Centre, Italy
06P39
Association between Hemophilia and Inherited Throm -
bophilia: A Single Center Survey
Tagliaferri A 1 , Di Perna C 1 , Riccardi F 1 , Rivolta G 1 , Pattacini
C 1 , Franchini M 2
1 Regional Reference Centre for Inherited Bleeding Disorders
and 2 Immunohematology and Transfusion Centre, University
Hospital of Parma, Parma, Italy
06P40
Inter-Observer Reliability of Three Different Radiographic
Evaluation Systems for Hemophilic Arthropathy
Takedani H 1
, Fujii T2 , Kobayasi Y3 , Haga N4 Tatsunami S5 1Research Hospital of The Institute of Medical Science, The
University of Tokyo, 2Hiroshima University Hospital, 3Fukuoka Houeikai Hospital, 4The University of Tokyo, 5St. Marianna
University School of Medicine, Japan
06P41
Relationship between Hemarthrosis and Hemophilic
Arthropathy
Takedani H 1 , Fujii T 2 , Miura A 3 , Amano K 4 , Matumoto T 5 ,
Higasa S 6
1 Research Hospital of the Institute of Medical Science,
University of Tokyo, 2 Hiroshima University Hospital, 3 Nishitaga
National Hospital, 4 Tokyo Medical University Hospital, 5 Mie
University Hospital, 6 Hyogo College of Medicine, Japan
06P42
ADAMTS13 Levels may Influence the Clinical Expression of
Severe Hemophilia A
Teitel J 1 , Walker I 2 , Harrington A 1 , Almonte T 2 , Jiang D 1 , Lau H 1
1 University of Toronto, 2 McMaster University, ON, Canada
06P43
A New Bleeding Score for a Quantitative Assessment of
Bleeding in Hemorrhagic Disorders
Delahaye M, Trossaert M, Billon M, Lefrancios A, Sigaud M,
Fouassier M
Haemophilia Center, University Hospital, Nantes, France

Index of Poster Presenters cont’d
06P44
Morphine Consumption Post-Arthroplasty in Patients with
Severe Hemophilia: Is the Peripheral Nerve Block Still
Contraindicated?
Desdoits A1 , Trossaërt M2 , Lejus C1 1Anaesthesiology-Reanimation, University Hospital Hôtel-
Dieu and Hôpital Mère-Enfant., Nantes, France, 2Hemophilia Center, University Hospital, Nantes, France
06P45
Assessment of Response to Intra Articular Rifampicin into
14 Target Knee Joints in Adolescents
Vidyatilake H1 , Yogananda P2 1 2 Lady Ridgeway Children’s Hospital, Faculty of Medicine,
University of Colombo, Sri Lanka
06P46
A Multi-Centre, Multi-National, Open-Label Sequential Trial
Comparing Pharmacokinetics and Safety of a New
Recombinant FVIII Compound (N8) and Advate ® in Patients
with Hemophilia A
Martinowitz U1 , Viuff D2 , Santagostino E3 , Brand B4 , Klamroth
R5 , Morfini M6 , Misgav M1 , Tiede A7 , Bjerre J2 1Institute of Thrombosis and Hemostasis, Sheba Medical
Center, Tel Hashomer, Israel, 2Medical and Science,
Haemophilia, Novo Nordisk, Soeborg, Denmark,
3Department of Internal Medicine and Medical Specialties,
Angelo Bianchi Bonomi Hemophilia and Thrombosis Center,
IRCCS Maggiore Hospital Foundation and University of Milan,
Milan, Italy, 4Dept. of Internal Medicine, Division of
Haematology, Zurich, Switzerland, 5Vivantes Klinikum im
Friedrichshain, Klinik für Innere Medizin – Angiologie und
Hämostaseologie, Berlin, Germany, 6Az Osp Careggi Centro
Emofilici, Firenze, Italy, 7Hannover Medical School, Dept.
Haematology, Haemostasis, Oncology and Stem Cell
Transplantation, Hannover, Germany
06P47
Comparison of a New Recombinant Factor VIII Product (N8)
and Advate ® in an International, Multi-Centre, Randomized
and Blinded Field Study of Simulated Post Infusion Samples
Viuff D1 , Barrowcliffe T, Ezban M, Saugstrup T, Lillicrap D
1Medical and Science, Haemophilia, Novo Nordisk A/S,
2 3 Soeborg, Denmark, Whitby, U.K., Pharmocology
Management, Novo Nordisk A/S, Maalev, Denmark, 4Medical and Science, Haemophilia, Novo Nordisk A/S, Soeborg,
Denmark, 5Dep. of Pathology and Molecular Medicine,
Richardson Laboratory Queens University, Kingston, ON,
Canada
06P48
A Case Presentation of an Unusual Intramural Small Bowel
Bleed in a Patient with Severe Hemophilia B
Ward J, Craig J, Kerr R
Ninewells Hospital & Medical School, Dundee, Angus, U.K.
06P49
Clinical Retrospective Analysis of 780 Patients in a Single
Hemophilia Center in China
Wu J, Li B, Ding K, Zheng C, Xu X
Anhui Provincial Hospital Affiliated of Anhui Medical
University, China
06P50
Hemophilic Pseudotumor in Chinese Patients: A
Retrospective Single-Center Analysis of 14 Cases
Yang R, Xue F, Sun C
Institute of Hematology and Blood Diseases Hospital,
Chinese Academy of Medical Sciences and Peking Union
Medical College, China
CLINICAL TRIALS AND POTENTIAL STUDIES
07P08
Continuous Infusion of Clotting Factor Concentrates: More
Inhibitor Generation?
Auerswald G, Bade A, Moorthi C, Overberg D
Prof.-Hess-Children´s Hospital, Bremen, Germany
07P09
The Hemophilia Inhibitor PUP Study (HIPS) – Design and
Methods
Brown D1 , Reipert B2 , and Santagostino E 3
1University of Texas Health Science Center-Houston and MD
Anderson Cancer Center, Houston, Texas, U.S.A., 2Baxter BioScience, Vienna, Austria, 3IRCCS Ca’ Granda Foundation,
Policlinico Maggiore Hospital, Milan, Italy
07P10
Reliability of Blinded and Unblinded Acquisition and
Interpretation of Ultrasound (US) for Assessment of
Hemophilic Knees and Ankles
Doria A1 , Keshava S2 , Man C1 , Mohanta A1 , Jarrin J1 ,
Gibikote S2 1The Hospital for Sick Children, Toronto, ON, Canada,
2Christian Medical College, Vellore, India
07P11
Long-term Clinical Safety of ADVATE [Antihemophilic Factor
(Recombinant), Plasma/Albumin-Free Method] among
Japanese Subjects: A Two-Year Update of the Post-
Authorization Safety Surveillance Program
Fukutake K1 , Hanabusa H2 , Taki M3 , Shima M4 , Shirahata A5 ,
Advate PASS study group6 1 2 Tokyo Medical University Hospital, Ogikubo Hospital, Tokyo,
3St. Marianna University School of Medicine Yokohama City
Seibu Hospital, Kanagawa, 4Nara Medical University, Nara,
5University of Environmental and Occupational Health Japan,
Fukuoka, and 6Baxter BioScience Japan, Medical Affairs
Clinical Trial, Tokyo, Japan
49
Posters, Sunday and Monday

Posters, Sunday and Monday
Index of Poster Presenters cont’d
07P12
Pharmacokinetic, Efficacy and Safety Data of the First
Recombinant Factor VIII from a Human Cell Line
Knaub S1 , Jansen M1 , Zozulya N2 , Plyushch O2 1 2 Octapharma AG, Hematology Scientific Center of Russian
Academy of Medical Science, Lachen, Russia
07P13
A Prospective, Randomized, and Crossover Study of an
Activated Prothrombin Complex Concentrate for Secondary
Prophylaxis in Patients with Hemophilia A and Inhibitors (Pro-
FEIBA): Subject Demographics and Safety Data
Leissinger C1 , Négrier C2 , Berntorp E3 , Windyga J4 , Serban
M5 , Bülent A6 , Lassila R7 , Kavakli K8 , Zulfikar B9 , Gringeri A10 1Louisiana Center For Bleeding And Clotting, Tulane
University Medical Center, Tulane, France 2Hemophilia Treatment Center, Hôpital Edouard Herriot, University Claude
Bernard, Lyon, France, 3Malmö University Hospital, Malmö
Centre for Thrombosis and Hemostasis, Malmö, Sweden,
4Institute of Hematology and Transfusion Medicine, Warsaw,
Poland, 5Emergency Clinic for Children, Timisoara, Romania,
6 7 Çukurova University, Adana, Turkey, Division of Coagulation
Disorders, Helsinki University Central Hospital, Helsinki,
Finland, 8University of Ege, Izmir, Turkey, 9Istanbul University,
10 Istanbul, Turkey, Bianchi Bonomi Hemophilia and
Thrombosis Center, University of Milan, Milan, Italy
07P14
Phase I, Randomized, Double-Blind, Placebo-Controlled,
Single-Dose Escalation Study of the rFVIIa Variant (BAY 86-
6150) in Hemophilia A or B with or without Inhibitors
Mahlangu J1 , Coetzee M2 , Laffan M3 , Windyga J4 , Yee T5 ,
Schroeder J6 1Hemophilia Comprehensive Care Center, Charlotte Maxeke
Johannesburg Academic Hospital And University Of The
Witwatersrand, 2Bloemfontein Haemophilia Treatment
Centre, University of the Free State, Bloemfontein, South
Africa, 3Imperial College, Hammersmith Hospital, London,
U.K., 4Institute of Hematology and Transfusion Medicine,
Warsaw, Poland, 5The Royal Free Hospital, London, U.K.,
6Bayer Schering Pharma AG, Berlin, Germany
07P15
Long-Term Clinical Safety of FEIBA, Activated Prothrombin
Complex Concentrate (APCC) in Japanese Inhibitor Subjects:
An Update of Post-Authorization Safety Surveillance (PASS)
Program
Midori S 1 , Kagehiro A2 , Ei K3 , Shinji M4 , Tadashi M5 , Satoshi
H6 , Teruhisa F7 , Michio S8 and the FINE study group9 1 2 Nara Medical University, Nara Tokyo Medical University
Hospital, 3Ogikubo Hospital, 4St. Marianna University School
of Medicine, Kanagawa, 5Nagoya University School of
Medicine, Aichi, 6Hyogo College of Medicine, Hyogo,
7 8 Hiroshima University Hospital, Hiroshima, University of
Environmental and Occupational Health Japan, Fukuoka,
and 9Baxter BioScience Japan, Medical Affairs Clinical Trial,
Tokyo, Japan
50
07P16
Long-Acting Glycopegylated Recombinant Activated Factor
VII (LA-rFVIIa) is Safe and Shows a Prolonged FVIIa Half-Life
after Single and Multiple Administrations in Hemophilia A
and B Patients, Making it Suitable for Development as
Prophylactic Treatment of Patients with Hemophilia and
Inhibitors
Møss J1 , Stenmo C1 , Jimenez-Yuste V2 , Bottcher S1 ,
Fernandez, I2 1 2 Novo Nordisk A/S, Denmark, Hospital Universitario La Paz,
Madrid, Spain
07P17
Efficacy, Safety and Immunogenicity of Wilate ® in Children
Under 6 Years of Age with Inherited von Willebrand Disease
Nowak-Goettl U1 , Kruempel A1 , Russo A2 , Jansen M3 , Knaub S4 1University Hospital, Westfälische Wilhelms-Universität,
Münster, Germany, 2University Hospital, Johannes Gutenberg-
3 Universität Mainz, Germany, Octapharma Produk -
tionsgesellschaft mbH, Vienna, Austria, 4Octapharma AG,
Lachen, Switzerland
07P18
Safety and Efficacy of B-Domain-Deleted Recombinant FVIII
– Final Results of a 10-Year Pharmacovigiliance Study
Westfeld M1 , Pollmann H2 for the ReFacto ® Phar -
macovigilance Data Monitoring Board
1Wyeth Pharma GmbH - ein Unternehmen der Pfizer-Gruppe,
2 Muenster, ITH - Institut für Thrombophilie und
Haemostaseologie, Bonn, Germany
07P19
Two-year Interim Results of a Non-Interventional Trial to
Assess the Safety and Efficacy of Treatment with
Recombinant Factor IX
Westfeld M1 , Pollmann H2 , Oldenburg J3 1Wyeth Pharma GmbH - ein Unternehmen der Pfizer-Gruppe,
2 Muenster, ITH - Institut für Thrombophilie und
Haemostaseologie, 3Universitaetsklinikum Bonn, Germany
07P20
Clinical Efficacy of a Novel VWF-Containing FVIII
Concentrate, Wilate ® , in the Prophylaxis and Treatment of
Bleeding Episodes in Previously Treated Hemophilia A
Patients
Klukowska A1 , Windyga J2 , Batorova A3 1Department of Pediatrics, Hematology and Oncology,
Medical University of Warsaw, Warszawa, Poland,
2Department of Hemostasis Disturbances and Internal
Diseases, Institute of Hematology and Transfusiology,
Warszawa, Poland, 3University Hospital Clinic Haematology
& Blood Transfusion, Bratislava, Slovak Republic

Index of Poster Presenters cont’d
07P21
Effectively Platform for Coagulation Recombinant Protein
Production by Transgenic Farm Mammals
Yang C, Chang Y
Animal Technology Institute Taiwan, Republic of China
07P22
Safety and Efficacy of Plasma/Albumin-Free Recombinant
Factor VIII for the Treatment of Previously Treated Patients
with Hemophilia A in China: A 6 Month Compassionate Use
Study
Yang R1 , Zhao Y, Sun J, Wang X, Yu M
1Department of Hematology, Institute of Hematology &
2 Blood Diseases Hospital, Tianjin, Department of
Hematology, Peking Union Medical College Hospital, Beijing,
3Department of Hematology, Nanfang Hospital, Guangzhou,
4Transfusion Department, Nanfang Hospital, Shanghai,
5Medical Affairs, Baxter China Investment Co Ltd, Beijing,
Republic of China
07P23
Intracranial Hemorrhage (ICH) in Hemophilia A and B: An
Italian Retrospective Survey
Zanon E1 , Rocino A2 , Santagostino E3 , Messina M4 , Pasca S5 ,
Valdrè E6 1 2 Clinica Medica II Azienda Ospedaliera Di Padova, Centro
Emofilia e Trombosi Ospedale S.Giovanni Bosco Napoli,
Centro Emofilia e Trombosi Bianchi Bonomi Ospedale
Maggiore Milano, 4Centro Emofilia Ospedale Infantile Regina
5 Margherita Torino, Centro Emofilia Istituto
ImmunoTrasfusionale Azienda Ospedaliera Maria della
Misericordia, 6UO Angiologia e Malattie Coagulazione
Bologna, Italy
07P24
Pharmacokinetics of a Recombinant Albumin-Fused, Human
Coagulation Factor VIIa (rVIIa-FP) Exhibiting Prolonged Serum
Half-Life in Different Animal Species
Zollner S, Weimer T, Schmidbauer S, Raquet E, Mueller-
Cohrs J, Schulte S
CSL Behring GmbH, Marburg, Germany
CLOTTING FACTOR CONCENTRATES
08P02
Evaluation of the Emergency Home Doses of Clotting Factor
Concentrates in Hemophilia Patients at Hemocentro de Belo
Horizonte
Barbosa A, Murao M, Cerqueira A, Junior M
Hemocentro de Belo Horizonte, Brazil
08P03
Octanate ® with 50% Volume-Reduced Formulation: Meeting
the Needs of Individual Patients
Belyanskaya L 1 , Putz M 2 , Gruber G 2 , Stadler M 2 , Gerlach B 3 ,
Martens A 3 , Khair K 4 , Walter O 1
1 Octapharma AG, Lachen, Switzerland, 2 Octapharma
Pharmazeutika Produktionsges .m.b.H, Vienna, Austria,
3 Octapharma GmbH, Langenfeld, Germany, 4 Great Ormond
Street Hospital for Children NHS Trust, London, U.K.
08P04
Evaluation of QoL in the Treatment of Hemophilia A Patients
with Inhibitors Before and After ITI Therapy with Octanate®
Vorobyev P1 , Borisenko O1 , Zozulya N2 , Zhulev Y3 , Telnova E4 ,
Tonoyan A4 1Russian Society for Pharmacoeconomics and Outcomes
Research, 2Hematological Scientific Center of Russian
Academy of Medical Sciences, 3Russian Hemophilia Society,
4Federal Service on Surveillance in Healthcare and Social
Development of Russian Federation, Russia
08P05
Comparable In-Vitro Potency and Efficacy of 40K PEG-rFIX
and BeneFIX® in TEG® in Hemophilia B Patient Blood
Christiansen M1 + 2 , Sorensen B1 , Viuff D1 , Ostergaard H1 ,
Segel S1 1 , Lethagen S + 2
1 2 Novo Nordisk A/S, Maaloev, Denmark, Copenhagen
University Hospital, Denmark
08P06
GlycoPEGylated Long Acting Factor VIIa and rFVIIa
(NOVOSEVEN®) Show Similar Efficacy in Blood from
Hemophilia A Patients Using Thromboelastography (TEG®)
Christiansen M1,2 , Sorensen B1 , Viuff D1 , Ezban M1 , Andersen
S1 1 , Lethagen S + 2
1 2 Novo Nordisk A/S, Maaloev, Denmark, Copenhagen
University Hospital, Denmark
08P07
Pharmacokinetics of OPTIVATE ® , A High Purity FVIII and
VWF Concentrate in VWD Patients
Dash C, Gillanders K, Akanezi C
Bio Products Laboratory, Elstree, U.K.
08P08
Suitability of High Purity Factor IX Concentrate (Replenine-
VF) for Administration by Continuous Infusion
Dash C, Feldman P, Waterhouse S, Gascoigne E
Bio Products Laboratory, Eltree, U.K.
51
Posters, Sunday and Monday

Posters, Sunday and Monday
Index of Poster Presenters cont’d
08P09
Same Prevalence but Low Response of Inhibitors in African
Hemophiliacs Receiving Low Quantity of Factor Concentrates
Saliou D, Aïssatou S, Moussa S, Bamar Guèye Y, Dièye T,
Oumar AT, Sall A, Thiam D, Diakhaté L
Service d’Hématologie, Université Cheikh Anta Diop, Dakar,
Sénégal
08P10
Functional Characterization of Recombinant GlycoPEGylated
FIX (40K PEG-rFIX) after Intravenous Administration to
Hemophilia B dogs (HB)
Ezban M1 , Hansen L1 , Hermit M1 , Tranholm M1 , Østergård
H1 , Nichols T2 1 2 Novo Nordisk A/S, Maaloev, Denmark University of North
Carolina, Chapel Hill, North Carolina, U.S.A.
08P11
Levels of Transforming Growth Factor- (Tgf- ) in Concentrates
of Factor VIII Manufactured in Unc-Hemoderivados
Farias F, Guglielmone H, Navarro D, Moya C and Vitali MS
Area de Desarrollo de Productos y Procesos, UNC-
Hemoderivados, Córdoba, Argentina
08P12
Restoration of Thrombin Generation in Factor XI-Deficient
Plasma Using a Factor XI Concentrate
Feldman P, Hardway C
Bio Products Laboratory, Elstree, U.K.
08P13
BERIATE®P in the Treatment of Patients with Hemophilia A:
Update of a Long-Term Pharmacovigilance
Klamroth R1 , Zimmermann R2 , Kurnik K3 , Holzhauer S4 ,
Geist M5 1 2 Vivantes Klinikum Berlin, Germany, Kurpfalzkrankenhaus
Heidelberg, Germany, 3Dr. v. Haunersches Childrens Hospital
Munich, Germany, 4University Hospital Charité Berlin,
Germany, 5CSL Behring, Germany
08P14
Update of a Long-Term Pharmacovigilance Project: Helixate®
NexGen for the Treatment of Hemophilia A
Oldenburg J1 , Petrini P2 , Santagostino E3 , Pabinger I4 ,
Geist M5 , Lenk H6 1 2 University Hospital Bonn, Germany, Karolinska Sjukhuset
Stockholm, Sweden, 3A. Bianchi Bonomi Haemophilia Center
Milan, Italy, 4University Hospital Vienna, Germany, 5CSL Behring GmbH, Germany, 6University Hospital Leipzig,
Germany
52
08P15
An Accurate and Routinely Adapted Enzyme-Linked
Immunosorbent Assay for Type 2N von Willebrand Disease
Diagnosis
Caron C 1 , Ternisien C 2 , Wolf M 3 , Fressinaud E 3 , Veyradier A 3 ,
Goudemand J 1 for the National Reference Centre on von
Willebrand disease (CRMW)
Hematology Department of 1 Lille, 2 Nantes, 3 Clamart, France
08P16
Prolonged Circulatory Half Life for rFVIIa After Conjugation
to Hydroxyethy1 Starch
Hey T and Hackett F
Fresenius Kabi Deutschland GmbH, HESylation® Technology,
Friedberg, Germany
08P17
Generation of Recombinant FVIII Purification Antibody of
N8
Hansen J, Bolt G, Kjærgaard K, Kristensen C, Steenstrup T
Novo Nordisk A/S
08P18
Concept and Structure Model of Factor IX Albumin Fusion
Proteins
Horn C1 , Steuber H2 , Metzner H1 , Kuo W1 , Weimer T1 , Schulte
S1 1 2 CSL Behring GmbH, Marburg, Germany, Institute of
Biochemistry, University of Lübeck, Germany
08P19
Concept and Structure Model of Factor VIIa Albumin Fusion
Proteins
Horn C1 , Steuber H2 , Weimer T1 , Wormsbächer W1 , Liebing
U1 , Kuo W1 1 2 CSL Behring GmbH, Marburg, Germany, Institute of
Biochemistry, University of Lübeck, Germany
08P20
Therapy by rFVIIa (Novoseven) in Patients with Hemophilia
A and Inhibitor: Factors Influencing Total Therapy
Effectiveness
Hulíková M 1
, Hulíková J1 , Brabec P2 1Center of Haemostasis and Thrombosis, Hemo Medika,
Košice, Slovakia, 2Institute of Biostatistics and Analyses,
Masaryk University, Brno, Czech Republic
08P21
Transforming Growth Factor Beta (TGF- 1) Content in
Octanate ® – Assessment and Methodological Issues
Kannicht C, Fisseau C, Fuchs B
Octapharma R&D, Molecular Biochemistry, Berlin, Germany

Index of Poster Presenters cont’d
08P22
An Ultrapure Plasma-Derived Monoclonal Antibody Purified
Factor IX Concentrate, Results of the Phase III and IV Clinical
Study
Mauser-Bunschoten E1 , Kleine Budde I2 , Lopaciuk S3 ,
Koopman MMW4 , van der Meer FJM5 , Novàkovà IRO6 , Ypma
P 7 , van der Linden PWG 8 , Strengers PFW2 1Van Creveldkliniek and Hematology, University Medical
Centre Utrecht, Utrecht, the Netherlands, 2Sanquin Blood
Supply Foundation, Amsterdam, the Netherlands, 3Institute of Hematology and Blood Transfusion, Warsaw, Poland,
4 5 Academisch Medisch Centrum, Amsterdam, Leiden
University Medical Centre, Leiden, 6University Medical Centre
St. Radboud, Nijmegen, 7HAGA Hospital, location Leyenburg,
Den Haag, 8Kennemer Hospital, location EG, Haarlem, the
Netherlands
08P23
Low Inhibitor Incidence in Previously Untreated Hemophilia
A Patients (PUPs) Treated with Octanate ®
Klukowska A1 , Laguna P1 , Komrska V2 , Jansen M3 1 2 Warsaw Medical University, Russia, FN Motol, Czech
Republic, 3Octapharma, Austria
08P24
In-Vitro Immunogenicity Studies of a New High Purity Factor
X Concentrate
Lloyd J, John E, Feldman P
Bio Products Laboratory, Elstree, U.K.
08P25
Purification of Blood Clotting Factor VII: Suitable for
Therapeutic Application
Madych S, Danysh T
Institute of Blood Pathology and Transfusion Medicine,
UAMS, Lviv, Ukraine
08P26
NovoSeven® for Surgery in Inherited FVII Deficiency: Data
from STER (Seven Treatment Evaluation Registry)
Mariani G1 , Batorova A2 , Ingerslev J3 , Auerswald G4 , Schved
J5 , Siragusa S6 1Internal Medicine & Hematology Unit, University of L’Aquila,
Italy, 2The National Haemophilia Centre, Institute of
Haematology and Blood Transfusion, University Hospital,
Bratislava, Slovakia, 3Centre for Haemophilia and Thrombosis,
Aarhus University Hospital, Skejby, Aarhus N Denmark,
4Department of Pediatrics, Central Hospital, Bremen,
5 Germany, Hemophilia & Thrombosis Centre CHU
Montpellier, France, 6Hematology, University of Palermo,
Italy
08P27
Efficacy and Safety of KOGENATE ® Bayer in Patients with
Hemophilia A During Surgical Procedures
Miesbach W, Krekeler S, Alesci S
University Hospital Frankfurt, Germany
08P28
Bioequivalence of B-Domain Deleted and Plasma Derived
FVIII Concentrates
Morfini M1 , Iorio A2 , Mazzucconi M3 , Cinotti S1 , Zanon E4 ,
Paladino E1 1 2 Hemophilia Centre of Florence, University of Perugia,
3Hemophilia Centre of Rome- La Sapienza University,
4Hemophilia Centre of Padova, Italy
08P29
A Survey of FVIII Use in 19 European Countries
O’Mahony B
Irish Haemophilia Society, Dublin, Ireland
08P30
The Effect of Reduced Sampling Time Points in a Population
Pharmacokinetic Model of ADVATE in Pediatric and Adult
Patients with Hemophilia A
Oh M1 , Björkman S2 , Schroth P1 , Fritsch S1 , Collins PW3 ,
Fischer K4 , Blanchette VS5 , Casey K1 , Spotts GD1 , and
Ewenstein BM1 , for the rAHF-PFM Clinical Study Group
1 2 Baxter BioScience, Austria and US, Department of
Pharmaceutical Biosciences, Uppsala University, Uppsala,
Sweden, 3University Hospital of Wales, Cardiff, U.K., 4Van Creveldkliniek, University Medical Center, Utrecht, NL,
5Hospital for Sick Children, Toronto, ON, Canada
08P31
Effect of Different Monoclonal Anti-FVIII-Antibodies on the
Hemostatic Activity of Plasma-Derived and Recombinant
FVIII-Concentrates in Absence and Presence of VWF
Pillitteri D, Scholz T, Krause M, Kirchmaier C
German Diagnostic Clinic, Wiesbaden, Germany
08P32
Hemophilia Treatment in Serbia in 2009 – Quantity of
Products and Frequency of Therapy Complications
Rakic L, Mikovic D, Jankovic G, Kovac M, Maslac A
Blood Transfusion Institute of Serbia, Belgrade, Serbia
08P33
Product Characteristics of Human Cell Line Recombinant
Factor VIII, (Human-cl rhFVIII)
Sandberg H1 , Ramström M1 , Stenlund P1 , Kannicht C2 ,
Agerkvist I1 1 2 Octapharma AB, Stockholm, Sweden, Octapharma,
Molecular Biochemistry, Berlin, Germany
53
Posters, Sunday and Monday

Posters, Sunday and Monday
Index of Poster Presenters cont’d
08P34
Safety of Solvent Detergent Viral Inactivated Intermediate
Purity Factor VIII Concentrate
Shaw-Schwyzer R, Mbele B, Gillham A
Haemophilia Clinic, Department of Paediatrics, Charlotte
Maxeke Johannesburg Academic Hospital and University of
the Witwatersrand, Johannesburg, South Africa
08P35
Preservation of Activity and Prolonged Efficacy of rFVIII after
Site-Specific Modification with High Molecular Weight
Hydroxyethyl Starch
Sommer J1 , Sim D1 , Leong L1 , Hacket F2 , Subramanyam B1 ,
Haaning J1 1Bayer HealthCare Pharmaceuticals, Richmond, CA, U.S.A.,
2Fresenius Kabi Deutschland GmbH, Bad Homburg, Germany
08P36
Considerations on Long-Acting Coagulation Factors –
Exemplified With FVIIa
Stennicke H, Andersen H, Karpf D, Ezban M, Moess J,
Soerensen B
Novo Nordisk A/S, Maaloev, Denmark
08P37
Design of a Novel Long-Acting Recombinant Coagulation
Factor VIII
Stennicke H, Kjalke M, Moeller F, Johansen P, Oevlisen K,
Karpf D
Novo Nordisk A/S, Maaloev, Denmark
08P38
Preclinical Pharmacokinetic (PK) Evaluation of Glycopegylated
Long Acting rFVIII
Karpf DM, Kjalke M, Olsen EHN, Pelzer H, Jespersgaard C,
Thim L, Bjørn SE, Agersø H, Stennicke HR
Biopharmaceuticals Research Unit, Novo Nordisk A/S,
Maaloev, Denmark
08P39
Patients’ Difficulties with Transfer Devices Used for
Reconstitution of Factors VIII and IX
Vincent I1 , Clément R2 , Hosten B1 , Taburet A1 , Rothschild C2 ,
Lambert T1 1 2 CHU de Bicêtre-APHP, Hôpital Necker – APHP, France
08P40
BAY 81-8973 – A New Full-Length Recombinant FVIII
Product-Using Novel Manufacturing Technologies
Vogel JH, Huesslein A, Goudar C, Severs J, Garger S,
Bamberger T, Rastogi S, Liu S, Wang E, McDonald T
Bayer Healthcare, Berkeley, California, U.S.A.
54
08P41
Prolonged Serum Half-life of a Recombinant, Albumin-Fused,
Human Coagulation Factor IX (rIX-FP) in Different Animal
Species
Metzner H, Weimer T, Raquet E, Nolte WM, Pragst I, Zollner S,
CSL Behring GmbH, Marburg, Germany
08P42
Cost Effectiveness Analysis for Octanate ® in ITI in
Comparison to NovoSeven ® in the Treatment of Haemophilia
Patients with Inhibitors: Russian Experience
Zozulya N, Plyushch O
Haematological Scientific Center RAMS, Moscow, Russia
08P43
Immune Tolerance Induction with Octanate ® in Hemophilia
A Patients With Inhibitors and A Poor Prognosis: Progress
Report on an Ongoing Prospective Data Collection
Zozulya N1 , Plyushch O1 , Vdovin V 2 , Svirin P2 , Andreeva T3 ,
Benedik Dolnicar M4 , Severova T1 , Klimova N3 , Escuriola C5 ,
Kreuz W5 1Haematological Scientific Center RAMS, Moscow, Russia,
2 3 Izmailovskiy Children Hospital, Moscow, Russia, Saint-
Petersburg city hemophilia treatment center, Saint-
4 Petersburg, Russia, National Haemophilia Center,
Haematooncology Department, University Children’s
hospital, Ljubljana, Slovenia, 5Johann-Wolfgang-Goethe University Hospital, Frankfurt am Main, Germany
COAGULATION
09P03
Importance of Anti-Thrombin Binding in the Clearance of
FVIIa After Intravenous Administration to Hemophilia Patients
Agersø H1 , Pelzer H1 , Brophy D2 , Martin E2 , Ezban M1 1 2 Novo Nordisk A/S, Maaloev, Denmark, Virginia
Commonwealth University, Richmond, VA, U.S.A.
09P04
Characterization and Measurement of the Non-Proteolytical
Activation of rFXIII (rFXIIIa°)
Andersen M1 , Kristiansen G2 , Hørlyck L2 1Biopharmaceutical Research Unit, Novo Nordisk A/S,
Denmark, 2CMC Supply, Novo Nordisk A/S, Denmark
09P05
Conformational Changes of Recombinant FXIII upon Both
Proteolytic and Non-Proteolytic Activation Studied by HX-MS
Andersen M, Faber J
Biopharmaceutical Research Unit, Novo Nordisk A/S,
Denmark

Index of Poster Presenters cont’d
09P06
Prediction of Bleeding Tendencies in Hemophilia A Patients
on Prophylactic Treatment Using a Novel Reaction-Diffusion
Assay of Hemostasis
Balandina A, Kumskova M, Kopylov K, Karamzin S, Fadeeva
O, Panteleev M
National Research Center for Hematology, Moscow, Russia
09P07
Evaluation of Hemodyne HAS Parameters in a Patient with
Hemophilia A and An Inhibitor Who Has a Poor Clinical
Response to Standard Dose rFVIIa
Brophy D1 , Martin E1 , Carr M2 , Nolte M3 , Kuhn J3 , Ezban M4 1Virginia Commonwealth University Coagulation
Advancement Laboratory, Richmond, VA, U.S.A., 2Novo Nordisk, Inc., Princeton, NJ, U.S.A., 3Central Virginia Center
for Coagulation Disorders, Virginia Commonwealth University,
Richmond, VA, U.S.A., 4Novo Nordisk A/S, Malov, Denmark
09P08
Using Global Hemostasis Laboratory Parameters to Identify
rFVIIa Response
Brophy D1 , Martin E1 , Ezban M2 , Hedner U2 , Carr M3 , Barrett J4 1Virginia Commonwealth University Coagulation
Advancement Laboratory, Richmond, VA, U.S.A., 2Novo Nordisk A/S, Malov, Denmark, 3Novo Nordisk, Inc., Princeton,
NJ, U.S.A., 4Central Virginia Center for Coagulation Disorders,
Virginia Commonwealth University, Richmond, VA, U.S.A.
09P09
Inhibitor of Activated Protein C as an Adjuvant for Hemophilia
Treatment
Butenas S1 , Whelihan M1 , Brummel-Ziedins K1 , Rivard G2 ,
Mann K1 1University of Vermont, Dept. of Biochemistry, Burlington,
VT, U.S.A., 2Hospital St. Justine, Montreal, QC, Canada
09P10
Corn Trypsin Inhibitor (CTI) for Thrombin Generation (TG)
Assays: To Add or Not to Add
Chantarangkul V, Mancuso E, Lemma L, Clerici M,
Santagostino E, Tripodi A
A Bianchi Bonomi Hemophilia and Thrombosis Center, Milan,
Italy
09P11
Liver Transplantation with Mild Hemophilia A: Contribution
of the Rotary Thromboelastography
Desprez D1 , Faradji A2 , Cuby C3 , Mauvieux L1 , Grunebaum L1 1 2 Laboratory of Haematology, Regional Center for the
Treatment of Haemophilia, 3Department of Anesthesiology,
CHRU, Strasbourg, France
09P12
Pro-coagulant Activity of Laminaria Japonica Derived
Fucoidan (BAX513) Depends on the Interaction with the C-
Terminus of Tissue Factor Pathway Inhibitor
Palige M, Dockal M, Gerstenbauer G, Redl C, Knappe S,
Ehrlich H, Scheiflinger F,
Baxter Innovations GmbH, Orth Donau, Austria
09P13
Quantization of Changes in VWF and FVIII Following Elective
Orthopedic and Coronary Artery Bypass Graft Surgery in
Normal Individuals
Kahlon A1 , Grabell J1 , Tuttle A1 , Engen D2 , Hopman W3 ,
Lillicrap D4 , James P1 1Medicine, Kingston General Hospital, Kingston, ON, Canada,
2Anesthesiology, Kingston General Hospital, Kingston, ON,
Canada, 3Community Health and Epidemiology, Kingston
General Hospital, Kingston, ON, Canada, 4Pathology and
Molecular Medicine, Queen’s University, Kingston, ON,
Canada
09P14
Combination of Recombinant Factor VIIa and Fibrinogen
Corrects the Coagulopathy of Idiopathic Thrombocytopenic
Purpura
Larsen OH1 , Stentoft J2 , Ingerslev J1 , Sørensen B1,3 1Centre for Haemophilia and Thrombosis, Aarhus University
Hospital, Skejby, Denmark, 2Department of Haematology,
Aarhus University Hospital, Aarhus, Denmark, 3Haemostasis Research Unit, St Thomas’ Hospital, London, United Kingdom
09P15
Discrepancy between One-Stage and Two-Stage Factor VIII
Assays in Hemophilia A Patient: Molecular Genetic
Background
Pavlova A, Delev D, Brondke H, Vidovic N, Niemann B,
Oldenburg J
Institute for Experimental Haematology and Transfusion
Medicine, Bonn, Germany
09P16
Measurement of Factor VIII – von Willebrand Factor Complex
(FVIII – VWF) by Using Enzyme Immunoassay (EIA) Techniques
Pelzer H, Hilden I
Novo Nordisk, Maaloev, Denmark
09P17
Guidance for the Use of Different APTT Reagents on
Warfarinised Patients
Pickering W, Brooks S, Chowdary P, Riddell A
Katherine Dormandy Haemophilia and Thrombosis Unit,
Hampstead, U.K.
55
Posters, Sunday and Monday

Posters, Sunday and Monday
Index of Poster Presenters cont’d
09P18
A Novel Factor Xa Variant for Treatment of Bleeding
Disorders
Pittman D1 , Shields K1 , Rose-Miranda R1 , Losey H1 , Erbe D1 ,
Ivanciu L2 1Biocorrection Research Unit, BioTherapetics Research &
Development, Pfizer,Cambridge, MA, USA, 2The University
of Pennsylvania and The Children’s Hospital of Philadelphia,
PA, U.S.A.
09P19
Comparative Study of the Quality of Fresh Frozen Plasma
Obtained by Plasmapheresis and by Traditional Methods
Reutemann E, Molinas M, Ahumada A, Canavesio L
1Laboratorio De Hemoderivados Presidente Illia, Universidad
Nacional De Córdoba, Argentina
09P20
Influence of the Pre-Analytical Specimen Storage Conditions
on Thrombin Generation Assay
Salvagno G1 , Astermark J2 , Franchini M3 , Guidi G1 , Lippi G3 ,
Berntorp E2 1 2 Verona University Hospital, Verona, Italy, Malmö University
Hospital, Malmö, Sweden, 3Azienda Ospedaliera di Parma,
Parma, Italy
09P21
Congenital Bleeding Disorders in Karachi & Region
Shamsi T, Borhany M, Naz A, Mirza I, Parveen K, Khan A
National Institute of Blood Disease and Bone Marrow
Transplantation, Pakistan, Karachi, Pakistan
09P22
Characterisation of N8 - a New Recombinant Factor VIII
(rFVIII)
Vandahl B, Pedersen J, Klausen N, Gruhler A, Kjalke M, Thim L
Novo Nordisk A/S, Maaloev, Denmark
DATABASES AND REGISTRIES
10P02
The Development of the “Hemovida Web – Coagulopatias”:
A National Web-Based Database on Hereditary Bleeding
Disorders in Brazil
Barca D1 , Daisson T1 , Rezende S2 , Simões B1 , Genovez G1 1Coordenação Geral de Sangue e Hemoderivados, Ministério
da Saúde, 2Universidade Federal De Minas Gerais, Belo
Horizonte, Brazil
10P03
The International Factor IX Treatment Network Survey
Berntorp E1 , Waters J2 , Astermark J1 , Donfield S2 , Shapiro A3 1Centre for Thrombosis and Haemostasis, Malmö University
Hospital, Sweden, Lund University, Sweden, 2Rho, Inc.,
3Indiana Hemophilia and Thrombosis Center, Inc.,
Indianapolis, IN, U.S.A.
56
10P04
WFH: Annual Global Survey
Brooker M
World Federation of Hemophilia, Montreal, QC, Canada
10P05
Genetic Epidemiological, Demographic, Clinical, and
Biochemical Characterization of Hemophilia in Cuba: First
Report
D Castillo1 , Lardoeyt R2 , Almagro D1 , Gutiérrez A1 , Lam R1 ,
Lavout K 1 , Agramonte O1 , Campos M 4 , M Tejeda 1 , Guerra
T 5 , Navia A3 , Zamora Y1 1Institute of Hematology and Immunology, Havana City,
2 3 Center of National Genetics, Eliseo Camaño Children
Hospital of Matanzas, 4Pepe Portilla Children Hospital of
Pinar del Río, 5Gustavo Aldereguía Clinical–Surgical Hospital
of Cienfuegos, Cuba
10P06
FranceCoag Network: A National Multicenter Prospective
Cohort for Congenital Bleeding Disorders
Chambost H1 , Demiguel V2 , Gautier P3 , Gay V4 , Négrier C5 ,
Suzan F2 1Hemophilia Centre, Children Hospital La Timone, Marseille,
2 3 French Institute for Public Health Surveillance, Hemophilia
Centre, Caen, 4Hemophilia Centre, Chambéry, 5Hemophilia Centre, Lyon, France
10P07
Screening of Hemophilia in Algiers (Algeria)
Chennoukh K, Berkouk Y, Bensadok M, Zidani N,
Benmegherbi F, Belhani M
Department of Hematology and Blood Banking, University
Hospital of Beni Messous, Algiers, Algeria
10P08
A Data Collection Tool to Determine the Incidence of CVAD-
Related Infection in Hemophilia
Yeoh Z1,2 , Furmedge J1 , Ekert J1 , Barnes C1 1Henry Ekert Haemophilia Treatment Centre, Royal Children’s
Hospital, 2Melbourne Medical School, University of
Melbourne, Australia
10P09
New Data from the ONE Registry
Chambost H1 , Kavakli K2 , Laffan M3 , Oldenburg J4 ,
Santagostino E5 1Haemophilia Center, Children Hospital La Timone, Marseille,
France, 2Department of Pediatric Hematology, Izmir, Turkey,
3Imperial College London, Hammersmith Hospital, London,
U.K., 4University Clinic Bonn, Germany, 5IRCCS Maggiore
Hospital, Milan, Italy

Index of Poster Presenters cont’d
10P10
Using a Registry to Monitor Inhibitor Development in
Hemophilia: First Results of EUHASS
Fischer K1 , Makris M2 , Calizzani G3 , Hay CRM4 , Ludlam CA5 ,
Lambert T6 , Lassila R7 , Mannucci PM8 on behalf of the
EUHASS participants
1 2 University Medical Centre Utrecht, the Netherlands, Royal
Hallamshire Hospital, Sheffield, U.K., 3Centro Nazionale
Sangue, Rome, Italy, 4Manchester Royal Infirmary, U.K., 5Royal Infirmary of Edinburgh, U.K., 6Hopital Bicetre, Paris, France,
7 8 Helsinki University Central Hospital, Finland, Angelo Bianchi
Bonomi Haemophilia and Thrombosis Centre, Milan, Italy
10P11
Transition to a Web Based Architecture of the Italian
Hemophilia Registry Network
Oliovecchio E1 , Marchesini E1 , Matino D1 , Contino L2 , Alatri
A3 , Carloni M4 1 2 Hemophilia Centre, University of Perugia, Hemophilia
Centre, Torino, 3Hemophilia Centre, Cremona, 4Hemophilia Centre, Macerata, 5Hemophilia Centre, Sassari, 6Hemophilia Centre, Vallo della Lucania, Italy
10P12
Hemophilia in Central and Western Europe: A Comparison
O’Mahony B, Noone D
Irish Haemophilia Society, Dublin, Ireland
10P13
The European Network of Rare Bleeding Disorders (EN-RBD)
Project: The Bleeding Score (BS)
Peyvandi F1 ,Menegatti M1 , Palla R1 , Siboni SM1 , Bidlingmaier
C2 , Özdemir N3 , Kitanovski L4 , Peerlink K5 , Pergantou H6 ,
Ingerslev I7 , Giangrande P8 1A. Bianchi Bonomi Hemophilia and Thrombosis Center,
Fondazione IRCCS Ca’ Granda, Ospedale Maggiore
Policlinico, Università degli Studi di Milano and Luigi Villa
Foundation, Milan, Italy, 2Pediatric Hemophilia and
Thrombosis Centre, Dr. von Hauner‘s Children‘s University
Hospital, Munich, Germany, 3Department of Pediatric
Hematology-Oncology, Cerrahpasa Medical Faculty of
Istanbul University, Istanbul, Turkey, 4National Haemophilia
Center, University Children’s Hospital, Ljubljana, Slovenia,
5Hemofilie Centrum Leuven, Katholieke Universiteit, Leuven,
Belgium, 6Haemophillia Center, Haemostasis Unit, Agia Sofia
Children’s Hospital, Athens, Greece, 7Centre for Hemophilia
and Thrombosis, Dept of Clinical Biochemistry, University
Hospital Skejbi, Aarhus, Denmark, 8Oxford Haemophilia &
Thrombosis Centre, Nuffield Department of Clinical
Medicine, University of Oxford, U.K.
10P14
Genetic Analysis in a Large Cohort of Hemophilia A Patients:
A Useful Tool in the “Emilia-Romagna Regional Registry”
(Italy)
Riccardi F 1 , Rivolta G 1 , Martorana D 2 , Di Perna C 1 , Neri T 2 ,
Tagliaferri A 1
1 Regional Reference Center for Inherited Bleeding Disorders,
2 Molecular Genetics Unit, Parma, Italy
10P15
Australian Bleeding Disorders Registry
Rowell J1 , Caris S2 , Gunn S3 , Hogan C3 1 2 Royal Brisbane and Women’s Hospital, Haemophilia
Foundation Australia, 3National Blood Authority, Australia
10P16
National Registry of Hemophilia and Other Bleeding
Disorders in Syria
Ali T1 , Schved JF2 1Immune-Hematology and Blood Transfusion Unit, Division
of Hematology, Department of Laboratory, Faculty of
Medicine, Damascus University, and Syrian Hemophilia
Society, Syria, 2Montpellier Treatment Centre of Hemophilia,
Central Laboratory of Hematology, University Hospital,
Montpellier University, France
10P17
The Profile of Hemophilia and Other Hereditary Bleeding
Disorders in Brazil: First Report from “Hemovida Web –
Coagulopatias”, A National Web-Based Database
Simões B1 , Barca D1 , Rezende S2 , Daisson T1 , Genovez G1 1Coordenação Geral de Sangue e Hemoderivados, Ministério
da Saúde, 2Universidade Federal de Minas Gerais, Belo
Horizonte, Brazil
10P18
FranceCoag Network: A New Web Application is Available
Doncarli A1 , Demiguel V1 , Milien V1,2 , Bertrand M3 , Biron
Andreani C4 , Suzan F1 1Coordinating Centre of FranceCoag Network, French
Institute for Public Health Surveillance, Saint Maurice,
2Hemophilia Care Center - CHU Timone, Marseille,
3 4 Hemophilia Care Center - Besançon, Hemophilia Care
Center – Montpellier, France
10P19
Epidemiology of Hemophilia A and B in a Population from
Northeast Brazil
Vignal C1 , Seixas M1,2 , Streva A1 , Araujo L1 , Almeida D1 1HEMOBA - Foundation of Hematology and Hemotherapy of
Bahia, 2Research Center Gonçalo Moniz (CPqGM), Fiocruz,
Bahia, Brazil
57
Posters, Sunday and Monday

Posters, Sunday and Monday
Index of Poster Presenters cont’d
10P20
HemoRec Database – Registry of Inherited Bleeding
Disorders in Poland
Zawilska K1 , Zdziarska J2 , Chojnowski K3 , Klukowska A4 ,
Letowska M5 , Mital A6 , Podolak-Dawidziak M7 , Windyga J8 ,
Ovesna P9 , Brabec IP9 1Department of Internal Diseases and Hematology, J. Strus
Hospital, Karol Marcinkowski University of Medical Sciences,
Poznan, 2Department of Hematology, Jagiellonian University
School of Medicine, Cracow, 3Department of Hematology,
Medical University of Lodz, 4Department of Pediatrics,
Hematology and Oncology, Warsaw Medical University,
5Department of Diagnostics in Haematology and Transfusion
Medicine, Institute of Hematology and Blood Transfusion,
Warsaw, 6Department of Hematology and Transplantology,
Medical University of Gdansk, Poland, 7Department of Hematology, Blood Neoplasms and Bone Marrow
Transplantation, Wroclaw Medical University, Wroclaw,
8 Poland, Department of Hemostatic Disorders and
Internal Diseases, Institute of Hematology and
Blood Transfusion, Warsaw, Poland, 9Institute of Biostatistics
and Analyses, Masaryk University, Brno, Czech Republic
EDUCATION
12P03
Me and My Genes: Interactive Video for Teen Carriers
Stewart P, Curwin T, Cecchini C
Canadian Hemophilia Society, Montreal, QC, Canada
12P04
Education Package for Patients with Hemophilia and Family
Members at the International Training Center-Bangkok: An
Effective Model Using Limited Resources
Wongwerawattanakoon P1 , Chuansumrit A2 , Angchaisuksiri
P3 Sirachainan N2 Department of 1Nursing, 2Pediatrics, 3Medicine, Faculty of
Medicine, Ramathibodi Hospital, Mahidol University,
Bangkok, Thailand
12P05
Simple and Accurate Bedside Diagnostic Kit for Determining
Hemophilia A and B
Sasanakul W1 , Chuansumrit A1 , Kadegasem P1 , Chaiyaratana
W2 1 2 Department of Pediatrics,, Research Center, Faculty of
Medicine, Ramathibodi Hospital, Mahidol University,
Bangkok, Thailand
12P06
Emergency Preparedness in the Bleeding Disorders
Population
Crawford J and McAlister S
National Hemophilia Foundation Emergency Preparedness
Task Force, New York, NY, U.S.A.
58
12P07
Physical Activity in the Bleeding Disorders Population
Crawford J1 , McAlister S2 , Simmons G2 1National Hemophilia Foundation, New York, NY, U.S.A.,
2Centers for Disease Control and Prevention, Atlanta, GA,
U.S.A.
12P08
All About Hemophilia, A Guide for Families: Instructor’s
Manual for Health Professionals in Hemophilia Care
Decker K1,3 , Chan AKC1,2 , Seroski W1 , Bissonnette D3 , Floros
G3 , Lacasse L3 , Laudenbach L3 , Paradis E3 , Purcell S3 ,
Stain AM3 1Hamilton Health Science-McMaster Hospital, Hamilton, ON,
Canada, 2McMaster University, Hamilton, ON, Canada,
3Association of Nurses in Hemophilia Care (CANHC), Ontario
Region, ON, Canada
12P09
Results from a U.S. Spanish Language Education Survey
Felinczak S, Casas-Byots C, Felinczak S, Satterthwaite RL
Baxter Healthcare Corporation, Deerfield IL, U.S.A.
12P10
A Week-End Workshop for Hemophilia Care
Fribault A, Gruel Y, Fimbel B, Gélinard D, Gautier B,
Trossaert M
Fidel’hem
The Haemophilia Treatment Centre, Tours, France
12P11
The Fidel’Hem Educational Document
Fribault A, Gautier B, Guillon P, Makhloufi M, Bornancin N,
Roucoulet C
Fidel’Hem, Tours, France
12P12
The Change and Importance of Information through a Journal
for Hemophiliacs
Kinoshita M, Kushida K, Tomotsugu A
Bayer Yakuhin, Ltd., Japan
12P13
LINX©: An Educational Project for Children, Parents, and
Caregivers in Order to Optimize the Care of Hemophilia
Leenders L, Ferster A, Lê P
Hôpital Universitaire Reine Fabiola Bruxelles, Belgium
12P14
Capacity is the Tool: A National Project of Integrated
Management of Hemophilia in Panama, Educational Project
Moreno B and Villalaz L
Hospital del Niño, Panama City, Panama

Index of Poster Presenters cont’d
12P15
Developing Educational Materials for Other Bleeding
Disorders
Myles, E and the members of the von Willebrand and Rare
Bleeding Disorders Committee
World Federation of Hemophilia, Montreal, Canada
12P16
Hemophilia: The Importance of Diversification of
Communication Tools as Facilitating Agents in the Learning
Process of Hemophilia Patients and Carers
Souza C, Pinto M, Concellos L
1Centro dos Hemofilicos do Estado de Sao Paulo, Brazil
12P17
An Effective Coping Strategy to Face Stress in Children
affected by Hemophilia: Education and Training of Parents
Torres Ortuño AI, Cid Sabatel R, Nieto Munuera J, Moreno
Moreno M
Asociación Regional Murciana De Hemofilia, Murcia, Spain
12P18
Impact of Educational Programmes on Hemophiliacs and
Their Families in Pakistan: A Model for Developing Countries
Zafar T1,2 , Ehsan Y2 , Ikram N2,3 , Ahmad Z4 , Nazli F4 1 2 Islamabad Medical & Dental College, Haemophilia Patients
Welfare Society, Islamabad, 3Rawalpindi Medical College,
Rawalpindi, 4Pakistan Institute of Medical Sciences,
Islamabad, Pakistan
GENERAL
13P02
Assessment of Treatment and Health Outcomes among the
Severe Hemophilia A Population in Argentina Today
Bordone R1 , Epstein J2 , Xiong Y2 , Li-McLeod J2 1Centro dr Tratamiento Hemofilia Cordoba, Argentina,
2Baxter BioScience, Westlake Village, CA, U.S.A.
13P03
Comparison of Hemophilia Care and Outcomes Between
Countries
Giangrande P1 , Blanchette V2 , Collins P3 , Epstein J4 ,
Xiong Y4 , Li-McLeod J4 1 2 Churchill Hospital, Oxford, U.K., Hospital for Sick Children,
Toronto, ON, Canada, 3University Hospital of Wales, Cardiff,
U.K., 4Baxter BioScience, Westlake Village, CA, U.S.A.
13P04
Association of Acquired Factor X Deficiency and Severe
Mitral Stenosis: Success of Minimal Surgery
Kaci Z, Zidouni T, Belhani M, Berkouk Y, Chenoukh K
Isaad Hassani, Beni Messous, UH, Algers, Algeria
13P05
A Consensus Statement on Key Global Issues Relating to
Blood and Plasma
O’Mahony B 1 , Turner A
1 Irish Haemophilia Society, Dublin, Ireland, 2 National Blood
Authority, Australia
HEALTH ECONOMICS
14P02
Expected Value of Information of Future Hemophilia Trials
Abrahamyan L1, 3 , Blanchette V1, 5,6 , Willan A1, 4 , Beyene
J1, 3, 4 , Feldman B1,2,3,4 1Child Health Evaluative Sciences, RI, The Hospital for Sick
2 Children, Departments of Paediatrics, Division of
Rheumatology, The Hospital for Sick Children, 3Department of Health Policy Management & Evaluation, University of
Toronto, 4Dalla Lana School of Public Health, University of
5 Toronto, 5Departments of Paediatrics, Division of
Hematology/Oncology, The Hospital for Sick Children, 6on behalf of the Canadian Dose-Escalation Primary Prophylaxis
(CHPS) Study, Toronto, ON, Canada
14P03
Alternative Methods to Raise Funds for Programs in a
Hemophilia Center
Amaral J1 , Pereira R1 , Okazaki E2 , Cassis F2 , Villaça P2 ,
D’Amico E2 1Fundação Verzolini - Escola Politécnica- University of São
Paulo, 2Hospital Das Clinicas - Universidade De Sao Paulo,
Brazil
14P04
Differences in Annual Factor VIII Utilization by Patient and
Treatment Characteristics
Epstein J, Xiong Y, Li-McLeod J, Spotts G
Baxter BioScience, Westlake Village, CA, U.S.A.
14P05
Facts and Future Plans for Hemophilia in Iraqi Kurdistan
Khudair A, Asaad S
Hawler Medical University, Erbil, Iraq
14P06
Impact of Faster Bleeding Resolution on Health-Related
Quality of Life (HRQoL) and Quality Adjusted Life Years
(QALYs) in Hemophilia Patients with Inhibitors
Kowal S1 , Munakata J1 , Weatherall J2 , and Lee WC1 1 2 IMS Health, Falls Church, VA, U.S.A., Novo Nordisk A/S,
Søborg, Denmark
59
Posters, Sunday and Monday

Posters, Sunday and Monday
Index of Poster Presenters cont’d
14P07
Risk Sharing: Cost Comparison of Activated Prothrombin
Complex Concentrate (APCC) and Recombinant Factor VIIa
(rFVIIa) for Hemophilia Patients with Inhibitors Undergoing
Major Orthopaedic Surgeries
Bonnet P, Epstein J, Li-McLeod J
Medical Outcomes Research and Economics, Baxter
BioScience, Westlake Village, CA, U.S.A.
14P08
Patient and Caregiver Preferences for Hemophilia A
Treatments
Mohamed A1 , Johnson F1 , Epstein J2 , Li-McLeod J2 1RTI Health Solutions, Research Triangle Park, NC, U.S.A.,
2Baxter BioScience, Westlake Village, CA, U.S.A.
14P09
Healthcare Resource Utilization among Hemophilia A Patients
with Inhibitor Status in the U.S.
Tarantino M2 , Pipe S3 , Ye X4 , Xiong Y4 , Luo M4 , Valentino L1 1Rush University Medical Center, Chicago, IL, U.S.A.,
2University of Illinois, College of Medicine-Peoria, Peoria, IL,
U.S.A., 3University of Michigan, Ann Arbor, MI, U.S.A., 4Baxter Bioscience, Deerfield, IL, U.S.A.
14P10
Stability and Predictability of Treatment Cost among Non-
Inhibitor Hemophilia Patients in the U.S.
Pipe S1 , Tarantino M2 , Valentino L3 , Ye X4 , Xiong Y4 , Luo M4 1 2 University of Michigan, Ann Arbor, MI, University of Illinois
College of Medicine-Peoria, Peoria, IL, 3Rush University
Medical Center, Chicago, IL, Baxter Bioscience, Deerfield,
IL, U.S.A.
14P11
Cost-Effectiveness Analysis of Primary Prophylaxis Versus
On-Demand Treatment for Individuals with Severe
Hemophilia Based on the Joint Outcome Study
Matthew P1 , Boer R2 , Lalla A3 , Preblick R4 , Pocoski J5 1 2 University of New Mexico, New Mexico, U.S.A., Cerner
LifeSciences, California, U.S.A., 3Cerner LifeSciences,
California, U.S.A., 4Bayer Healthcare Pharmaceuticals, New
Jersey, U.S.A., 5Bayer Healthcare Pharmaceuticals, New
Jersey, U.S.A.
14P12
The Evolution Between 2001 and 2010 in the Costs of
Resolving a Mild to Moderate Bleeding Episode with pdaPCC
versus rFVIIa in the U.K. when Initiated Outside
Hospital
Riley P, Ashley D
Novo Nordisk Limited, Crawley, U.K.
60
14P13
Economic Comparison of Recombinant Activated Factor VII
Versus Plasma-Derived Activated Prothrombin Complex
Concentrate Using the Hemophilia Registries of the Czech
Republic
Salaj P 1 , Penka M 2 , Smejkal P 2 , Geierova V 1 , Ovesna P 3 ,
Dusek L 3
1 Institute of Haematology and Blood Transfusion,
2 Department of Clinical Hematology at Faculty Hospital Brno,
3 Institute of Biostatistics and Analyses at Masaryk University
in Brno, Prague, Czech Republic
14P14
Medical Cost Savings Associated with a Reduced Need for
Re-Treatment and Fewer Infusions Required per Bleed in the
Management of On-Demand Bleeds in Hemophilia Patients
with Inhibitors
Kowal S, Munakata J, Weatherall J1 , Lee W
1 2 3 4 IMS Health, IMS Health, Novo Nordisk, IMS Health
1 2 IMS Health, Falls Church, VA, U.S.A., Novo Nordisk A/S,
Søborg, Denmark
14P15
The Economic Consequences of Ineffective In-Patient On-
Demand Treatment for Hemophilia with Inhibitors
Pokras SM1 , Weatherall J2 , Petrilla AA1 , Lee WC1 1 2 IMS Health, Falls Church, VA, U.S.A., Novo Nordisk A/S,
Søborg, Denmark
14P16
A Comparison of School and Employment vs. Functional
Ability: Hemophilia Patients in Peru and the U.S.A.
Zappa S1 , Anderson A2 , Loayza N3 , Kuebler E4 1Cook Children’s Medical Center, Fort Worth, TX U.S.A.,
2 3 Dallas Children’s, Dallas, TX U.S.A., Hospital Dos de Mayo,
Lima Peru, 4Gulf States Hemophilia & Thrombophilia Center,
Houston, TX U.S.A.
14P17
Health Care Utilization and Cost in Persons with Factor VIII
Deficiency: Results of the Hugs VA Study
Zhou Z-Y1 , Johnson K1 , Riske B2 , Ullman M3 , Baker J4 , Koerper
M5 , Forsberg A6 , Miller B7 , Shapiro A8 , Huszti H9 1 2 University of Southern California, CA, U.S.A., University of
Colorado Denver, CO, U.S.A., 3University of Texas Health
Science at Houston, TX, U.S.A., 4University of California, Los
Angeles, CA, U.S.A., 5University of California, San Francisco,
CA, U.S.A., 6New England Hemophilia Center, Worcester,
MA, U.S.A., 7Children’s Hospital Los Angeles/USC, Los
Angeles, CA, U.S.A., 8Indiana Hemophilia & Thrombosis
Center, Indianapolis, IN, U.S.A., 9Children’s Hospital Orange
County, CA, U.S.A.

Index of Poster Presenters cont’d
HEMOPHILIA PROGRAMS AND
ORGANIZATIONS
15P02
Transitioning to Adulthood with a Bleeding Disorder
Cecchini C1 , Purves E2 , Brownlow M1 1 2 Canadian Hemophilia Society, Montreal, QC, Canada, BC
Children’s Hospital, Vancouver, BC, Canada
15P03
The French Haemophilia Molecular Laboratory Network: Five
Years’ Experience
Costa C, Vinciguerra C
Laboratoire de Genetique Moleculaire, Creteil, France
15P04
An Individual Communication Strategy from a National
Hemophilia Society
Duffy A, Noone D
1Irish Haemophilia Society, Dublin, Ireland
15P05
Hemophilia in Morocco: Current State and Prospects
El Khorassani M, Kababri M, Hessissen L, Khattab M, Kili A
The Treatment Center of Hemophilia, Hematology and
Pediatric Oncology Unit, Hospital of Rabat, CHU, Morocco
15P06
Education and Integration of the Entire Family into
Programmes
Greene D
and Activities: The Irish Experience
Irish Haemophilia Society, Dublin, Ireland
15P07
Volunteering for All – The Power of Volunteering of Person
with Hemophilia
Hu C, Wu Y, Lo C
Hemophilia Association of Taiwan, Republic of China
15P08
A Review of Services and the Needs of the Bleeding Disorder
Community in New Zealand
Lauzon C
Haemophilia Foundation of New Zealand, Canterbury, New
Zealand
15P09
The Importance of the World Federation of Hemophilia’s
Centre Twinning Program for the Improvement of
Haemophilia Care in Serbia
Mikovic D, Rakic L, Jankovic G
Haemostasis Department and Haemophilia Centre, Blood
Transfusion Institute of Serbia, Belgrade, Serbia
15P10
Using Consumer Input to Develop Relevant Bleeding
Disorder Resources
O’Callaghan S, Caris S
Haemophilia Foundation Australia, Glen Iris, Victoria,
Australia
15P11
Combined Programme for the Global Care of People with
Hemophilia: A Desire of Collaboration and Shared
Responsibility
Parra R1 , Ragull O2 , Cabré P2 1 2 Haemophilia Unit Hospital Vall D’Hebron, and Catalan
Association of Haemophilia, Barcelona, Spain
15P12
An Evidence-Based Approach to Management of a Multi-
Chapter Nation Hemophilia Organization
Tabatabaey A1,2 , Seyed Mojtaba MB2 , Ghodousi MS2 ,
Karami S3 1 2 Iranian Hemophilia Society; Mashhad University of Medical
Sciences, 3Islamic Azad University of Mobarakeh, Iran
15P13
An Important Step in Comprehensive Care for Hemophilia
in China: Phase I NNFH-China Project
Wang XF1 , Ding QL1 , Zhao YQ2 , Yang RC3 , Wu JS4 , Sun J4 ,
Zhang XS5 , Chu YG1 Cai HY1 , Suanne B1 , Wang HL1 1 2 Shanghai Ruijin Hospital, Peking Union Medical College
Hospital, 3Tianjin Hematology Hospital, 4Anhui Provincial
Hospital, 5Shangdong Blood Center, Republic of China
15P14
Hemophilia Care China: A Giant Step in Development by a
First Phase China/Novo Nordisk Foundation Project
Wang X1 , Zhao Y2 , Yang R3 , Wu J4 , Sun J5 , Zhang X6 1 2 3 Shanghai Ruijin Hospital, Peking Union Hospital, China
Institute of Hematology and Blood Disease Hospital, 4Anhui 5 Provincial Hospital, Guangzhou Nanfang Hospital,
6Shandong Blood Center, Republic of China
15P15
Pakistan Bait-ul-Mal, HPWS Collaboration for Hemophila
Care: A Unique Social Welfare Partnership
Zafar T2 , Ehsan Y2 , Ikram N2,3,1 1Islamabad Medical & Dental College, Islamabad, Pakistan,
2Pakistan Haemophilia Patients Welfare Society, Islamabad,
Pakistan, 3Rawalpindi Medical College, Rawalpindi, Pakistan
61
Posters, Sunday and Monday

Posters, Sunday and Monday
Index of Poster Presenters cont’d
INFECTIOUS COMPLICATIONS
16P05
Detection of HCV Mixed-Genotype Infection in the
Hemophilic Population
Aloisi N, Bastón M, Bracco M, Ruibal B, Pérez Bianco R,
Baré P
Academia Nacional de Medicina, Buenos Aires, Argentina
16P06
Presence of HCV Mixed-Genotype Infection; Association
with HIV Coinfection
Baré P1 , Aloisi N1 , Bastón M1 , Corti M2 , de Tezanos Pinto
M1,2 , Pérez Bianco R1,2 1 2 Academia Nacional De Medicina, Fundación de la
Hemofilia, Buenos Aires, Argentina
16P07
In Vitro System to Study Interactions between Human
Immunodeficiency Virus (HIV) and Hepatitis C Virus (HCV)
Bastón M, Baré P, Coraglia A, Bracco M, Ruibal B
Academia Nacional de Medicina, Buenos Aires, Argentina
16P08
Beneficial Effect of Successful HCV Treatment in Patients
with Inherited Bleeding Disorders: Non-Invasive Assessment
of Fibrosis by Liver Stiffness Measurement
Fransen van de Putte D1 , Fischer K1,2 , de Knegt R3 ,
Posthouwer D4 , van Erpecum K5 , Mauser-Bunschoten E1 1 2 Van Creveldkliniek, University Medical Center Utrecht, Julius
Center for Health Sciences and Primary Care, University
Medical Center Utrecht, 3Department of Gastroenterology
and Hepatology, Erasmus Medical Center Rotterdam,
4Department of Internal Medicine, University Medical Center
Utrecht, 5Department of Gastroenterology and Hepatology,
University Medical Center Utrecht, the Netherlands
16P09
The Burden of HCV Treatment in Patients with Inherited
Bleeding Disorders
Fransen van de Putte D1 , Fischer K1,2 , Posthouwer D3 ,
Mauser-Bunschoten E1 1 2 Van Creveldkliniek, University Medical Center Utrecht, Julius
Center for Health Sciences and Primary Care, University
Medical Center Utrecht, 3Department of Internal Medicine,
University Medical Center Utrecht, the Netherlands
16P10
High Frequencies of Exposure to the Novel Human
Parvovirus, Parv4 in Hemophiliacs and Injecting Drug Users
Detected by a Serological Assay for Parv4 Antibodies
Gomperts E1 , Sharp C2 , Simmonds P2 , Donfield S3 , Lail A3 ,
Delwart E4 1 2 Childrens Hospital Los Angeles, CA, U.S.A., University of
Edinburgh, Scotland, U.K., 3Rho Inc, Chapel Hill, NC, U.S.A.
4University of California San Francisco, CA, U.S.A.
62
16P11
Intracranial Bleeding in HIV Positive Hemophilia Patients on
HAART
Mauser-Bunschoten E, Fransen van de Putte D, Roosendaal
G, Schutgens R, Fischer K
Van Creveldkliniek, University Medical Center Utrecht, the
Netherlands
16P12
Radiofrequency Ablation of Hepatocellular Carcinoma in 3
Patients with Hemophilia A
Seita I1 , Amano K1 , Otaki M1 , Yotsumoto M1 , Imai Y2 , Fukutake K1 1 2 Department of Laboratory Medicine, and Department of
Internal Medicine, Tokyo Medical University Hospital, Japan
16P13
FIBROSCAN ® : Non-Invasive Assessment of Chronic Hepatitis
C Associated Liver Disease in Bleeding Disorders
Kitson M1 , Roberts S1 , Kemp W1 , Iser D2 , Street A3 , Tran H3 1 2 Department of Gastroenterology, Infectious Diseases Unit,
3Ronald Sawers Haemophilia Centre, The Alfred Hospital,
Victoria, Australia
16P14
Perioperative Treatment of Plasmatic and Thrombocytopenic
Coagulation Disorders in Hemophilia B: Thrombocytopenia
due to Chronic Hepatitis C
Wolf H-H1 , Tcherkes A1 , Frühauf A1 , Oehme A2 , Zeh A3 1Clinic of Internal Medicine, Dept. of Oncology, Hematology
and Hemostaseology, 2Institute of Medical Microbiology, and
3Clinic for Orthopedics, University Hospital, Halle, Germany
16P15
Retrospective Review of HIV in Hemophilia Population
Alzahrani H, Shaheen M, Al-Rajhi A, Hussain F, AbuRiash M
King Faisal Specialist Hospital and Research Center, Riyadh,
Saudi Arabia
LABORATORY SCIENCES
18P19
Could Global Hemostatic Methods (ETP and OHP) be
Instrumental in the Individualization of Patients and Tailoring
Treatment of Hemophilia A?
Antovic J1 , Mikovic D2 , Holmström M3 , Soutari N1 , Elfvinge
P4 , Antovic A4 1Coagulation, Department of Molecular Medicine and
Surgery, Karolinska Institutet and Clinical Chemistry
Karolinska University Hospital, Stockholm, Sweden,
2Hemostasis Department and Hemophilia Center, Blood
Transfusion Institute, Belgrade, Serbia, 3Hematology Center
Karolinska, Coagulation Unit, Karolinska University Hospital,
Stockholm, Sweden, 4Department of Clinical Sciences,
Danderyd Hospital, Division of Medicine, Karolinska Institutet,
Stockholm, Sweden

Index of Poster Presenters cont’d
18P20
Antiphospholipid Antibodies in Patients with Inherited
Hemophilia – A Laboratory Rather Than Clinical Problem
Bulikova A1 , Smejkal P1,2 , Zavrelova J2 , Chlupova G21 ,
Matyskova M21 , Penka M1,2 1Medical Faculty Masaryk University Brno, Czech Republic,
2Department of Haematology, Faculty Hospital Brno, Czech
Rebublic
18P21
Mixing Studies: Use of Specific Factor-Deficient Plasma
Allows for Confirmation of a Single Factor Deficiency as the
Cause of an Elevated APTT
Moffat K1,2 , Chan A3 , Leonard B2 1Hamilton Regional Laboratory Medicine Program, Hamilton,
ON, Canada, 2Department of Medicine, McMaster University,
Hamilton, ON, Canada, 3Department of Pediatrics, McMaster
University, Hamilton, ON, Canada
18P22
International Survey of Laboratory Tests Used in the Diagnosis
and Evaluation of Hemophilia A
Chitlur M and Gomez K
Children’s Hospital of Michigan, Detroit Medical Center,
Detroit, MI, U.S.A. on behalf of GEHEP
18P23
The Use of the New ReFacto AF Laboratory Standard (RLS
AF) Allows Reliable Measurement of FVIII:C Levels in ReFacto
AF Mock Plasma Samples by a One-Stage Clotting Assay
Pouplard C1 , Aillaud M2 , Dreyfus M3 , Sobas F4 , Ternisien C5 ,
Dubanchet A6 , Caron C7 1 2 Dept hematology-hemostasis, CHU Tours, France, Dept
hematology-hemostasis, CHU Marseille, France, 3Dept hematology-hemostasis, Kremlin Bicêtre AP, Paris, France,
4 5 Dept hematology-hemostasis, CHU Lyon, France, Dept
hematology-hemostasis, CHU Nantes, France, 6Dept hematology-hemostasis, Pfizer, Paris La Défense, France,
7University Hospital, Lille, France
18P24
Recent Initiatives and Ongoing Activities in External Quality
Assurance for Bleeding Disorders
Favaloro E1 , Bonar R2 , Sioufi J2 , Marsden K3 1 2 ICPMR, Westmead Hospital, Westmead, Australia, RCPA
Hematology QAP, Northmead, Australia, 3Pathology, Royal
Hobart Hospital, Hobart, Australia
18P25
Anti-FVIII Inhibitor Levels Measured by One-Stage Assay or
Chromogenic Assay Show Significant Discrepancies that
Might Lead to Inappropriate Clinical Decisions
Gilles J, Grailly S, Peerlinck K, Jacquemin M, Saint-Remy J
CMVB, University of Leuven, Leuven, Belgium
18P26
Contribution of Natural Anticoagulant Factors in Modulating
the Phenotypic Heterogeneity of Chinese Hemophiliac
Patients
Hua B, Zhao Y, Luo T, Fan L, Li K
Peking Union Medical College Hospital, Beijing, China
18P27
Effect of Measuring FVIII Chromogenically in the Bethesda
Assay for FVIII Inhibitors
Kershaw G1 , Jayakodi D2 , Dunkley S1 1 2 Royal Prince Alfred Hospital, Sydney, Australia, University
of Peradeniya, Sri Lanka
18P28
Why Do FVIII Assay Results Vary So Much Between Different
Centres? Data On FVIII:C Assay Design as Used by U.K.
NEQAS BC Participants
Kitchen S, Jennings I, Kitchen D, Woods T, Walker I
U.K. NEQAS Blood Coagulation, Sheffield, U.K.
18P29
Thrombin Generation Test (TGT): Could It Be a Good Tool for
the Care of Severe Hemophilia A with Inhibitors?
Lê P, Filippin L, Demulder A
Hôpital Universitaire Reine Fabiola Bruxelles, Belgium
18P30
New Immunoassay for Hepatitis C Virus Antibody Detection
with More Sensitivity
Luna-Záizar H1 , Romero-Flores M, Contreras A
1 2 CUCEI, University of Guadalajara, Mexico, Colegio de QFB
al servicio de Jalisco, Mexico, 3Coordinación de Investigación
en Salud IMSS-Jalisco, Mexico
18P31
Expanding Care of Bleeding Disorders in Brazil: Improvement
of Hemostasis Diagnostic Laboratory
Montalvão S1 , Sternick G2 , Rezende S3 1Unidade de Hemofilia do Hemocentro da UNICAMP,
2Ministério da Saúde- Coordenação Geral de Sangue e
Hemoderivados-CGSH/DAE/SAS, 3Universidade Federal De
Minas Gerais
18P32
Epitope Mapping of Factor VIII Inhibitor Antibodies in Thai
Hemophilia Patients with Inhibitors
Pongtanakul B, Narkbunnam N, Mahasandana C
Division of Hematology and Oncology, and Department of
Pediatrics, Siriraj Hospital, Mahidol University, Bangkok,
Thailand
63
Posters, Sunday and Monday

Posters, Sunday and Monday
Index of Poster Presenters cont’d
18P33
Factor VIII Measurement Using One-Stage-Clotting Assay: A
Calibration Curve Has Not Got to Be Systematically Included
in Each Run
Toulon P, Lattes S, Appert-Flory A, Fischer F, Jambou D
CHU Cimiez, Hematologie Biologique, Nice, France
LIFE STAGES
19P05
Evolution and Achievements in Uruguay; Integral National
Health Care Program for Hemophilia and other
Coagulopathies
Boggia B1 , Segovia A2, Rodriguez I3, Viano L4, Aleman L5,
Silva S4
1Programa Nacional En La Atencion Integral De La Hemofilia
Y Otras Coagulopatias, 2PAIHEC, 3Administracion Servicios
de Salud del Estado, 4Sevicio Nacional de Sangre, 5Centro Hospitalario Pereira Rossell, Montevideo, Uruquay
19P06
Peer to Peer Mentoring Programs Designed for Specific Life
Stages
Crawford J, McAlister S, Simmons G
National Hemophilia Foundation, New York, NY, U.S.A.
19P07
Intracranial Hemorrhage in the First Two Years of Life in
Children with Hemophilia
Soucie J1 , Kulkarni R2 , Abshire T3 , DiMichele D4 , Evatt
B5 ,Geraghty S6 1Centers For Disease Control and Prevention, Atlanta, GA,
2 3 Michigan State University, East Lansing, MI, BloodCenter of
Wisconsin, Milwaukee, WI 4Weill Cornell Medical College,
New York, NY, 5Centers for Disease Control and Prevention,
Atlanta, GA (retired), 6University of Colorado at Denver, CO,
U.S.A.
NURSES ISSUES
22P05
Going Electronic - Updating the Competency Framework
for Nurses Caring for Patients with Haemophilia and Related
Disorders
Bedford M1 , Khair K2 , Lawrence K3 1 2 Canterbury Christ Church University, Canterbury, Great
Ormond Street Haemophilia Comprehensive Care
3 Centre,London, Cambridge Haemophilia Centre
Addenbrooke’s NHS Trust Cambridge, United Kingdom
64
22P06
Central Venous Access Devices (CVADs) and Infections in
Severe Hemophilia in Four French Centers: The Importance
of Good Practice and Therapeutic Education
Gautier B 1 , Youinou F 1 , Lezeau P 2 , Fribault A 3 , Makhloufi M 4 ,
Trossaërt M 1
1 Fidel’hem, Hemophilia Treatment Center, Nantes, France,
2 Hemophilia Treatment Center, Kremlin Bicetre, France,
3 Hemophilia Treatment Center, Tours, France, 4 Hemophilia
Treatment Center, Necker, Paris, France
22P07
Hemophilia Nurse Training in South Africa: An Eight Year
Reflection of Ongoing Education
Cruickshank A-L
University of Cape Town, Cape Town, South Africa
22P08
The New Role of Hemophilia Nurses in Home Treatment
Monitoring with the Electronic Patient Diary System
Haemoassist ®
Mondorf W, Dingeldein E, Mondorf C, Mahnel R
In Thera - Investigating Advances in Therapy/Haemostas
Frankfurt
22P09
Improving Integrated Care Between Hospital and Community
to Improve Hemophilia Services
Farrell A
Bristol Royal Hospital for Children, Bristol, United Kingdom
22P10
Is Your Tool Box Full? Identifying Gaps in Knowledge and
Educational Needs
Floros G, Crymble S, O’Neill J, Teitel J
1St. Michael’s Hospital, Toronto, ON, Canada
22P11
The Complexities and Advances in the Role of the
Hemophilia Nurse Specialist
Franklin E
Bristol Haemophilia Centre, Bristol, United Kingdom
22P12
‘Grandma’s Five’: A Simple Teaching Tool for Parents of a
Newly Diagnosed Child with a Bleeding Disorder
Frey MJ, Fleming P, Sabo C, Litch E, Merritt D, Sopfe M
Children’s Hospital of Michigan, Detroit, MI, U.S.A.
22P13
A Nurse-Led Telephone Clinic for Paediatric Patients with
Mild or Moderate Hemophilia and Related Bleeding
Disorders
Garside S
St James’ University Hospital, Leeds, United Kingdom

Index of Poster Presenters cont’d
22P14
The Nursing Management of a FVII Deficient Patient with
an Inhibitor
Garside S
St James University Hospital, Leeds, United Kingdom
22P15
Therapeutic Ventriloquist Helps Children with Hemophilia
to Infuse Themselves
Golan G, Bashari D, Hadasy D
National Hemophilia Center, Ramat Efal, Israel
22P16
FIDELHEM, The French Society of Nurses for Haemophilia,
von Willebrand Disease and Rare Bleeding Disorders Care
Guillon P1 , Fribault A2 , Roucoulet C3 , Maloukhfi M4 , The
FIDELHEM Society
1 2 Treatment Hemophilia Centre,Caen,France, Treatment
Hemophilia Centre, Tours, France, 3Treatment Hemophilia
Centre, Reims, France, 4Teatment Hemophilia Centre, Necker,
Paris, France
22P17
An Education Programme for Nursing Staff at Our Lady’s
Children’s Hospital Crumlin, Ireland, to Facilitate Care for
Children with Hereditary Coagulation Disorders
Kelly I, Kavanagh M, Brady B
Our Lady’s Childrens Hospital, Dublin, Ireland
22P18
Development of National Hemophilia Nursing Standards
Laudenbach L1,4 , Floros G2,4 , Lacasse L3,4 1Victoria Hospital, London Health Sciences Centre, London,
2 3 St. Michael’s Hospital, Toronto, Ottawa Hospital, Ottawa,
4Canadian Association of Nurses in Hemophilia Care, Ottawa,
ON, Canada
22P19
Improving the Quality of Life of Hemophilia Patients
Osorio A1 , Gutierrez B2 1 2 Tabasqueña de Hemofilia A.C., Hospital Dr. Gustavo
Rovirosa, Tabasqueña, Mexico
22P20
Von Willebrand in Nunavik: A Resource Binder Created with
Our Partners
Sabourin C, Warner M
Montreal Children’s Hospital Congenital Hemostasis Services,
McGill University Health Centre, Montreal, QC, Canada
22P21
The Challenges of Nursing Hemophilia Patients in Elective
Orthopaedic Surgery with Inhibitors
Short L, McGowan-Smyth K
Churchill Hospital, Oxford, United Kingdom
22P22
The Development of a ‘Hemophilia Quick Reference Guide’
for Pediatricians and General Practitioners Treating
Childhood Hemophilia
Stain A 1 , Purves E 2 , Wu J 2 , Carcao M 3
1 Department of Nursing, The Hospital For Sick Children,
Toronto, ON, 2 Division of Hematology/ Oncology, and
3 Division of Hematology/Oncology, B.C. Children’s Hospital,
Vancouver, BC, 4 Division of Haematology/Oncology, The
Hospital for Sick Children, Toronto, ON, Canada
22P23
Development of a Structured Education Program for Parents
Learning How to Access Their Child’s Infusaport When the
Hemophilia Treatment Centre has a Very Small Population
Starosta H, Daly J, Fenton E
Royal Hobart Hospital, Tasmania, Australia
22P24
Review of a Nurse-Led Hemophilia Genetics Clinic
Westoby A, Falconer C
St James’s Hospital, Leeds, United Kingdom
PLATELET DISORDERS
28P05
Pattern of Bleeding and Response to Therapy in Glanzmann
Thrombasthenia
Borhany M, Pahore Z, Shamsi T, Taj M, Ansari S, Farzana T
National Institute of Blood Disease and Bone Marrow
Transplantation, Karachi, Pakistan
28P06
A Homozygous Missense Mutation in GPIIb Exon 6 and a
Homozygous Frame Shift Mutation in GPIIIa Exon 9 Causing
Glanzmann Thrombasthenia
Pillitteri D, Pilgrimm A, Scholz T, Krause M, Kirchmaier C
28P07
Glanzmann Thrombasthenia Registry (GTR): A Tool for the
Development of Consensus Guidelines for the Management
of Glanzmann’s Thrombasthenia (GT)
Poon M1 , d’Oiron R2 , Zotz R3 , di Minno G4 1University of Calgary, Foothills Hospital, Calgary, AB,
Canada, 2AP-HP, University Paris XI - Hôpital Bicêtre, Le
Kremlin Bicêtre, France, 3Hemostasis Institute, Düsseldorf,
Germany, 4Federico II University, Naples, Italy
28P08
Glanzmann Thrombasthenia: A Single Centre Result
Salcioglu Z1 , Sayilan Sen H1 , Aydogan G1 , Akcay A1 , Akici F1 ,
Baslar Z2 1 2 Clinics of Pediatric Hematology-Oncology and I.U. C.M.S.
Internal Medicine, Hematology Department, Istanbul, Turkey
65
Posters, Sunday and Monday

Posters, Sunday and Monday
Index of Poster Presenters cont’d
28P09
Early Manifestation of a Crohn-Like Colitis in an One-Year-Old
Female Patient with Hermansky-Pudlak Syndrome-1 (HPS1)
Schelling J1 , Lang T1 , Orsó E2 , Aslanidis C2 , Schmitz G2 ,
Melter M1 1Department of Paediatrics And Juvenile Medicine
Regensburg, Germany, 2Department of Clinical Chemistry
and Laboratory Medicine, Regensburg, Germany
28P10
Analysis of MYH9-Related Disorder in a Cohort of Pediatric
Patients
Van Eimeren V, Pluthero F, Kahr W
Hospital For Sick Children, Toronto, ON, Canada
28P11
Glanzmann Thrombasthaenia – A Single Centre Experience
of Different Therapeutic Approaches to Achieve Hemostasis
in 3 Patients
Ward J, Maddox J, Kerr R
Ninewells Haemophilia Centre, Ninewells Hospital & Medical
School, Dundee, U.K.
WOMEN AND BLEEDING DISORDERS
36P04
Cerebral Pseudotumour in a Hemophilic Woman: Removal
and Good Evolution
BenSadok M, Belhani M
Isaad Hassani (Beni Messous) UH, Algiers, Algeria
66
36P05
Post Partum Changes in the Level of Factor VIII and von
Willebrand Factor
Huq FY2 , Kulkarni A1 , Bapir M1 , Egbam E1 , Tuddenham E2 ,
Kadir RA
1 ,2
1 Department of Obstetrics and Gynaecology, and
2 Haemophilia Centre and Thrombosis Unit, Royal Free
Hospital, London
36P06
The Effects of Mode of Delivery, Maternal and Fetal Factors
on the Coagulation System in the Term Neonate
Osmond M1 , Huq FY1 , Kulkarni A1 , Riddell A2 , Smith C3 , Lee
C2 , Kadir RA1, 2
1Department of Obstetrics and Gynaecology, and
2Haemophilia Centre and Thrombosis Unit, Royal Free
Hospital, London, U.K., 3Department of Population Studies
and Statistics, University College London, London, U.K.
36P07
Proposal and Validation of a Novel Quantitative Approach
(Quem) for the Evaluation of Menstrual Blood Losses:
Preliminary Implementation for the Management of
Menorrhagia in Congenital Bleeding Disorders
Napolitano M1 , Mariani G1 , Dolce A2 , Carta G3 , Orecchioni
A4 , Grandone E5 1Internal Medicine & Hematology Unit, University of L’Aquila,
Italy, 2Central Institute of Statistics, L’Aquila, Italy, 3Obstetrics & Gynecology University of L’Aquila, Italy, 4Laboratorio Analisi, Ospedale S. Salvatore L’Aquila, Italy, 5Centro Emostasi
e Trombosi, Ospedale Sollievo della Sofferenza S. Giovanni
Rotondo, Italy

Index of Poster Presenters cont’d
Wednesday and Thursday
Posters are on display during exhibit hours. Authors will be
present at their posters for a question and answer period
on Tuesday, July 13 from 15:45-16:30. Presenting authors
are in bold.
DENTAL ISSUES
11P12
The Use of a New Hemostatic Agent: Ankaferd Blood
Stopper in Hemophiliacs
Ak G, Çakır O, Kazancıo lu HO, Zülfikar B
University of Istanbul Faculty of Dentistry, Department of
Oral Surgery and Oral Medicine, Istanbul, Turkey
11P13
Odontological Study of 50 Patients with Hemophilia or von
Willebrand Disease in the Region of Murcia
Centeno Cortés J1 , Burgos Marcos J1 , Cabañas Periañez V2 ,
García Candel F2 1 2 Asociación Regional Murciana De Hemofilia, Servicio de
Hematología Ciudad Sanitaria Virgen de la Arrixaca, Murcia,
Spain
11P14
Study of the Oral-Dental Health in a Group of Hemophiliac
Children
Burgos MJ1 , Centeno Cortés J1 , García Candel F2 , Cabañas
Periañez V2 1Asociación Regional Murciana De Hemofilia,
2Servicio de Hematología Ciudad Sanitaria Virgen de la
Arrixaca, Murcia, Spain
11P15
Management of Oral Bleeding in Third Molar Surgery with
Recombinant Factor VIIa in Patients with Hemophilia A with
High Inhibitor Titers and Factor Deficiency
Conejo A
Caja Costarricense De Seguro Social, San Jose, Republic of
Costa Rica
11P16
Dental Information Leaflet
Edmonds C
Dublin Dental School and Hospital, Dublin, Ireland
11P17
The Strategy for Creating the Competence Dentists for
Management of Hemophilia Patients in Thailand
Suwannuraks M, Sri-Udomporn N, Im-Erbsin T
Dental Division, Ramathibodi Hospital, Mahidol University,
Bangkok, Thailand
INHIBITORS
17P10
Iliopsoas Hematoma in Patients with Hemophilia and Inhibitor
Nuñez R 1 , Sedano C 2 , Lopez-Fernández M 3 , Altisent C 4 , Cid
A 5 , Mingot E 6
1 Unidad de Hemofilia, Hospital Virgen del Rocio, Sevilla,
2 Hematología, Hospital Marqués de Valdecilla, Santander,
3 Hematología, Complejo Hospitalario A Coruña, 4 Unitat
d’Hemofilia, Hospital Vall d’Hebron, Barcelona, 5 Unidad de
Hemostasia y trombosis, Hospital la Fe, Valencia,
6 Hematología, Hospital Carlos Haya, Málaga, Spain
17P11
A New Early Prophylaxis Regimen that Avoids Immunological
Danger Signals Can Reduce Factor Eight (FVIII) Inhibitor
Development Independent from Product Type Used
Auerswald G1 , Bidlingmaier C2 , Engl W3 , Chehadeh H3 ,
Reipert B3 , Kurnik K2 1 2 Prof.-Hess-Children´s Hospital, Bremen, Germany, Dr. von
Haunersches Children’s Hospital, Munich, Germany, 3Baxter Innovations GmbH, Vienna, Austria
17P12
Treatment of Inhibitors in Children with Severe Hemophilia B
Baker K, Efford J, Henderson L, Khair K, Liesner R, Mathias M
Great Ormond Street Hospital, London, United Kingdom
17P13
Immunotolerance Treatment. Experience in a Single
Hemophilia Centre
Perez Bianco R1-2 , Baques A1 , Baduel C1 ; Neme D2 , Casinelli
MM1-2 , Tezanos Pinto M1-2 , Candela M1 1Academia Nacional de Medicina, Buenos Aires, Argentina.
2Fundación de la Hemofilia, Buenos Aires, Argentina
17P14
Severe Allergic Reaction Following Administration of
Recombinant Factor VIII: A New Entity or a Coincidental
Occurrence?
Bashari D, Avni D, Levinas M, Kenet G, Lubetsky A,
Martinowitz U
1National Hemophilia Center, Sheba Medical Center, Tel-
Hashomer, Israel
17P15
The Combination of Octaplex® and Octanate® Restores
Thrombin Generation Capacity in FVIII Inhibitor Plasma In-
Vitro
Berntorp E1 , Pock K2 , Laher-Kheirallah I2 , Janisch S2 , Walter
O3 , Roemisch J2 1 2 Malmö University Hospital, Octapharma PPGmbH, Research
& Development, Vienna, Austria, 3Octapharma AG,
International Business Units, Lachen, Switzerland
67
Posters, Tuesday and Wednesday

Posters, Tuesday and Wednesday
Index of Poster Presenters cont’d
17P16
The Use of Global Hemostatic Measures to Monitor Response
to Bypassing Agent Therapy During Orthopaedic Surgery
in a Patient with Severe Hemophilia and a Factor VIII Inhibitor
Biss T1 , Knaggs K2 , Varty P1 , Talks K1 1Newcastle Regional Haemophilia Centre, The Newcastle
upon Tyne Hospitals NHS Trust, U.K., 2Department of
Haematology, Freeman Hospital, The Newcastle upon Tyne
Hospitals NHS Trust, U.K.
17P17
Pro-Pact: Retrospective Prophylaxis Patient Case Collection
of rFVIIa Treatment in Hemophilia Patients with Inhibitors
Blanchette V, on behalf of the PROPACT Steering
Committee
Hospital for Sick Children, Toronto, ON, Canada
17P18
Risk Factors of Inhibitor in 321 PUPS with Severe Hemophilia
A: Results of the FranceCoag Network
Calvez T1 , d’Oiron R2 , Donadel-Claeyssens S3 , Héritier V4 ,
Vinciguerra C5 , Goudemand J6 1 2 Inserm & UPMC UMR-S 943, Paris, France, Haemophilia
Centre of Kremlin Bicêtre, France, 3Haemophilia Centre of
Toulouse, France, 4French Institute for Public Health
5 Surveillance, Saint-Maurice, France, Haematology
Department, Lyon-Herriot, France, 6Haemophilia Centre of
Lille, France
17P19
Single Dose rFVIIa for Severe Hemophilia A (HA) with
Inhibitors: Report of the Experience in Argentina
Perez Bianco R1, 2 , Candela M2 , Neme D1 1Fundacion Nacional de la Hemofilia - Buenos Aires,
Argentina., 2Instituto de Investigaciones Hematologicas
“Mariano R. Castex” - Academia Nacional de Medicina -
Buenos Aires, Argentina
17P20
Incidence of Inhibitors at the Algiers Hemophilia Center
(Algeria)
Chennoukh K, Bensadok M, Berkouk Y, Louanchi L, Kaci Z,
Belhani M
Department of Hematology and Blood Banking, University
Hospital of Beni Messous, Algiers, Algeria
17P21
Prophylactic Treatment with FEIBA and Subsequent Immune
Tolerance Induction Therapy to Improve Inhibitor Eradication
on Hemophilia A Patients With Inhibitor
Chien S, Chen Y
Tri-Service General Hospital, Taipei City, Taiwan
68
17P22
Evaluation of Room Temperature Stable Recombinant
Activated Factor VII During Continuous Infusion: Product
and Microbiological Stability Over 24 Hours
Cooper D 1 , Christensen A 2 , Jensen J 2 , Nøhr A 2
1 Novo Nordisk Inc., Princeton, NJ, U.S.A., 2 Novo Nordisk
A/S, Gentofte, Denmark
17P23
Immune Tolerance Induction (ITI) With a FVIII Concentrate
with High VWF Content in Inhibitor Patients With Previous
Unsuccessful ITI and/or Negative Predictors of ITI Response
Coppola A1 , Arbasi M2 , Biasoli C3 , Messina M4 , Tagliaferri
A5 , Scaraggi F6 1Regional Reference Centre For Coagulation Disorders,
Federico II University Hospital, Milan, Italy, 2Centre for
Bleeding Disorders, Transfusion Medicine, Hospital of
Piacenza, 3Transfusion and Haemophilia Centre, Bufalini
Hospital, Cesena, 4Paediatric Regional Reference Centre for
Bleeding and Thrombotic Disorders, Regina Margherita
Children Hospital, Turin, 5Regional Reference Centre for
Haemophilia, University Hospital, Parma, 6Haemostasis and
Thrombosis Centre, Dep. of Internal Medicine, University of
Bari, Bari, Italy
17P24
Predictors of Success in Immune Tolerance Induction (ITI) in
Hemophilia A Patients with High-Responding Inhibitors: The
Italian ITI Registry
Coppola A, Margaglione M, Santagostino E, Rocino A,
Castaman G, Iorio A
Regional Reference Centre for Coagulation Disorders,
Federico II University Hospital, Milan, Italy
17P25
Pharmacokinetics of Factor VIII Concentrates in Subjects with
Hemophilia A Who Are Bethesda Negative for Factor VIII
Inhibitors and ELISA Positive for Antibodies Reacting with
Different Factor VIII Preparations
Rivard G1 , Dedeken L1 , Vincent A1 , Lillicrap D2 , Meilleur C1 ,
Fan L1 1 2 CHU Sainte-Justine, Montreal, Canada, Queen’s University,
Kingston, Canada
17P26
The Use of Bypassing Agents in Factor VIII and IX Inhibitors:
A European Survey
Dolan G, Holme PA
Nottingham University Hospital, Nottingham, U.K.,
Rikshospitalet, Oslo, Norway,
on behalf of the European Haemophilia Therapy
Standardisation Board (EHTSB)

Index of Poster Presenters cont’d
17P27
F8 Haplotype and Recombinant Product Use in the
Hemophilia Inhibitor Genetics Study (HIGS)
Schwarz J1 , Donfield S1 , Winkler C2 , Binns-Roemer E2 ,
Berntorp E3 , Astermark J3 and the HIGS Study Group
1 2 Rho, Inc., Chapel Hill, NC, U.S.A., National Cancer Institute
at Frederick, Frederick, MD, U.S.A., 3Malmö University
Hospital, Malmö, Sweden
17P28
Functional-Molecular Magnetic Resonance Imaging for Early
Characterization of Hemophilic Arthropathy in a Rabbit
Model
Doria A1 , Amirabadi A1 , Miller E2 , Cheng H1 , Zhong A1 ,
Sussman M3 1The Hospital For Sick Children, Toronto, ON, Canada
2Children’s Hospital of Eastern Ontario, Ottawa, ON, Canada,
3Toronto General Hospital, Toronto, ON, Canada
17P29
New INSIGHT in Inhibitor Development in Mild/Moderate
Hemophilia A: Inhibitors Arise After More Exposure Days
than in Severe Disease
Eckhardt C, Peters M, Fijnvandraat K
Paediatric Haematology, Emma Children’s Hospital,
Amsterdam, the Netherlands
17P30
Surgery as a Risk Factor for Inhibitor Development in
Hemophilia A: A Systematic Review
Eckhardt C1, 2 , Van der Bom J3 , Van der Naald M2 , Peters M1 ,
Kamphuisen P2 , Fijnvandraat K1 1Paediatric Haematology, Emma Children’s Hospital,
Amsterdam, the Netherlands, 2Vascular Medicine, Academic
Medical Center, Amsterdam, the Netherlands, 3Clinical Epidemiology, Leiden University Medical Center, Leiden, the
Netherlands
17P31
A Sensitive and Specific Chromogenic Assay for the
Detection of “Functional FVIII Inhibitors”
Ghosh K, Pinto P, Kulkarni B, Shetty S
Department of Haemostasis and Thrombosis, National
Institute of Immunohaematology (ICMR), KEM Hospital,
Mumbai, India
17P32
Surgery and Transfusions Are Associated With Higher
Inhibitor Incidence in 104 PUPS With Severe Hemophilia A
Goudemand J1 , Bridey F2 , Rothschild C3 , Gruel Y4 , Vinciguerra
C5 , Grouin J6 , Négrier C7 , Calvez T8 , Tellier Z2 1 2 3 Haemophilia Centres of Lille, LFB, Les Ulis, Paris-Necker,
4 5 6 Tours, Haematology Department, Lyon-Herriot, University
of Rouen, 7Lyon-Herriot, 8Inserm & UPMC UMR-S 943, Paris,
France
17P33
Determinants of High Titer Inhibitor Development: The Canal
Study
Gouw S 1,2 , Mancuso E 3 , Santagostino E 3 , van den Berg M 2, 4 ,
van der Bom J 5
1 Department of Paediatrics, Wilhelmina Children’s Hospital,
UMCU, the Netherlands, 2 Department of Laboratory
Medicine, University Medical Center Utrecht, Utrecht, the
Netherlands, 3 Angelo Bianchi Bonomi Haemophilia and
Thrombosis Centre, Department of Internal Medicine and
Dermatology, IRCCS Maggiore Hospital, Mangiagalli and
Regina Elena Foundation and University of Milan, Milan, Italy,
4 Meander Medical Center, Amersfoort, the Netherlands,
5 Department of Clinical Epidemiology, Leiden University
Medical Center, the Netherlands
17P34
Sequential Combined Bypassing Therapy is Safe and Effective
in the Treatment of Unresponsive Bleeding in Adults and
Children with Hemophilia and Inhibitors
Gringeri A1 , Fisher K2 , Karafoulidou A3 , Klamroth R4 , López-
Fernández M5 , Mancuso E1 1Angelo Bianchi Bonomi Haemophilia and Thrombosis
Centre, Fondazione Ospedale Maggiore Policlinico and
University of Milan, Milan, Italy, 2Van Creveldkliniek,
Department of Hematology, University Medical Center
Utrecht, Utrecht, the Netherlands, 32nd Blood Transfusion
Center and Hemophilia Center, Laikon General Hospital,
Athens, Greece, 4Hämophilie-Zentrum, Am Vivantes-Klinikum
in Friedrichshain Zentrum für Gefäßmedizin Berlin, Germany,
5Servicio de Hematología y Hemoterapia, Complexo
Hospitalario Universitario A Coruña, A Coruña, Spain
17P35
A Comparison of Prescribed and Actual Recombinant Factor
VIIa (rFVIIa) Dosing in Pediatric Versus Adult Patients with
Congenital Hemophilia With Inhibitors (CHwI): Analysis of
the Dosing Observational Study in Hemophilia (DOSE)
Gruppo R1 , Kessler C2 , Neufeld E3 , Shapiro A4 , Cooper D5 ,
Carr, Jr. M5 1Cincinnati Children’s Hospital Medical Center, Cincinnati,
OH, U.S.A., 2Georgetown University Medical Center,
Washington, DC, U.S.A. 3Childrens Hospital of Boston, MA,
U.S.A., 4Indiana Hemophilia and Thrombosis Center,
Indianapolis, IN, U.S.A. 5Novo Nordisk Inc., Princetown, NJ,
U.S.A.
17P36
International Prospective Randomised Immune Tolerance
(ITI) Study: Interim Analysis of Therapeutic Efficacy and Safety
Hay C1 , Goldberg I2 , Foulkes M1 , DiMichele D2 1 2 University Dept of Haematology, Manchester, U.K., Weill
Medical College of Cornell University, U.S.A.
69
Posters, Tuesday and Wednesday

Posters, Tuesday and Wednesday
Index of Poster Presenters cont’d
17P37
The Spanish Immune Tolerance Induction Registry: 2009
Update
Haya S1 , Martín M2 , Parra R3 , Soto I4 , López MF5 , Moreno M6 ,
Pérez R7 , Sedano C8 Gutiérrez MJ9 , González R10 , Paloma
MJ11 , Prieto M12 , Mingot E13 Mateo J14 , Giménez F15 , Bergua
JM16 , Maicas M17 , Marrero C18 , Campos R19 , Moret A1 , Cid
AR1 , Dasí MA20 , Altisent C3 , Batlle J5 , García F6 , Jiménez V2 and
Aznar JA1 1Unidad de Hemostasia y Trombosis, H. Universitario La Fe,
Valencia; 2Unidad de Coagulopatías Congénitas, H. La Paz;
3 4 Unidad de Hemofilia, H. Vall d`Hebron, Barcelona; Servicio
de Hematología, Hospital Central de Asturias; 5Servicio de
Hematología, Complejo Hospitalario Juan Canalejo, A
Coruña; 6Servicio de Hematología H. Virgen de la Arrixaca,
Murcia; 7Unidad de Hemofilia, H. Virgen del Rocío, Sevilla;
8Servicio de Hematología, H. Marqués de Valdecillas,
Santander; 9Servicio de Hematología, H. Virgen de las Nieves,
Granada; 10Servicio de Hematología, H. Xeral-Cies, Vigo;
11Servicio de Hematología, H. Virgen del Camino, Pamplona;
12Servicio de Hematología, H. General Yagüe, Burgos;
13Servicio de Hematología, Hospital Regional Carlos Haya.
Málaga; 14Servicio de Hematología, H. Sant Pau, Barcelona;
15Servicio de Hematología, H. Torrecárdenas, Almería;
16Servicio de Hematología, H. San Pedro de Alcántara,
Cáceres; 17Servicio de Hematología, H. General de Albacete;
18 19 Servicio de Hematología, HUNSC, Tenerife; Servicio de
Hematología, H. SAS Jerez de la Frontera, Cádiz; 20Unidad de Hematología Pediátrica, H. Universitario La Fe. Valencia,
Spain
17P38
Addition of Mycophenolate Mofetil (MMF) to Immune
Tolerance Therapy (ITT) in Five Children With Severe
Hemophilia A and ‘Resistant’ Inhibitors
Henderson L, Baker K, Efford J, Khair K, Liesner R, Mathias M
Haemophilia Center, Great Ormond Street Hospital for
Children NHS Trust, London, U.K.
17P39
An Analog of rFVIIa, NN1731, Speeds Wound Healing in a
Mouse Model of Hemophilia B
Hoffman M1 , Ezban M2 , Monroe D3 1Duke University Medical Center, Durham, North Carolina
U.S.A., 2Novo Nordisk A/S, Måløv, Denmark, 3University of
North Carolina, Chapel Hill, North Carolina, U.S.A.
70
17P40
Effect of Plasma-Derived or Recombinant Factor VIII on
Inhibitor Development: A Systematic Review
Iorio A 1 , Halimeh S 2 , Goldenberg N 3 , Kenet G 4 , Young G 5 ,
Brandao L 6
1 Hemophilia Centre, University Of Perugia, Italy, 2 Hemophilia
Centre, Duisburg, Germany, 3 Hemophilia Centre,
Denver/Aurora, U.S.A., 4 Hemophilia Centre, Tel-Hashomer,
Israel, 5 Hemophilia Centre, Los Angeles, U.S.A., 6 Hemophilia
Centre, Toronto, Canada
17P41
IgG Subclasses of FVIII Inhibitors in Severe Hemophilia A
Patients:
Analysis by Flow Cytometry
Irigoyen M1 , Galassi N1 , Bracco M1 , Candela M1-2 , Pérez
Bianco R1-2 , Primiani L2 1Instituto De Investigaciones Hematológicas- Academia
Nacional De Medicina De Buenos Aires, 2Fundación Argentina de Hemofilia, Buenos Aires, Argentina
17P42
Lupus Anticoagulant Status in Patients with High Responder
Inhibitors: Incidence and Impact on Bleeding Tendency
Kavakli K, Balkan C, Karapinar D, Ay Y, Bilenoglu B
Ege University Children’s Hospital Dept. Hematology, Turkey
17P43
Effect of FEIBA on Platelet Activation and Platelet-Monocyte
Conjugate Formation
Dunkley S, Uhr E, Kershaw G, Zhao L
Royal Prince Alfred Hospital, Sydney, Australia
17P44
New Model of Antibody-Induced Hemophilia A for the
Assessment of Bypass Therapies
Kisucka J, Rose-Miranda R, Carito B, Albert L, Shields K,
Korakas K
Pfizer, Cambridge, MA, U.S.A.
17P45
Immune Tolerance Induction in Polish Children with Severe
Hemophilia A and Inhibitor - High Responders
Klukowska A, Laguna P
Dept of Pediatrics, Hematology and Oncology, Warsaw,
Poland
17P46
Inhibitor Eradication Practices in Adult Patients – Results of
a Global Survey
Kruse-Jarres R1 , Lavigne-Lissalde G2 , Mahlangu J3 1 2 Tulane University, New Orleans, LA, U.S.A., University
Hospital, Montpellier, France, 3Hemophilia Comprehensive
Treatment Center, Johannesburg, South Africa

Index of Poster Presenters cont’d
17P47
Familial Concordance and Haplotypes Distribution of F8
Intragenic Polymorphisms in Severe Hemophilia A Patients
That Developed Inhibitors to the Factor VIII
Luna-Záizar H1 , González-Ramos I2 , Ana Rebeca J3 , López-
Jiménez J, Mundo-Ayala J2 1 2 CUCS, CUCEI, Universidad de Guadalajara, Genética
Humana, CUCS, Universidad de Guadalajara, 3División de
Genética, CIBO, IMSS, Mexico
17P48
Engineering Factor VIIa Molecules with Improved Therapeutic
Properties for Treatment of Patients with Inhibitors
Madison E1 , DeLuca-Flaherty C1 , Erbe D2 , McCluskie K2 ,
Blouse G1 , Thanos C1 1 2 Catalyst Biosciences, Inc., San Francisco, CA, U.S.A., Pfizer,
Cambridge, MA, U.S.A.
17P49
Type of Factor VIII Product as Risk Factor for Inhibitor
Development in Patients with Hemophilia A and Null
Mutations
Mancuso M1 , Mannucci P1 , Rocino A2 , Garagiola I1 , Tagliaferri
A3 , Santagostino E1Angelo Bianchi Bonomi Hemophilia and
Thrombosis Center, IRCCS Ca’ Granda Foundation, Policlinico
Maggiore Hospital and University of Milan, 2Hemophilia Center, San Giovanni Bosco Hospital, Naples, 3Hemophilia Center, University Hospital, Parma, Italy
17P50
Inhibitor Titres Continue to Decrease While on Prophylaxis
with FEIBA
McClure W1 , Ritchie B2 , Dower N3 1Dr. John Akabutu Comprehensive Centre For Bleeding
Disorders, and 2University of Alberta Hospital, Edmonton,
AB, Canada, 3Stollery Children’s Hospital, Edmonton, Alberta,
Canada
17P51
FVIII Inhibitor-Reacting Regions in Hemophilia A
Moret A1 , Aznar J1 , Martin M2 , Parra R3 , Lopez M4 , Haya S1 1Unidad de Hemostasia y Trombosis, Hospital Universitario
La Fe, Valencia, 2Unidad de Coagulopatias Congenitas,
Hospital La Paz, Madrid, 3Unidad de Hemofilia, Hospital Vall
d’Hebron, Barcelona, 4Servicio de hematologia, Complejo
Hospitalario Universitario, A Coruña, Spain
17P52
Surgical Interventions with FEIBA (SURF): International
Registry-Based Analysis of Surgery in Hemophilia Patients
with Inhibitors
Negrier C 1 , Pousse M 1 , Numerof R 2 , Stephens D 2 , Wong WY 2 ,
Pirck M 3 , Baghaei F 4 and Yee T 5
1 Hôpital Edouard Herriot, Lyon, France; 2 Baxter Healthcare
Corporation, Westlake Village, CA, United States; 3 Baxter
Innovations GmbH, Vienna, Austria; 4 Sahlgrenska University
Hospital, Gothenburg, Sweden; 5 Royal Free Hospital, London,
United Kingdom
17P53
Acute Bleeding Episodes Impact Quality of Life (QoL) in
Patients/Families with Congenital Hemophilia with Inhibitors
(CHwI): Analysis of Bleed vs. Non-Bleed Days from the Dosing
Observational Study in Hemophilia (DOSE)
Neufeld E1 , Recht M2 , Sabio H3 , Cooper D4 , Wilke C5 , Gut R4 1 2 Childrens Hospital of Boston, Oregon Health and Science
University, 3Wake Forest University, Baptist Medical Center,
4 5 Novo Nordisk Inc., University of Illinois, Chicago, United
States
17P54
Successful Treatments of Life-Threatening Hemorrhages and
Perioperative Managements by Continuous Infusions of
Factor VIII in an Acquired Hemophilia A Patient
Otaki M1 , Amano K1 , Suzuki T1 , Mori Y2 , Aoki T2 , Fukutake K1 ,
1 2 Department of Laboratory Medicine, and the third
Department of Surgery, Tokyo Medical University, Tokyo,
Japan
17P55
A Retrospective Study of Octaplex ® in the Treatment of
Bleeding in Patients with Hemophilia A Complicated by
Inhibitors
Pock K1 , Berntorp E2 , Futema L3 , Knaub S4 , Walter O5 ,
Trawnicek L6 , Roemisch J7 1Octapharma PPGmbH, Research & Development, Vienna,
Austria, 2Malmö Centre for Thrombosis and Haemostasis,
University Hospital, Malmö, Sweden, 3Octapharma Brazil,
Lyda, Brazil, 4Octapharma AG, Clinical R&D Coagulation,
Lachen, Switzerland, 5Octapharma AG, International Business
Units, Lachen, Switzerland, 6Octapharma PPGmbH, Clinical
R&D, Vienna, Austria, 7Octapharma PPGMBH, Vienna, Austria
71
Posters, Tuesday and Wednesday

Posters, Tuesday and Wednesday
Index of Poster Presenters cont’d
17P56
Impact of Acute Bleeding Episodes and Bypassing Agent
(BPA) Administration on Patient/Caregiver/Family Daily
Activities in Congenital Hemophilia with Inhibitors: Analysis
of the Dosing Observational Study in Hemophilia (DOSE)
Recht M1 , Neufeld E2 , Sharma V3 , Cooper D4 , Wilke C5 , Gut R4 1Oregon Health and Science University, Portland, OR, U.S.A.,
2 3 Childrens Hospital of Boston, MA, U.S.A., Brown Cancer
Center, Louisville, KY, U.S.A., 4Novo Nordisk Inc., Princeton,
NJ, U.S.A., 5University of Illinois, Chicago, IL, U.S.A.
17P57
Polymorphisms in the VWF Gene and Development of FVIII
Inhibitors in Patients with Severe Hemophilia A
Repesse Y1 , De Loncamps A1 , Costa C2 , Kaveri S3 , Borel-
Derlon A1 , Lacroix-Desmazes S3 1Laboratoire d’hematologie, CHU de Caen, Caen, France,
2AP-HP, Groupe Henri Mondor-Albert Chenevier, Service de
Biochimie, UF de Genetique Moleculaire, INSERM Unité 84,
Creteil, France., 3Centre de Recherche des Cordeliers, eq
16, Université Pierre et Marie Curie, Paris, France
17P58
The Natural History of Factor VIII Inhibitors in Patients with
Congenital Hemophilia A without Immunotolerance Induction
Rezende S1 , Caram C2 , de Souza R3 , de Sousa J4 , Cerqueira
A5 , van der Bom J6 1Universidade Federal de Minas Gerais, Belo Horizonte,
Brazil,
2Grupo de Estudo da Hemostasia e Trombose –
GETHe/UFMG, 3Prefeitura de Pará de Minas, 4Target M&E
Consultoria, and 5Fundação HEMOMINAS, Belo Horizonte,
Brazil, 6Leiden University Medical Center, Leiden, the
Netherlands
17P59
The Haemophilia RER Network: Characteristics of Patients
with Inhibitor in the Registry
Rivolta G1 , Tagliaferri A1 , Biasoli C2 , Pedrazzi P3 , Valdrè L4 ,
Arbasi M5 1Regional Reference Centre For Inherited Bleeding Disorders,
University-Hospital of Parma, Parma. Italy, 2Haemophilia Centre of Cesena, Cesena. Italy, 3Haemophilia Centre of
Modena, Modena. Italy, 4Haemophilia Centre of Bologna,
Bologna. Italy, 5Haemophilia Centre of Piacenza, Piacenza,
Italy
17P60
Factor VIII and IX Genotype Characterisation of Hemophilia
Patients with Transient or Permanent Inhibitors in Argentina
Rossetti L1 , Szurkalo I1 , Primiani L2, 3 , Neme D2, 3 ,
Candela M1, 2, 3 , Pérez Bianco R1, 2, 3
1Instituto de Investigaciones Hematológicas Mariano R
Castex, Academia Nacional de Medicina de Buenos Aires,
2 3 Fundación de la Hemofilia Alfredo Pavlovsky, Grupo
Argentino de Estudio de Inhibidores en Hemofilia (GADEI),
Buenos Aires, Argentina
72
17P61
Addressing Clinical Issues Related to FVIII Inhibitors Using a
Human BCR Transgenic Mouse: The Model
Benhida A 1 , VanderElst L 1 , Ectors F 2 , Gilles JG 1 , Jacquemin
M 1 , Saint-Remy JM 1
1 Center for Molecular and Vascular Biology, University of
Leuven, and 2 GIGA, University of Liège, Belgium
17P62
Addressing Clinical Issues Related to FVIII Inhibitors Using a
Human BCR Transgenic Mouse: Formation and Suppression
of FVIII Inhibitors
Carlier V, Grailly S, Benhida A, Gilles JG, Jacquemin M, Saint-
Remy JM
Center for Molecular and Vascular Biology, University of
Leuven, Belgium
17P63
European Initiative to Prevent Joint Damage in Hemophilia
Children with Inhibitors (ENJOIH) – A Prospective Study
Santagostino E1 , Auerswald G2 , Jimenez-Yuste V3 , Ljung R4 ,
Morfini M5 , Rocino A6 , Young G7 1A. Bianchi Bonomi Hemophilia and Thrombosis Center,
IRCCS Cà Granda Foundation, PoliclinicoMaggiore Hospital,
Milan, Italy, 2Prof. Hess Children’s Hospital, Klinikum Bremen-
Mitte, Bremen, Germany, 3Haematology Department,
Hospital Universitario La Paz, Madrid, Spain, 4Department of Paediatrics and Coagulation Disorders, University Hospital,
Malmö, Sweden, 5Agency for Hemophilia, Reference Center
for Inherited Bleeding Disorders of Tuscany, Department of
Emergency and Reception, Azienda Ospedaliero Universitaria
Careggi, Florence, Italy, 6Haemophilia and Thrombosis
Center, S.Giovanni Bosco Hospital, Naples, Italy, 7Children’s Hospital of Orange County, Orange, CA, U.S.A.
17P64
The Distinct Role of the Hemostatic Components in the
Mode of Action of FEIBA ®
Varadi K, Schoppmann A, Turecek P, Gritsch H, Ehrlich H,
Schwarz H
Baxter BioScience, Vienna, Austria
17P65
[18-F] Fluorodeoxyglucose (FDG) Positron Emission
Tomography (PET) Imaging for Detection of Hemophilic
Arthropathy in a Rabbit Model
Shammas A1 , Charron M1 , Metser U2 , Amirabadi A1 , Zhong
A1 , Doria A1 1 2 The Hospital For Sick Children, and Princess Margaret
Hospital, Toronto, Canada

Index of Poster Presenters cont’d
17P66
Frequency of Factor VIII (FVIII) Inhibitor Levels in Patients
with Hemophilia A in Karachi
Shamsi T1 , Borhany M1 , Ansari S1 , Kumari M1 , Sangji Z3 , Ur
Rehman Z2 1National Institute of Blood Disease and Bone Marrow
Transplantation, 2Fatimid Foundation, and 3Husaini Blood
Bank, Karachi, Pakistan
17P67
Prospective ADVATE Immune Tolerance Induction Registry
(PAIR): An Update
Spotts G, Luu H, Wu L, Stephens D, McCulloch-Bayr A,
Ewenstein B
Baxter Healthcare Corporation, Westlake Village, CA, U.S.A.
17P68
Sequential Therapy with APCC and rFVIIA in Two Hemophilia
Inhibitor Patients Undergoing Four Dental Extraction
Procedures
Stefanska-Windyga E, Czubak G, Baran B, Windyga J
Department of Disorders of Haemostasis and Internal
Medicine, Institute Of Haematology and Transfusion
Medicine, Warsaw, Poland
17P69
The Natural History of Inhibitors on 545 HA and 92 HB
Patients Followed Up at Castelfranco Veneto Hemophilia
Centre
Tagariello G, Sartori R, Tassinari C, Belvini D, Salviato R,
Radossi PHaemophilia
Center Transfusion and Haematology Haemophilia,
Castelfranco Veneto, Italy
17P70
Efficacy of Rituximab as Monotherapy in the Treatment of
Children with Hemophilia and High Response Inhibitors
Tlacuilo-Parra A, García-Mendoza A, Garibaldi-Covarrubias
R, Soto-Padilla J, Toro-Castro L, García-Delgadillo M
UMAE Hospital De Pediatria CMNO IMSS, Guadalajara,
Mexico
17P71
Recombinant Glycopegylated FIX (40K PEG-Rfix)
Demonstrates Prolonged Half-Life in Several Animal Species
Hansen L1 , Ezban M1 , Henrik O1 , Nichols TC2 , Agersø H1 ,
Tranholm M1
1 2 Novo Nordisk A/S, Maaloev, Denmark, University of North
Carolina, Chapel Hill, NC, U.S.A.
17P72
Patient/Caregiver-Reported Bleed Symptoms and Reasons
for Starting/Stopping Treatment with Recombinant Factor
VIIa (rFVIIa): Analysis of the Dosing Observational Study in
Hemophilia (DOSE)
Valentino L 1 , Walsh C 2 , Reding M 3 , Young G 4 , Tugal O 5 ,
Cooper D 6
1 RUSH University Medical Center, Chicago, IL, U.S.A., 2 Mount
Sinai Medical Center, New York, NY, U.S.A., 3 University of
Minnesota, Fairview, MN, U.S.A. 4 Childrens Hospital of Los
Angeles, CA, U.S.A. 5 New York Medical College, Westchester
County, NY, U.S.A., 6 Novo Nordisk Inc., Princeton, NJ, U.S.A.
17P73
Incidence of Inhibitors among Multi-Transfused Patients with
Hemophilia A: A Meta-Analysis of Prospective Cohort Studies
Van Der Bom J1 , Kamphuisen P2 , Navickis R3 , Wilkes M3 1Leiden University Medical Center, Leiden, the Netherlands,
2Amsterdam Medical Center, Amsterdam, the Netherlands,
3Hygeia Associates, San Francisco, CA, U.S.A.
17P74
Comparison of ITT-Course and Outcome in Hemophilia
Inhibitor Patients Treated with APCC and/or rFVIIa
Vidovic N, Petri M, Goldmann G, Niemann B, Horneff S,
Brackmann HH, Oldenburg J
Institute of Experimental Haematology and Transfusion
Medicine, University Clinic Bonn, Germany
17P75
The Prevalence of Factor VIII Inhibitors and Genetic Aspects
of Inhibitor Development in Chinese Patients with Hemophilia
A
Wang X1 , Yang R2 , Zhao Y3 , Wu J4 , Sun J5 , Zhang X6 1 2 3 Shanghai Ruijin Hospital, Peking Union Hospital, China
Institute of Hematology and Blood Disease Hospital, 4Anhui 5 Provincial Hospital, Guangzhou Nanfang Hospital,
6Shandong Blood Center, Republic of China
17P76
Serial Courses of Rituximab as Effective Treatment of
Inhibitors to FVIII or FIX in Adult Patients with Severe
Hemophilia A (HA) or B (HB)
Wieduwilt M, Phelan D, Karp S, Francis D, Fogarty P
Comprehensive Hemophilia Treatment Center, Adult
Program, University of California, San Francisco, CA, U.S.A.
17P77
Switch to Recombinant Factor VIII after Previously Successful
Immune Tolerance Induction with FVIII/von Willebrand Factor
Concentrates in Children with Severe Hemophilia A
Pergantou H, Xafaki P, Platokouki H
Haemophilia/Haemostasis Unit, Aghia Sophia Children’s
Hospital, Athens, Greece
73
Posters, Tuesday and Wednesday

Posters, Tuesday and Wednesday
Index of Poster Presenters cont’d
17P78
Major Orthopedic Elective Surgery for Hemophilia Patients
with Inhibitors
Yoo M1 , Cho Y1 , Kim K1 , Chun Y1 , Ryu K1 , Park Y2 1 2 Department of Orthopedic Surgery and Department of
Pediatrics, College of Medicine, Kyunghee University, Seoul,
Korea
17P79
Patient/Caregiver-Reported Recombinant Factor VIIa (rFVIIa)
Dosing for Acute Bleeds in Patients with Congenital
Hemophilia with Inhibitors (CHwI): Results from the Dosing
Observational Study in Hemophilia (DOSE)
Young G1 , Walsh C2 , Gruppo R3 , Cooper D4 1Childrens Hospital of Los Angeles, Los Angeles, CA, U.S.A.,
2Mount Sinai School of Medicine, New York, NY, U.S.A.,
3Cincinnati Children’s Hospital Medical Center, Cincinnati,
OH, U.S.A., 4Novo Nordisk Inc., Princeton, NJ, U.S.A.
17P80
Successful Hemorrhage Management with Highly Purified
VWF/FVIII Complex Concentrate as First Line Therapy in Two
Patients Affected by Acquired Hemophilia A
Zanon E, Sartori M, Spiezia L, Campello E, Milan M
Clinica Medica II Azienda Ospedaliera Di Padova, Italy
MILD HEMOPHILIA
20P02
Recurrent Massive Bleeding After Cholecystectomy as a First
Symptom of Mild Hemophilia B in Patient with Normal APTT
Chojnowski K1 , Glowacki A2 , Treliñski J1 1Department of Haematology, Medical University of Lodz,
Poland, 2Department of Vascular and General Surgery,
Copernicus Memorial Hospital, Lodz, Poland
20P03
Incidence of Inhibitor in Mild/Moderate Hemophilia (MH)
Patients Within the FranceCoag Network
d’Oiron R1 , Demiguel V2 , Borel-Derlon A3 , Donadel-
Claeyssens S4 , Goudemand J5 , Guillet B6 1Haemophilia Centre, AP-HP Hopital Bicetre, Le Kremlin-
Bicetre, France, 2Coordinating Centre of FranceCoag
Network, French Institute for Public Health Surveillance,
Saint-Maurice, France, 3Haemophilia Centre, Caen, France,
4 5 Haemophilia Centre, Toulouse, France, Haemophilia Centre,
Lille, France, 6Haemophilia Centre, Rennes, France
20P04
Mild Hemophilia in Sweden
Ekholm C, Mattson E, Astermark J, Ljung R, Berntorp E
Malmö Centre for Thrombosis and Haemostasis, Lund
University, Sweden
74
20P05
Carotid Endarterectomy and Triple Aorto-Coronary Bypass
Grafting in a Patient with Hemophilia A
Elezovic I 1, 5 , Antic D 1 , Matic D 2, 5 , Simic D 2, 5 , Markovic D 3 ,
Mikic A 4
1 Institute of Haematology Clinical Center of Serbia, Belgrade,
2 Institute of Cardiology Clinical Center of Serbia, Belgrade,
3 Institute of Anestesiology and Reanimation Clical Centre of
Serbia, 4 Institute of Cardiovascular Surgery Clinical Centre
of Serbia, Belgrade, 5 School of Medicine, University of
Belgrade, Serbia
20P06
Treatment and Its Complications in Mild and Moderate
Hemophilia A: Three decades of Experience; First Results
of a European Cohort study (INSIGHT)
Eckhardt C, Peters M, Fijnvandraat K
Paediatric haematology, Emma Children’s Hospital,
Amsterdam, the Netherlands
20P07
Patterns of Bleeding, Ages atFirst Bleeding Episode and at
Diagnosis in Severe and Mild/Moderate Hemophilia
Gamba G1 , Lodo F2 , Trinchero A1 , Montani N1 , Ghidelli N1 1 2 University of Pavia, and Fondazione IRCCS Policlinico, San
Matteo, Pavia, Italy
20P08
Understanding the Mild Hemophilia Experience
Nilson J1 , Mulder K2 , Hahn M3 , Hilliard P4 , Jarock C5 ,
Steele M6 ,
1Saskatchewan Bleeding Disorders Program, Saskatoon, SK,
2Manitoba Bleeding Disorders Program, Winnipeg, MB,
3Congenital Hemostasis Services, Montreal Children’s
Hospital, Montreal, QC, 4Comprehensive Care Hemophilia
Program, Toronto, ON, 5Pediatric Bleeding Disorders Clinic,
IWK, Halifax, NS, 6Southwestern Ontario Bleeding Disorder
Program, London, ON, Canada
20P09
-257T>G Substitution in the F8 Promoter Region is
Associated with Mild Hemophilia A and Resistance to DDAVP
Therapy
Riccardi F1 , Rivolta G1 , Franchini M2 , Di Perna C1 , Neri T3 ,
Tagliaferri A1 1Regional Reference Center for Inherited Bleeding Disorders,
2Immunohematology and Transfusion Center of Parma, and
3Molecular Genetics Unit, Parma, Italy
20P10
Mild Hemophilia and Trauma
van Wanroij H, Dielen I, Amtari M, Laros B, Nováková I
Haemophilia Comprehensive Centre (Department of
Haematology), Radboud University Nijmegen Medical
Centre, the Netherlands

Index of Poster Presenters cont’d
MOLECULAR GENETICS OF BLEEDING
DISORDERS
21P09
Performance of Inverse Shifting-PCR (IS-PCR) to Investigate
F8 Intron 22 Inversions and Potential Rearrangements
Involving Int22h Recombination
Abelleyro M, Radic P, Rossetti L, Zuccoli J, Larripa I, De Brasi C
IIHema, National Academy of Medicine, Buenos Aires,
Argentina
21P10
Factor VIII Gene Mutations and Polymorphisms in IL10 and
TNFA Genes in Patients with Severe Hemophilia A in
Venezuela
Albánez S1 , Porco A1 , Ruiz-Sáez A2 , Boadas A2 , De Bosch N2 1Laboratorio de Genética Molecular Humana B, Universidad
Simón Bolívar, and 2Centro Nacional de Hemofilia, Banco
Metropolitano de Sangre, Caracas, Venezuela
21P11
Detection of Factor IX Gene Mutations by High-Resolution
Melting Analysis
Classen J1 , Pepermans X1 , Hermans C2 , Lannoy N1 1 2 Center of Human Genetics and Departement of
Haematology, Cliniques Universitaires Saint-Luc, Bruxelles,
Belgium
21P12
Safety Retroviral System To Generate A Human Recombinant
Factor VIII Producer Cell Line
Cristina Correa De Freitas M, Maria Fontes A, de Castilho
Fernandes A, Maria Russo-Carbolante E, Picanco-Castro V,
Tadeu Covas D
National Institute of Science And Technology in Stem Cells,
Sao Paulo, Brazil
21P13
Ex Vivo Genetic Modification of Liver-Derived Mesenchymal
Stem Cells with Human Factor IX as Therapeutic Approach
for Hemophilia B
De Castilho Fernandes A, Maria Fontes A, Ursoli Ferreira
Melo F, Candido Almeida D, Vianna Bonini Palma P, Tadeu
Covas D
National Institute of Science and Technology in Stem Cell
and Cell Therapy – FMR, Sao Paulo, Brazil
21P14
Identification of 5 Novel Mutations in Tunisian Families with
Hemophilia B Disease
Elmahmoudi H1 , Gouider E2 , Khoudjetelkhil H1 , Ben Amor M1 ,
Meddeb B2 , Elgaaied A1 1 2 Faculté des sciences de Tunis, Tunisia, Centre de Traitement
des Hémophiles, Hopital Aziza Othmana Tunis, Tunisia
21P15
Generation and Characterization of Murine Model With
Hemophilia A and Severe Combined Immunodeficient
Disease (SCID) for Factor VIII Studies
Gonsales Da Rosa N, Maria Fontes A, de Castilho Fernandes
A, Strazza Rodrigues E, Navarro Ueda Yaochite J, Tadeu
Covas D
National Institute of Science and Technology in Stem Cell
and Cell Therapy, Sao Paulo, Brazil
21P16
National Center of Genetics Study on Hemophilia: Mexican
Database and Multidisciplinary Diagnosis Program
Jaloma Cruz AR1 , Luna Zaizar H2 , López Jiménez JJ2 , Mundo
Ayala JN2 , González Ramos IA2 , Esparza Flores MA3 1Centro de Investigación Biomédica de Occidente, IMSS,
2Centro Universitario de Ciencias de la Salud, de Guadalajara,
3Federación de Hemofilia de la República Mexicana, A.C.
Universidad, Mexico
21P17
Haplotype Analysis to Determine Founder Effect in 150
Belgian Hemophilia A Patients
Lannoy N1 , Soree N1 , Pepermans X1 and Hermans C2 1 2 Centre of Human Genetics and Department of
Haematology, Université Catholique de Louvain, Belgium
21P18
Hemophilia A: Genetic Characterization in Patients and
Relatives
Linari S1 , Frusconi S2 , Romolini C2 , Minuti B2 , Morfini M1 ,
Torricelli F2 1Agency For Haemophilia -A.O.U. Careggi - Florence, Italy,
2Genetic Unit- A.O.U Careggi - Florence, Italy
21P19
Characterisation of Natural FVIII Variants of the B-Domain
Regarding Their Biological Activity
Pahl S1 , Schwaab R2 , Oldenburg J3 , Herbiniaux U4 ,
Aburubaiha Z5 1 2 Uniclinic Bonn, Institut of Haematology and
Transfusionmedicine, 3Institute of Experimental Haematology
and Transfusion Medicine, 4Department of Molecular
Haemostaseology, 5University Clinic Bonn, Bonn, Germany
21P20
A Newly Discovered Mutation among Austrian Hemophilia
A Patients: Population Genetic Analysis to Trace Common
Ancestry
Reitter S1 , von Haeseler A2 , Horvath B3 , Freitag R3 , Pabinger-
Fasching I1 , Mannhalter C3 1Medical University of Vienna, Department of Medicine I,
2 3 Center for Integrative Bioinformatics Vienna, Department
of Medical and Chemical Laboratory Diagnostics, Medical
University of Vienna, Austria
75
Posters, Tuesday and Wednesday

Posters, Tuesday and Wednesday
Index of Poster Presenters cont’d
21P21
Genetic Analysis of Patients with Factor VII Deficiency
Riccardi F1 , Di perna C1 , Rivolta G1 , Martorana D2 , Angeri
F1 , Tagliaferri A1 1Regional Reference Center For Inherited Bleeding Disorders,
and 2Molecular Genetics Unit, Parma, Italy
21P22
Characterisation of the Deletion Breakpoints in Patients with
Severe Hemophilia A: Large Deletions and Inhibitors
Roth L1 , Schneppenheim R1 , Oyen F1 , Marschalek R2 1University Medical Center Hamburg-Eppendorf, Dept. of
2 Pediatric Hematology and Oncology, Institute of
Pharmaceutical Biology / ZAFES / DCAL, Johann-Wolfgang-
Goethe-University Frankfurt, Germany
21P23
A Segregation Ratio Distortion of Mutated F8 Alleles in
Hemophilia A Carriers
Tizzano E, Baena M, Venceslá A, Alias L, Cornet M, Baiget M
Department of Genetics, Hospital Sant Pau, Sant Pau,
Barcelona, Spain
21P24
Hemophilia A Genotyping Using dHPLC: Experience
Concerning 486 Patients
Vinciguerra C1 , Fretigny M1 , Zawadzki C2 , Bertrand M3 ,
Chambost H4 , Negrier C5 1Hematology Laboratory- EA4174 /Hospices Civils De Lyon
- Université Lyon 1, France, 2Haematology Department and
EA-2693, University Hospital, Lille, France, 3Hemophilia Center, CHU Besancon, France, 4Hemophilia Center, CHU
Thimone, AP-HM, Marseille, France, 5Hemophilia Center-
Hospices Civils De Lyon - Université Lyon 1, France
21P25
Molecular Analysis of Hemophilia: Guidelines from the French
Haemophilia Care Centre Network
Vinciguerra C1 , Costa C2 , Trossaert M3 , d’Oiron R4 , Boisseau
P5 , Négrier C6 1Hematology laboratory, Hospices Civils De Lyon, Université
Lyon, 2Genetic Laboratory, Hopital Henri-Mondor, Creteil,
3Hemophilia Center, CHU Nantes,
4Haemophilia Centre, AP-HP Hopital Bicetre, Université Paris
XI, Le Kremlin Bicetre, 5Genetic Laboratory, CHU Nantes,
6Centre régional de traitement de l’hémophilie, Hospices
Civils de Lyon, Université Lyon, France
21P26
hFIX Gene Therapy in Murine Hemophilia B by Hydrodynamic
Delivery and Site-Specific Genomic Integration
Zhang L, Gu D, Du W, Lui P, Lu S, Yang R
State Key Laboratory of Experimental Hematology, Institute
of Hematology & Blood Diseases Hospital, Chinese Academy
of Medical Sciences & Peking Union Medical College, Tianjin,
China
76
MUSCULOSKELETAL ISSUES
22P22
Aggressive Hemophilic Pseudotumor: A Case of Atypical
Progression
Querol F 1 , Aparisi F 2 , Amador R 3 , Pérez-Alenda S 1 , Abad-
Franch L 1 , Aznar J 1
1 Universidad De Valencia. Unidad Hemostasia Y Trombosis
Hospital La Fe. Valencia, 2 Servicio de Radiología
Rehabilitación, Hospital la Fe, Valencia, 3 Servicio de
Oncología Radioterápica Hospital la Fe, Valencia, Spain
22P23
Hemophiliac Arthropathy; Present and Future in the Children
of Tabasco, Mexico
Castro S
Tabasqueña de Hemofilia A.C, Tabasqueña, Mexico
22P24
Total Knee and Hip Replacement for Patients with
Hemophilia: Brno Experience
Chlupova G, Smejkal P, Messner P, Krbec M, Chaloupka R,
Penka M
Department of Clinical Haematology and Department of
Orthopaedic Surgery, University Hospital and Medical Faculty,
Masaryk University, Brno, Czech Republic
22P25
Assessing the Value of MRI Diagnostics in Hemophilic
Arthropathy
Den Uijl I1,2 , De Schepper A3 , Grobbee D2 , Fischer K1,2 1Van Creveldkliniek, Dept. Haematology, UMC Utrecht, the
Netherlands, 2Julius Center for Health Sciences and Primary
Care, UMC Utrecht, the Netherlands, 3Department of
Radiology, University Hospital Antwerp, Belgium
22P26
Rheumatologic Indices vs. Orthopedic Joint Scores to Evaluate
Early-Phase Joint Involvement in Severe Hemophilia A
Di Minno M, Cimino E, Russolillo A, Coppola A, Marrone E,
Cerbone A
Federico II University, Naples, Italy
22P27
Evaluation of Intra-Articular Rifampicin in Reducing Pain,
Hemarthrosis, and Improving Joint Motions in Hemophilic
Arthropathy
Rezazadeh S1 , Haghighat A1 , Babanezhad Z2 , Karimi M1 1Department of Orthopedic, Chamran Hospital, Shiraz, Iran,
2Haematology Research Centre, Shiraz University of Medical
Sciences, Shiraz, Iran

Index of Poster Presenters cont’d
22P28
Correlation of Hemophilic Arthropathy with Genetic Markers
of Bleeding Tendency and Inflammation
López Jiménez JJ1 , Soto Padilla J2 , Ortega Ricardo 2 ,
Garibaldi R2 , Tlacuilo Parra JA2 , Jaloma Cruz AR3 1Genética Humana, Centro Universitario de Ciencias de la
Salud, Universidad de Guadalajara, 2UMAE del Hospital de
Pediatría, 3Centro Médico de Occidente, IMSS, Centro de
Investigación Biomédica de Occidente, IMSS, Guadalajara,
Mexico
22P29
Long-Term Outcomes of Radiosynoviorthesis for Hemophilic
Arthropathy
Manco-Johnson M, Weidel J, Funk S, Ross C, Shearer R
Hemophilia Center, University of Colorado Denver, CO,
U.S.A.
22P30
Relationship of Hemophilic Arthropathy and
Osteoporosis/Osteopenia in Patients with Severe Hemophilia
(A, B) Referred to Hemophilia Center of Kerman, Iran
Naderi A1, Nikvarz M2 , Arasteh M3 Kerman Medical University, Kerman, Iran
22P31
Prevalence of Iliopsoas Hematoma in Patients with
Hemophilia Over a 10-Year Period (1998 -2008) in HEMORIO
– Regional Hemophilia Center of Rio de Janeiro – Brazil
Oliveira S, Renni M, Oliveira M
Hemorio, Rio de Janeiro, Brazil
22P32
The History and Original Surgical Technique of Extensor
Supracondylar Osteotomy
Pirpilashvili M
Georgien Center of Traumatology and Orthopaedy, Tbilisi,
Georgia
22P33
Ultrasound Evaluation of Synovial Hyperplasia after
Radioactive Synoviorthesis in Hemophilic Synovitis: A
Preliminary Study of 10 Patients
Saïed W, Douira-Khomsi W, Louati H, Ben Hassine L, Guider-
Bel HAE, Bellagha I6
Children Hospital of Tunis, Tunis, Tunisia
22P34
A Comparison between the Complications and Long-Term
Outcome of Hip and Knee Replacement Therapy in Patients
with and without Hemophilia: A Controlled Retrospective
Cohort Study
Sikkema T 1 , Boerboom A 2 , Meijer K 1
1 Divison of Haemostasis and Thrombosis, Department of
Haematology, University Medical Centre Groningen,
2 Department of Orthopaedics, University Medical Centre
Groningen, Linden, the Netherlands
22P35
The Not-So Funny Bone: Underlying Pathology and Surgical
Approaches to Ulnar Neuropathies at the Elbow in People
with Hemophilia
Stewart M, Halliday B, Rowell J, Zeissink B Queensland
Haemophilia Centre, Royal Brisbane and Women’s Hospital,
Queensland, Australia
22P36
Condition of Target Joints in Children with Hemophilia A
and Factor VIII Inhibitor during Immunotolerance Induction
Svirin PV1 , Vdovin VV2 , Shiller EE2 , Larina LE2 , Doniush EK2 ,
Petrov VJ2 , Soskov GI2 , Jatsenko EA2 1Russian National Center of Pediatric Hematology, Oncology
/ Immunology and 2Izmailovskaya Children Hospital, Moscow,
Russia
22P37
Arthroscopic Ankle Arthrodesis for Hemophilic Arthropathy:
Two Case Reports
Tsukamoto S, Tanaka Y, Matsuda T, Shinohara Y, Taniguchi
A, Tomiwa K
Department of Orthopaedic Surgery, Nara Medical University,
Nara, Japan
22P38
Assessment of Bone Density and Strength Using Peripheral
Quantitative Computed Tomography (pQCT) in Children
with Hemophilia; Preliminary Report
Xafaki P1 , Balanika A2 , Pergantou H1 , Papakonstantinou O2 ,
Platokouki H1 1Haemophilia Centre- Haemostasis Unit, “Aghia Sophia”
Children’s Hospital of Athens, 22nd Radiology Department,
University General Hospital of Athens “Attikon”, Greece
77
Posters, Tuesday and Wednesday

Posters, Tuesday and Wednesday
Index of Poster Presenters cont’d
22P39
Association of Self-Reported Joint Pain and Motion Limitation
with Clinical Range of Motion Assessment in Patients with
Hemophilia A
Zhou Z-Y1 , Johnson K1 , Koerper M2 , Wu J1 , Curtis R3 , Riske
B4 , Forsberg A5 , Ullman M6 , Lou M1 1 2 University of Southern California, CA, U.S.A., University of
California, San Francisco, CA, U.S.A., 3Department of Health
Services, Richmond, CA, U.S.A., 4University of Colorado
Denver, CO, U.S.A., 5UMass Memorial Hospital, MA, U.S.A.,
6University of Texas Health Science at Houston, TX, U.S.A.
OTHER
24P05
Venous Thromboembolism in Males with a Severe Form of
Hemophilia: The Experience of One Centre
Dulíèek P1 , Malý J1 , Pecka M1 , Beránek M2 1Internal Department, Division of Hematology and
2Department of Clinical Biochemistry, Charles University,
Hradec Králové, Czech Republic
24P06
Immunologic Reactivity in Patients with Hemophilia
Kazimova M
Azerbaijan State Advanced Training Institute, Baku,
Azerbaijan
24P07
EUHASS: The First 12 Months of a European Adverse Event
Reporting System for Hemophilia
Markis, M
Royal Hallamshire Hospital, Sheffield, United Kingdom
24P08
Applying New Technologies When Taking Care of Hemophilia
Patients
Montaño Mejía CA
Bogota, Colombia
24P09
Thromboelastography Reveals Kinetics of LPS-Induced
Coagulopathy and Correlates to Fetal Outcome in a Rat
Model of Pregnancy Complications
Othman M, Renaud S, Quirt J, MacDonald-Goodfellow S,
and Graham C
Laurentian University- St Lawrence College Collaborative
BScN Program, Kingston, ON, Canada
78
24P10
Trauma-Related Bleeding Complications in South African
Hemophilia Patients (2000–2009): Clinical Presentation,
Management, and Prognostic Factors
Sissolak G 1 , Dippenaar A 1 , Cruickshank A-L 2 , Desai F 3 ,
Karabus C, McDonald A 2
Tygerberg Hospital Haemophilia Comprehensive Treatment
Centre 1 , Groote Schuur Hospital Haemophilia Comprehensive
Treatment Centre 2 , Red Cross War Memorial Children’s
Hospital Haemophilia Comprehensive Treatment Centre 3 ,
Cape Town, South Africa
OTHER TREATMENT MODALITIES
25P02
MRI and US: Looking for a Precocious Diagnosis of Joint
Diseases
Aparisi Rodriguez F, Querol Fuentes F, Beltran Mayor J,
Cifrian Cavada C, Ramirez Latorre O, Gomez J
Hospital La Fe, Valencia, Spain
25P03
Against the Prejudice - Ethic Use of Factor VIII Products in
the Adolescent Population During Social Interventions &
Hemophiliac Camps
Balliel W1 , Hamulyak K2 1 2 AUGMENTO - HTC and Department of Hematology,
Maastricht UMC, Maastricht, the Netherlands
25P04
Case Report on Intra-Articular Hyaluronic Acid in the
Treatment of Chronic Hemophilic Arthropathy in a Patient
with Severe Hemophilia A
Chan R, Osip J, Baumann K, Reding M
University of Minnesota Medical Center, Fairview, Center for
Bleeding and Clotting Disorders, Minneapolis, MN, U.S.A.
25P05
Managing Hemorrhagic and Thromboembolic Risk in Patients
with Acquired Hemophilia
Coppola A, Tufano A, Cimino E, Guida A, Battipaglia G, Di
Minno MND
Regional Reference Centre for Coagulation Disorders,
Federico II University, Naples, Italy
25P06
Procoagulant Activity of Sulfated Polysaccharides
Dockal M, Knappe S, Panholzer E, Palige M, Ehrlich H,
Scheiflinger F
Baxter Innovations GmbH, Orth Donau, Austria

Index of Poster Presenters cont’d
25P07
Acquired Hemophilia: A Case Report of Successful Treatment
with Combined Immunosuppressive Therapy
Hlusi A, Prochazkova J, Slavik L, Ulehlova J, Krcova Vera
Fakultní Nemocnice Olomouc, Olomouc, Czech Republic
25P08
Liver Biopsy in a Child with Complex Coagulation Disorder,
Compensated by Prothombic Complex Concentrate (PCC)
Lavalle E1 , Cerviño G1 and Citrín E2 Sanatorio Americano Montevideo, Uruguay
25P09
Treatment and Outcome of Acquired Hemophilia A from
1999-2008 in Singapore General Hospital
Lee YS, Kam Grace LS, Chuah C, Heng LL, Ng HJ
Department of Haematology, Singapore General Hospital,
Singapore
25P10
Middle Genicular Artery Embolisation in Hemophilic Children
and Adolescents; 6 Years Follow-Up
Lopez F, Capetillo G, Magdaleno F, Castro S, Ramon E,
Zurita E
Tabasqueña de Hemofilia A.C., Tabasqueña, Mexico
25P11
Chronic and Hypertrophic Knee Synovitis Treated by
Conformational Radiotherapy (RT3D); A Case Report
Magdaleno F1, 2 , Quintero E2 , Quevedo E1 , Hernández M1 1 2 Tabasqueña de Hemofilia A.C., Hospital “Dr. Juan Graham
Casasus”, Tabasqueña, Mexico
25P12
An Electronic Documentation System in Haemophilia
Provides Otherwise Unavailable Feedback for Continuous
Quality Control – First Results from the Haemoassist ® System
Westfeld M1 , Mondorf W2 , Klamroth R2 , Siegmund B2 ,
Tuischer J1 , Pollmann H2 1Wyeth Pharma GmbH - ein Unternehmen der Pfizer-Gruppe,
Muenster, 2Scientific Board of the Haemoassist Panel
Germany
25P13
Assistance to Hemophiliacs in an Emergency Room:
Importance of Imaging Tests
Quintana M1 , Martí M2 , Fabra S1 , Gómez Bravo R1 , Bernabeú D1 1 2 Servicio de Urgencias and Servicio de Radiodiagnóstico,
Hospital Universitario La Paz, Madrid, Spain
25P14
Laser Control of Hemostasis in the Extraction of Temporary
Teeth in a Patient with Hemophilia A; Case Report
Rueda M 1, 2 , Isidro L 1
1 Tabasqueña de Hemofilia A.C., 2 Hospital del Niño,
Tabasqueña, Mexico
25P15
Salvage Therapy with Rituximab for Inhibitors: The Parent’s
Experience
L Scott, R Scott
Haemophilia Foundation of New Zealand, Auckland, New
Zealand
25P16
Kinetic Superficial Electromyography (EMG) in Children and
Young Adults with Hemophilia; Individual Therapy Decisions
and Quality Control
Seuser A1 , Navarrete Duran M2 , Chaverri P3 , Wendel M4 ,
Auerswald G5 1 2 Kaiser-Karl-Klinik Bonn, Germany, Childrens Hospital San
José, Costa Rica, 3Hospital Mexico San José, Costa Rica,
4 5 Institut for Motion Analysis Bonn, Germany, Prof. Hess
Children’s Hospital Bremen, Germany
25P17
Diagnosis of Glanzmann’s Thrombasthenia Using Monoclonal
Antibody
Solis R1, 2 , Santos E2 , Zurita E1 , Castro S1 , Lopez F1 1 2 Tabasqueña de Hemofilia A.C., Laboratorios Diagnostica,
Tabasqueña, Mexico
25P18
HLA-B27 in Patients with Severe Hemophilia in Southeast
Mexico
Solis R1 , Vazquez T2 , Castro S1 , Lopez F1 , Zurita E1 1 2 Tabasqueña De Hemofilia A.C., Laboratorios Diagnostica,
Tabasqueña, Mexico
PEDIATRIC ISSUES
26P04
Evaluation of Prevalence and Severity of Bleeding Symptoms
in Children with Type 3 von Willebrand Disease Using a
Pediatric Bleeding Questionnaire
Biss T1 , Blanchette V2 , Clark D2 , Wakefield C2 , James P3 , Rand M2 1Newcastle Regional Haemophilia Centre, The Newcastle
upon Tyne Hospitals NHS Trust, U.K., 2Department of
Hematology/Oncology, The Hospital for Sick Children,
Toronto, Canada, 3Department of Medicine, Queen’s
University, Kingston, Canada
79
Posters, Tuesday and Wednesday

Posters, Tuesday and Wednesday
Index of Poster Presenters cont’d
26P05
Hemophilia A in a Premature Infant
Cruz E, Morais S1 , Matos R1 , Oliveira MJ2 , Fernandes PC2 ,
Campos M1 1 2 Hematology Unit and Neonatology Unit, Santo António
Hospital, Porto, Portugal
26P06
Congenital Factor XIII Deficiency as Cause for Intracraneal
Hemorrhage
Dasi Carpio M1 , Argiles B1 , Cid A2 , Carreras M1 , Aznar J2 ,
Peinador M1 1 2 Pediatric Hematology Unit and Congenital Coagulopathies
Unit, La Fe University Hospital, Valencia, Spain
26P07
Fully Implantable Central Venous Access Device-Related
Infections in Hemophilia: An Australian Paediatric Institution
Experience
Yeoh Z1, 2 , Furmedge J1 , Ekert J1 , Barnes C1 1Henry Ekert Haemophilia Treatment Centre, Royal Children’s
Hospital, and 2Melbourne Medical School, the University of
Melbourne, Australia
26P08
Successful Use of Hemoleven® During Surgery in a Three-
Year-Old Boy with Congenital Factor XI Deficiency
Girisch M, Wiegand G, Hofbeck M, Hauch H
University Children’s Hospital, Tuebingen, Germany
26P09
Hemophilia – Genes and Inheritance: Views of Affected
Young Individuals
Khair K1 , Gibson F1, 2 , Meerabeau L3 1Great Ormond Street Hospital for Children NHS Trust
London, 2London South Bank University, 3Health Care
University of Greenwich, London, United Kingdom
26P10
Complications of CV Therapy: Catheter Damage in
Hemophilic Patient - Case Report
Laguna P1 , Godlewski K2 , Klukowska A1 , Matysiak M1 ,
1 2 Dept. Pedriatrics, Hematology and Oncology and Dept.
Cardiology and General Pediatrics WUM, Poland
26P11
First Results of Whole Blood Platelet Function Studies in
Children and Young Adults with Hemophilia
Lohse J, Tauer J, Feldmann S, Graefe D, Knoefler R
Children’s Hospital, Dept. of Pediatric Hematology, Oncology
and Hemostaseology, University Hospital Carl Gustav Carus
Dresden, Germany
80
26P12
Use of Recombinant Activated Factor VII (rFVIIA) in Pediatric
Patients with High Bleeding Risk
Sciuccati G, Hepner M, Feliú Torres A, Pieroni G, Avalos
Gomez J, Bonduel M
Hospital De Pediatria, Prof Dr Juan P Garrahan, Buenos,
Aires, Argentina
26P13
Growth of Children with Hemophilia
Subbaraya N1 , Brabin B1 , Keenan R2 , Hanagavadi S3 1 2 Liverpool School of Tropical Medicine, Liverpool, U.K., Alder
Hey Children’s NHS Foundation Trust, Liverpool, U.K.,
3Karnataka Hemophilia Care and Hematology Research
Centre, Davangere, India
26P14
Impact of Hemophilia Management Practices on Children
Subbaraya N1 , Keenan R2 , Hanagavadi S3 , Bolton-Maggs
P4 , Brabin B1 1 2 Liverpool School of Tropical Medicine, Liverpool, U.K., Alder
Hey Children’s NHS Foundation Trust, Liverpool, U.K.,
3Karnataka Hemophilia Care and Hematology Research
Centre, Davangere, India, 4New Manchester Royal Infirmary,
Manchester, U.K.
26P15
Clinical Experience With ADVATE During the First 50
Exposure Days: Data From Two Post-Authorization Safety
Surveillance (PASS) Programs in Japan
Taki M1 , Hanabusa H2 , Fukutake K3 , Shima Midori 4 , Shirahata
A5 and the Advate PASS study group6 1St. Marianna University School of Medicine Yokohama City
Seibu Hospital, Kanagawa, 2Ogikubo Hospital, Tokyo, 3Tokyo Medical University Hospital, Tokyo, 4Nara Medical University,
Nara, 5University of Environmental and Occupational Health
Japan, Fukuoka, and 6Baxter BioScience Japan, Medical
Affairs Clinical Trial, Tokyo, Japan
26P16
Low Dose Secondary Prophylaxis Reduces Joint and Severe
Bleeding in Severe and Moderate Hemophilia Children: A
Multicenter Pilot Study in China
Wu R1 , Sun J2 , Zhang X3 , Luke K4 , Poon M5 1Beijing Children’s Hospital Affiliated to Captial Medical
University, Beijing, China 2Hemophilia Center, Hematology
Department, Nanfang Hospital, Guangzhou, China,
3Hemophilia Center, Shandong Blood Bank, Jinan, China,
4University of Ottawa, Children’s Hospital of Eastern Ontario,
Ottawa, ON, Canada, 5University of Calgary, Foothills
Hospital, Calgary, AB, Canada

Index of Poster Presenters cont’d
PHYSIOTHERAPY AND REHABILITATION
27P19
Incidence of Sports in Patients with Hemophilia A and
Inhibitor
Barriuso RC1 and Moreno MM2,3 1 2 Federación Española de Hemofilia, Asociación Regional
Murciana de Hemofilia, 3Hospital Universitario Virgen de la
Arrixaca, Murciana, Spain
27P20
Clinical Guidelines on Rehabilitation After Multiple Joint
Procedures
De Kleijn P
UMC Utrecht, Utrecht, the Netherlands
27P21
The Role of Physiotherapy within the Comprehensive Care
Team: A Patient Perspective
Floros G, Crymble S, Hadley D, O’Neill J, Teitel J
St. Michael’s Hospital, Toronto, ON, Canada
27P22
Evaluation of Dynamic Gait Parameters in a Subject with
Hemophilic Arthropathy of the Knees: A Single Case Study
González L1 , Garcia-Masso X1 , Perez-Alenda S1 , Gallach J1 ,
Querol F2 , Aznar J2 1 2 University of Valencia, Valencia, Spain, University Hospital
LA FE, Valencia, Spain
27P23
Evaluation of Sports and Exercises in Patients with
Hemophilia
Beheshtipoor N, Karimi M, Zahedi Z, Haghnegahdar A
Hematology Research Center, Shiraz University of Medical
Sciences, Shiraz, Iran
27P24
Recovery of Range of Knee Motion After Total Knee
Arthroplasty
Kubota M1 , Takedani H1 , Goto M2 1The University of Tokyo Research Hospital of the Institute of
Medical Science, 2The University of Tokyo Hospital, Tokyo,
Japan
27P25
Physiotherapy Management Following Surgical Excision of
a Heterotropic Bone Formation of the Elbow in a Patient
with Severe Hemophilia A
Squire S
St. Paul’s Hospital, Vancouver, BC, Canada
27P26
Orthotics in the Managing of Articular Contractures in
Patients with Hemophilia
Valencia D 1 , Jara I 2 , Silva O 1
1 Uiniversidad Nacinal de Colombia, 2 Clinica Infantil
Colsubsidio, Bogota, Colombia
27P27
The Impact of a Specific Aqua-Training for Adult Hemophilia
Patients Results – Results of the Watercise Study (WAT-QoL)
v. Mackensen S 1 , Wieloch A 2 , Zäch D 3 , Eifrig B 4 , Kalnins J 5 ,
Zeller W 3
1 Institute and Policlinics for Medical Psychology, University
Medical Centre Hamburg-Eppendorf, Germany, 2 Hamburg,
Germany, 3 Medical Office Verpoort & Zeller, Internal
Medicine/Haematology and Oncology, Hamburg, Germany,
4 Department of Internal Medicine II and Haemostaseology
Clinic, University Medical Centre Hamburg-Eppendorf,
Germany, 5 Medbaik, Maarmagen, Germany
PROPHYLAXIS
29P07
New Promising Method to Tailor Prophylaxis Regimen in
Hemophilia
Alvarez Román M, Fernández Bello I, Martín M, Butta N,
Jiménez-Yuste V, Rodríguez de la Rúa A
Idipaz-Hospital Universitario La Paz, Madrid, Spain
29P08
Bleeding Pattern in Patients with Severe Hemophilia A:
Results from a Prospective 10 Year Study
Avila M1 , Feldman B2,3,4,5 , Marjorie M2 , Amesse C6 , Stain A1 ,
Blanchette V1,2 1Departments of Paediatrics, Division of Hemato -
logy/Oncology, The Hospital For Sick Children, Toronto,
Canada, 2Child Health Evaluative Sciences Program, The
Hospital For Sick Children Research Institute, Toronto,
3 Canada, Departments of Paediatrics, Division of
Rheumatology, The Hospital For Sick Children, Toronto,
Canada, 4Health Policy Management & Evaluation, University
of Toronto, Canada, 5Dalla Lana School of Public Health,
University of Toronto, Canada, 6CHU Sainte-Justine, Montreal,
Canada
29P09
Different Regimens of Prophylaxis Treatment in Young Severe
Hemophilia A Patients: Comparisons on Efficacy, FVIII
Consumption, and Therapy Compliance
Biondo F, Santoro C, Baldacci E, Torelli F, Leporace A,
Mazzucconi M
Dipartimento Di Biotecnologie Cellulari Ed Ematologia,
University of Roma, Roma, Italy
81
Posters, Tuesday and Wednesday

Posters, Tuesday and Wednesday
Index of Poster Presenters cont’d
29P10
The Year in Review: Describing Prophylaxis and Adherence
in Children with Severe Hemophilia A Using Patient Infusion
Diaries
Bos C, Chan A, Webert K, Almonte T, Decker K, Goldsmith R
McMaster Hemophilia Clinic, Hamilton ON, Canada
29P11
Prophylaxis with rFVIIa Three Times a Week for Patients with
Severe Hemophilia and Inhibitors: A Single Centre Experience
Cermelj M, Gerardo P, Pollola J
Department of Haemophilia, Instituto William Osler, CABA,
Buenos Aires, Argentina
29P12
Turning Severe into Moderate Hemophilia by Prophylaxis;
Are We Reaching Our Goal?
den Uijl IEM1,2 , Grobbee DE2 , Fischer K1,2 1Van Creveldkliniek, Dept Haematology, UMC Utrecht, the
Netherlands, 2Julius Center for Health Sciences and Primary
Care, UMC Utrecht, the Netherlands
29P13
International Study Demonstrates the Benefits of Prophylaxis
Collins P1 , Giangrande P2 , Blanchette V3 , Epstein J4 , Xiong
Y4 , Li-McLeod J4 1University Hospital of Wales, Cardiff, United Kingdom,
2 3 Churchill Hospital, Oxford, United Kingdom, Hospital for
Sick Children, Toronto, ON, Canada, 4Baxter BioScience,
Westlake Village, CA, U.S.A.
29P14
Prophylaxis in Hemophilia in Tunisia
Gouider E and Meddeb KB
Hemophilia Treatment Centre Aziza Othmana Hospital
Tunisia, Tunis, Tunisia
29P15
Clotting Factor Concentrates Given to Prevent Bleeding and
Bleeding-Related Complications in People with Hemophilia
A or B
Iorio A1 , Marchesini E1 , Marcucci M1 , Kent S2 1 2 Unversity of Perugia, Perugia, Italy, University of Alberta,
Calgary, AB, Canada
29P16
Prophylaxis in Hemophilic Children in Poland
Klukowska A, Laguna P, Matysiak M
Dept. Pedriatrics, Hematology and Oncology WUM, Warsaw,
Poland
82
29P17
Prophylaxis with Novoseven® in Factor VII Deficiency:
Preliminary Results from STER (Seven Treatment Evaluation
Registry)
Auerswald G1, Michaels L, Altisent C., Di Minno G., Dolce
A., Napolitano M., Mariani G., on behalf of the STER Study
Group
29P18
Comparison of Prophylaxis, On-Demand, or Combined
Treatment in 20-35 Year Old Males with Severe Hemophilia
in 4 European Countries
O’Mahony B, Noone D
Irish Haemophilia Society, Dublin, Ireland
29P19
An Economic Model to Evaluate the Cost-Effectiveness of
Prophylaxis Regimens on Hemophilia Patients with Inhibitors
Knight C1 , Plun-Favreau J2 , Johal S1 1 2 RTI Health Solutions, Zurich, Switzerland, Novo Nordisk,
Zurich, Switzerland
29P20
Long-Term FEIBA Prophylaxis in Pediatric Hemophilia A
Patients with High-Titer Inhibitors
Saxena, K1 , Hawk S2 , Singh P2 , Stevens B2 , and Sexauer C2 1 2 Children’s Hospital, Boston, MA, U.S.A. and University of
Oklahoma Children’s Hospital, Oklahoma City, Oklahoma,
U.S.A.
29P21
LA-N8, A New Long-Acting Recombinant FVIII with
Prolonged Hemostatic Effect in a FeCl3 Induced Injury Model
in F8-KO Mice
Møller F, Tranholm M, Kjalke M, Thim L, Olsen E,
Jespersgaard C
Novo Nordisk A/S, Maaloev, Denmark
29P22
LA-N8, A New Long-Acting rFVIII with Prolonged Hemostatic
Effect in a Murine Joint Bleeding Model in FVIII-Deficient
Mice
Øvlisen K, Tranholm M, Olsen E, Kjalke M, Thim L, Stennicke H
Novo Nordisk A/S, Maaloev, Denmark
PSYCHOSOCIAL ISSUES
30P17
Systemic Family Therapy: An Effective Tool to Manage
Hemophiliac’s Family Dynamic
Vallin Antunes S1 , dos Reis Tomaz M1 , de Morais Horta A2 1Universidade Federal de São Paulo -Depto Oncologia Clinica
e Experimental, 2Universidade Federal de São Paulo, Depto
de Enfermagem, Brazil

Index of Poster Presenters cont’d
30P18
Impact of Hemophilia on Family Members in Kenya
Abdallah T
Kenya Haemophilia Association, Nairobi, Kenya
30P19
Psychopathological and Personality Aspects in Hemophilic
Patients: A Preliminary Study in Costa Rica
Boza-Calvo C1 , Jensen-Villalobos E1 , Sandoval M2 , Jiménez-
Cruz G2 , Salazar-Sanchez L1 1 2 CIHATA-University of Costa Rica, and Hemathology
Department, Hospital Mexico, San Jose, Costa Rica
30P20
Hemophilia and Childhood: How to Accompany the Child
Cabré P, Grases S, Tarrida C
Catalan Association of Haemophilia, Barcelona, Spain
30P21
FUNFILIA - Have Fun and Learn How to Live With Hemophilia
Dagnino A
Portuguese Hemophilia Society, Lisbon, Portugal
30P22
How to Implement and Develop a Psychology Department
Dagnino A
Portuguese Hemophilia Society, Lisbon, Portugal
30P23
Achieving More Rapid Treatment Through a High Trust
Network
D’Ambrosio C1 , Thompson A2 1 2 MyGirlsBlood 501 (C) (3), Mercer Island, WA, U.S.A., Puget
Sound Blood Center, Vancouver, WA, U.S.A.
30P24
Psychosocial Involvement in an Emerging Country
Duffy A
Irish Haemophilia Society, Dublin, Ireland
30P25
Is it Appropriate to Research Men with Hemophilias’ Beliefs
and Experiences of Talking about Hemophilia Using a Postal
Questionnaire?
Dunn N, Griffioen A, Miller R, Yee T
Katharine Dormandy Haemophilia & Haemostasis Unit,
London, U.K.
30P26
Evaluation of the Efficacy of the Parents Empowering Parents
(PEP) Program: A Program for Parents of Children with
Bleeding Disorders
duTreil S 1 , Rice J 2 , Merritt D 3 , Kuebler E 4
1 Tulane University Medical School / Louisiana Center For
Bleeding and Clotting Disorders, and 2 Tulane University
School of Public Health / Department of Biostatistics, New
Orleans, LA, U.S.A. 3 Children’s Hospital of Michigan /
Hemostatis Thrombosis Treatment Center, Detroit, MI, U.S.A.
4 University of Texas in Houston / Gulf States Hemophilia and
Thrombophilia Center, Houston, Texas, U.S.A.
30P27
The Saga of Contaminated Blood Products in Iran
Ghavidel A, Tabatabaey A
Iranian Hemophilia Society, Mashad, Iran
30P28
Building Bridges: PEP in Israel
Goldstein G1 , Bashari D, Avni D, Kennet G
National Hemophilia Center, Tel Hashomer, Israel
30P29
Suicide Among Males with Hemophilia in the US, 1998-2007
Gomperts E1 , Holtz J1 , Baker J3 , Geraghty S4 , Hudson M5 ,
Karp S6 , Osip J7 , Presley R2 1Children’s Hospital Los Angeles, Los Angeles, CA, U.S.A.,
2Centers for Disease Control and Prevention, Atlanta, GA,
U.S.A., 3University of California Los Angeles, Los Angeles,
CA, U.S.A., 4Mountain States Hemophilia Center, Aurora,
CO, U.S.A., 5Vanderbilt University Medical Center, Nashville,
TN, U.S.A., 6UC San Francisco, San Francisco, CA, U.S.A.,
7Center for Bleeding and Clotting Disorders, Minneapolis,
MN, U.S.A.
30P30
Liver Transplant: A New Experience in the Treatment of
Hemophiliacs: Related Psychological Aspects
Grases S, Cabré P, Tarrida C
Catalan Association of Haemophilia, Barcelona, Spain
30P31
Hemophilia: The Role of Psychology Directed to Low Income
Mothers in the Discovery of Capable and Productive Women
Hanashiro R
Centro Dos Hemofílicos Do Estado De São Paulo– CHESP,
São Paulo, Brazil
83
Posters, Tuesday and Wednesday

Posters, Tuesday and Wednesday
Index of Poster Presenters cont’d
30P32
Prevalence of Depression in Adults with Hemophilia
Iannone M1 , Pennick L1 , Damiano M1 , Weihs K2 , Ratts A1 ,
Stopeck A1 1Arizona Hemophilia and Thrombosis Treatment Center and
2Department of Psychiatry, University of Arizona, Tucson, AZ,
U.S.A.
30P33
Physicians Question the Psychological Dimension in the
Clinical Care of Patients with Hemophilia
Magli-Barioz D, Bella C, Stieltjes N, Torchet M
Hemophila Centre, Paris, France
30P34
Influence of “Hemophilia School” on Qualities of Hemophilia
Patients Life
Makhmudova A1 , Brandi S2 , Brunner S2 , Mukhammadiev M1 ,
Makhmudova M1 , Achilova A1
1Scientific Research Institute of Hematology and Blood
Transfusion and 2National Haemophilia Center in Uzbekistan,
Tashkent, Uzbekistan
30P35
Psychosocial Stresses in Young Children with Hemophilia
and Inhibitors
Manco-Johnson M, Taylor G, Riske B
Hemophilia Center, University of Colorado, Denver, CO,
U.S.A.
30P36
The Psychological Care of Patients with Hemophilia: The
Role of the Clinical Nurse Specialist
O Sullivan A, O Donnell J, Jamieson S
National Centre for Hereditary Coagulation Disorders, Dublin,
Ireland
30P37
A Model for the Development of the U.K. Inhibitor Support
Group
Robinson G
The Haemophilia Society, London, U.K.
30P38
Counselling Young Hemophiliacs for Better Compliance
Voskuilen M, Zijlstra-Jansen M, Wiel, van de H, Tamminga
R, Meijer K
Hemophilia Treatment Centre, University Hospital Groningen,
Groningen, the Netherlands
84
30P39
Analysis of a Diary Written by a Woman with Acquired
Hemophilia A Postpartum, in a Narrative Approach – A Case
Report
Wollter I 1 , Brodin E 2
1 Department Of Haematology And Coagulation, Coagulation
Centre, Sahlgrenska University Hospital, 2 Physiotherapy
Department, Sahlgrenska University Hospital, Institute of
Neuroscience and Physiology/Rehabilitation Medicine,
Sahlgrenska Academy at Göteborg University, Göteborg,
Sweden
QUALITY OF LIFE
31P06
Assessing Accessibility and Travel Time to Health Care for
Hemophiliac Patients: The Case of a French Region
Berger M
ESO - Rennes 2, Brittany, France
31P07
Assessment of Health-Related Quality of Life in Patients with
Severe Hemophilia with Reduced Bone Density
Khawaji M, Astermark J, Berntorp E
Malmö Centre for Thrombosis and Haemostasis, Lund
University, Sweden
31P08
Introducing the CHO-KLAT 2.0p
McCusker P1 , Young NL2 , Burke T2 , Holzhauer S3 , Fischer K4 ,
Altisent C5 , Granger J6 , Meunier S7, Wakefield C 8 ,
Blanchette V8 1 2 University of Manitoba, Winnipeg, MB, Canada, Laurentian
University, Sudbury, ON, Canada, 3University Hospital Berlin,
Berlin, Germany, 4University Medical Center Utrecht, Utrecht,
the Netherlands, 5Hospital Vall d’Hebron, Spain, 6Royal Manchester Children’s Hospital, Manchester, United
Kingdom, 7Hôpital Edouard Herriot, Lyon, France, 8 SickKids
Hospital, Toronto, ON, Canada
31P09
Factors Associated with Health-Related Quality of Life in
Hemophilia A Patients around the World
Blanchette V1 , Collins P2 , Giangrande P3 , Epstein J4 , Xiong
Y4 , Li-McLeod J4 1 2 Hospital for Sick Children, Toronto, Canada, University
Hospital of Wales, United Kingdom, 3Churchill Hospital,
Oxford, United Kingdom, 4Baxter BioScience, Westlake
Village, CA, U.S.A.

Index of Poster Presenters cont’d
31P10
Health-Related Quality of Life in Women with Heavy
Menstrual Bleeding – an Interim Analysis
Elfvinge P1 , Johansson E1 , Holmström M1 , Edlund M2 1Coagulation Unit, D102, Karolinska University Hospital,
Stockholm, Sweden, 2Department of Obstetrics and
Gynecology, Danderyds Hospital AB, Stockholm, Sweden
31P11
The Number of Factor VIII Dosage Strengths Offered is
Associated with the Percent of Single Vial Users
Epstein J, Xiong Y, Luo M, Li-McLeod J
Baxter BioScience, Westlake Village, CA, U.S.A.
31P12
Health Related Quality of Life in French Hemophilia
Population: A Comparative Analysis with French General
Population
Germain L1, 2 , Erpelding M1 ,2 , Doncarli A3 , Guerois C4 ,
Demiguel V3 , Suzan F3 , Lambert T5 , Polack B6 , Chambost H7 ,
Briançon S1,2,8 , for the FranceCoag Network
1 2 INSERM, CIC-EC CIE6, Nancy, France, CHU Nancy,
Epidémiologie et Evaluation Cliniques, Nancy, France,
3Centre coordinateur du Réseau FranceCoag, Département
des maladies chroniques et des traumatismes, Institut de
veille sanitaire, Saint-Maurice, France, 4Centre de Traitement
de l’Hémophilie (CTH), CHRU Tours, France, 5CTH, CHU
Kremlin-Bicêtre, AP-HP, Le Kremlin-Bicêtre, France, 6CTH, CHRU Grenoble, France, 7CTH, CHU Timone, AP-HM,
Marseille, France, 8Nancy-Université, Université Paul Verlaine
Metz, Université Paris Descartes, EA 4360 Apemac, Nancy,
France
31P13
The Assessment of Hemophiliac Patient’s Physical Activity
Through Accelerometers: A Quantitative Methodology
González L, Peiró-Velert C, Valencia A, Pérez E, Querol F,
Aznar J
University of Valencia, Valencia, Spain
31P14
Acupuncture for the Management of Chronic Pain in the
Hemophilia Population
Lambing A1 , Hanagavadie S2 1Henry Ford Hemophilia & Thrombosis Treatment Center,
Detroit, MI, U.S.A., 2Karnataka Hemophilia Society, Karnataka,
India
31P15
Body Alteration: Mutilation vs. Adornment
Lilley D, Dugdale M, Tuller J, Joyce C
University of TN Health Science Center, Memphis, TN, U.S.A.
31P16
Adherence to Therapy Among Hemophilia Patients in the
U.S.
Duncan N 1 , Shapiro A 1 , Ye X 2 , Epstein J 2 , Luo M 2
1 Indiana Hemophilia and Thrombosis Center, Indianapolis,
IN, U.S.A., 2 Baxter Bioscience, Deerfield, IL, U.S.A.
31P17
Psychosocial Aspects of Hemophilia: Solutions from
Rehabilitation and Physiotherapy
Querol F, González L, Pérez-Alenda S, Abad-Franch L,
Gallach J, Aznar J
Universidad De Valencia, Unidad Hemostasia Y Trombosis,
Hospital La Fe, Valencia, Spain
31P18
The Introduction of a Stress Management Clinic for Persons
with Haemophilia and Related Bleeding Disorders
Shiel H
National Centre for Hereditary Coagulation Disorders, Dublin,
Ireland
31P19
Improving Needle Care Experiences for Children with
Bleeding Disorders
von Baeyer C, Sims M, Nilson J
Saskatchewan Bleeding Disorders Program, Saskatoon, SK,
Canada
31P20
A Prospective Study of the Health-Related Quality of Life in
Hemophilia
Sretenovic M1 , Elezovic I1 , Djunic I1 , Antic D1 , Miljic P1 ,
Kovacevic P
1Clinic for Hematology, Clinical Center Serbia and
2Department of Psychology, Faculty of Philosophy, Belgrade
University, Belgrade, Serbia
31P21
Validation of the CHO-KLAT 2.0 and Haemo-QoL-A for
French Canada
Young N1 , St-Louis J2 , Hershon L2 , Burke T1 , Blanchette V3 ,
Rivard G2 1 2 Laurentian University, Sudbury, ON, Canada, CHU Sainte-
Justine, Montreal, QC, Canada, 3Hospital for Sick Children,
Toronto, ON, Canada
85
Posters, Tuesday and Wednesday

Posters, Tuesday and Wednesday
Index of Poster Presenters cont’d
31P22
Quality of Life in Patients with Congenital Hemophilia and
Inhibitors in Japan
Taki M1 , Tatsunami S2 , Shirahata A2 , Mimaya J2 , Takedani H2 ,
Makino K2 , Ohira K2 , Kojima K2 , Wada I2 , Yoshikawa K2 1Department of Pediatrics, St. Marianna University School
of Medicine Yokohama City Seibu Hospital, Kanagawa,
Japan, and 2The Research Committee on QOL Study
Regarding Coagulation Disorders in Japan, Kanagawa, Japan
31P23
Quality of Life in Parents of Children with Hemophilia - Results
of the ESCHQoL Study
Tedgard U1 , Ljung R1 , Bullinger M2 , von Mackensen S2 1Dept of Paediatrics, University Hospital, Malmo, Sweden,
2Institute of Medical Psychology, University Medical Centre
Hamburg-Eppendorf, Germany
31P24
Blood Coagulation Factor VIII Activity Simulation Software for
Optimal Dosage and Administration - for the Better Quality
of Life
Tomotsugu A, Yamauchi K
Bayer Japan, Osaka, Japan
31P25
Quality of Life Related to Health in Children Affected with
Hemophilia Under the Age of 15 by Community Valencia
(Spain)
Vañó L1 , Laguna S1 , Varela JA1 , Vila E1 , Ramón JA1 , Daras V1 ,
Espada L1 , Usach J1 , Perez S2 , Querol F2 , Aznar JA2 1 2 Asociación de Hemofilia de la Comunidad, and Unidad de
Hemostasia y Trombosis del Hospital La Fe de Valencia, Spain
31P26
Choices for a Better Future: The Lessons Learnt from an
Educational Project
Villaca PR1 , Okazaki E1 , Amaral JA2 , Sandoval E1 , Santos V1 ,
D’Amico E1 1Hospital Das Clinicas - Universidade de Sao Paulo and
Fundação Verzolini Escola Politecnica - University of São
Paulo, Brazil
31P27
Assessment of Health-Related Quality of Life in VWD Patients
– Results of the VWD-QoL Pilot-Study
Von Mackensen S
University of Hamburg, Germany
31P28
Longitudinal Assessment of Health Related Quality of Life
in Young Hemophilia Patients in Europe
Von Mackensen S
University of Hamburg, Germany
86
31P29
Content Validity of the Paediatric Hemophilia Quality of Life
Assessment Tool in China
Wu R1 , Young NL2 , Zhang J1 , Luke KH3 , Hang M4 , Blanchette
V4 , Sun J5 , Li X6 , Poon MC7 1 2 Beijing Children’s Hospital, Beijing, China, Laurentian
University, Sudbury, ON, Canada, 3Children’s Hospital of
Eastern Ontario, Ottawa, ON, Canada, 4Hospital for Sick
Children, Toronto, ON, Canada, 5Nanfang Hospital, Nanfang,
China, 6Chengdu Children’s Hospital, Chengdu, China,
7University of Calgary Foothills Medical Centre, Calgary, AB,
Canada
RARE CLOTTING FACTOR DEFICIENCIES
32P04
Single Center Experience on Rare Inherited Clotting Factor
Deficiency
Madkhali I, Owaidah T and Al-Zahrani H
King Faisal Specialist Hospital and RC, Riyadh, Saudi Arabia
32P05
The Factor XIII Database: A Look into the Mutational
Spectrum of F13 A and B Genes
Biswas A, Ivaskevicius V, Oldenburg J, Thomas A
Institute of Experimental Hematology and Transfusion
Medicine, Bonn, Germany
32P06
Clinical Manifestations of Lebanese Population with
Afibrinogenemia
Djambas Khayat C1, 2 , Bakhos- Asmar J1 , Germanos M2 ,
Samaha H1 , Khayat G2 , Sakr S1 1Lebanese Association for Hemophilia, Beirut, Lebanon,
2Hotel Dieu de France Hospital, Angers, France
32P07
Congenital Dysfibrinogenemia: Association between Clinical
Symptoms, Laboratory Parameters, and Genetic Mutations
Flommersfeld S, Fischer R, Kemkes-Matthes B, Heidinger K
University Center of Transfusion Medicine and Haemostasis,
Giessen and Marburg, Germany
32P08
A Novel Nonsense Mutation Identified in a Congenital
Afibrinogenemia Patient (FGB exon 7: GLU 369X) from
Tenerife, Canary Islands, Spain
García Talavera J1 , Neerman-Arbez M2 , Marrero C1 , León
A1 , de Agustin T3 1Hospital Universitario Ntra Sra de Candelaria, Tenerife,
Canary Islands, Spain,
2Geneva University Medical Centre, Switzerland, Geneva,
Switzerland, 3CSL Behring, Marburg, Germany

Index of Poster Presenters cont’d
32P09
Congenital Coagulation Factor I Deficiency, in the Islands of
Tenerife and La Palma
García Talavera J1 , Neerman-Arbez M2 , Marrero C1 , Leon
A1 , de Agustin T3 1Hospital Universitario Ntra Sra de Candelaria, Tenerife,
Canary Islands, Spain,
2Geneva University Medical Centre, Switzerland, Geneva,
Switzerland, 3CSL Behring, Marburg, Germany
32P10
FranceCoag Network is also the French Registry of Very Rare
Coagulation Bleeding Disorders
Goudemand J1 , Pouymayou K2 , Suzan F3 , Faradji A4 , Donadel-
Claeyssens S5 , Rothschild C6 1 2 University Hospital of Lille, University Hospital of Marseille,
3 4 French Institute for Public Health Surveillance, Hemophilia
Centre of Strasbourg, 5Hemophilia Centre of Toulouse,
6Hemophilia Centre of Paris-Necker, France
32P11
Constitutional Abnormalities of Fibrinogen: A Report of 22
Cases
Siala R, BenSalah N, Elborgi W, Hafsia R, Meddeb B,
Gouider E
Hemophilia Treatment Centre, Aziza Othmana Hospital,
Tunis, Tunisia
32P12
Frequency, Clinical Manifestations and Management of Rare
Bleeding Disorders in Fars Province, Southern Iran
Karimi M, Khadije G, Afrasiabi A, Beheshtipour N, Ardeshiri
R, Bordbar M
Hematology Research Center, Shiraz University of Medical
Sciences, Shiraz, Iran
32P13
Case report: A Family with 3 Members has Factor V and
Factor VIII Deficiency Combined Diagnosed and Managed
in National Institute of Hematology and Blood Transfusion
Nguyen TM, Nguyen AT, Nguyen TN
National Institute of Hematology and Blood Transfusion,
Hanoi, Vietnam
32P14
Genetic Analysis of FX Deficient Patients in Iran: Report of
Three Novel Mutations
Rassoulzadegan M, Rastegar LG, Ravanbod S, Fard-Esfahani
P, Ala FA
Comprehensive Haemophilia Care Centre, Tehran, Iran
32P15
Monitoring Low Dose Recombinant Factor VIIa Therapy in
Patients with Severe Factor XI Deficiency Undergoing Surgery
Riddell A 1 , Kadir R 1, 2 , Pollard D 1 , Tuddenham E 1 , Gomez K 1
1 Royal Free Hospital, and 2 UCL Medical School, London, U.K.
32P16
Retrospective/Prospective Evaluation of Dysfibrinogenemic
Patients at a Single Center: Clinical Features and Laboratory
Findings
Santoro C1 , Leporace A1 , Mazzucconi M1 , Biondo F1 ,
Menegatti M2 , Peyvandi F2 1 2 Hematology, Sapienza University of Rome, A Bianchi
Bonomi Hemophilia and Thrombosis Center, IRCCS Maggiore
Hospital, Mangiagalli and Regina Elena Foundation,
University of Milan and Luigi Villa Foundation, Milan, Italy
32P17
Rare Bleeding Disorders Are Not So Rare in This Tribe:
Penalty of Consanguineous in Breeding
Shamsi T, Borhani M, Ansari S, Farzana T, Nadeem M,
Pahore Z
National Institute of Blood Disease and Bone Marrow
Transplantation, Karachi, Pakistan
32P18
Successful Recombinant Activated Factor VII Prophylaxis for
a Child with Severe Factor VII Deficiency and Recurrent
Intracranial Hemorrhage
Unuvar A, Devecioglu O
Istanbul University, Istanbul School of Medicine, Division of
Pediatric Hematology-Oncology, Istanbul, Turkey
VASCULAR BLEEDING
33P04
Successful Treatment with Recombinant Factor VIIa of Severe
Bleeding in a Patient with Hereditary Hemorrhagic
Teleangiectasia
Moorthi C, Bade A, Overberg D, Auerswald G
Prof. Hess Children´s Hospital, Klinikum Bremen Mitte,
Bremen, Germany
33P05
Long-Term Stability Study of Factor VIII Anti-hemophilic 500
UI-UNC as Lyophilized Powder Produced in the
Hemoderivados Laboratory
Vilches A, Nieres H, Molinas M, Canavesio L, Ahumada A
Laboratorio de Hemoderivados Universidad Nacional de
Cordoba, Cordoba, Argentina
87
Posters, Tuesday and Wednesday

Posters, Tuesday and Wednesday
Index of Poster Presenters cont’d
VENOUS ACCESS
34P04
Outcomes of Portacaths in Children with Hemophilia: A
Comprehensive Care Centre Approach
Efford J, Baker K, Henderson L, Liesner R, Khair K,
Mathias M
Great Ormond Street Hospital Haemophilia Comprehensive
Care Centre, London, U.K.
34P05
Peripheral Arteriovenous Shunts for Venous Access in
Children with Hemophilia
Male C1 , Thom K1 , Hölzenbein T2 , Zwiauer K3 , Endres G4 1Department of Paediatrics, Medical University of Vienna,
Austria, 2Department of Vascular Surgery, Landeskrankenhaus
Salzburg, Austria, 3Department of Pediatrics, Landesklinikum
St. Pölten, Austria, 4Department of Pediatrics, Landeskran -
kenhaus Bregenz, Austria
34P06
Incidence of Sports in Patients with Hemophilia A and
Inhibitor
Torres Ortuño AI, Cuesta Barriuso R y Moreno MM
Asociación Regional Murciana De Hemofilia, Murcia, Spain
34P07
Relationship between the Management of Port-A-Cath in
Children and Degree of Parental Stress
Torres Ortuño AI, Cuesta Barriuso R y Moreno MM
Asociación Regional Murciana De Hemofilia, Murcia, Spain
34P08
Capturing Daily Home Treatment and Quality of Life
Assessments in Congenital Hemophilia with Inhibitors (CHwI):
Design, Disposition and Implications of the Dosing
Observational Study in Hemophilia (DOSE)
G. Young1 , D.L. Cooper2 , K. Hoffman3 , J. Kabawat3 and C.T.
Wilke4 .
1Childrens Hospital of Los Angeles, Los Angeles, California
U.S.A., 2Novo Nordisk Inc., Princeton, New Jersey U.S.A.,
3Outcome Sciences, Inc., Cambridge, Massachusetts U.S.A.,
4University of Illinois, Chicago, Chicago, Illinois U.S.A.
34P09
Improved Chance of Success? Hand Exercise and IV Access
Hollingdrake O, Stewart M, Zeissink B
Queensland Haemophilia Centre, Queensland, Australia
34P10
Teaching Intravenous Access: A Survey of Practice
Patterns in Australia
Zeissink B
Australian Haemophilia Nurse’s Group, Queensland,
Australia
88
VON WILLEBRAND DISEASE
35P02
A New Immunoturbidimetric Mono-Reagent Kit for
VWF:Ag in Q Hemostasis Analyzer
Ambros R 1 , Gassó S 2 , Montanini V 1 , Berga V 2 , Civit G 1
1 Diagnostic Grifols and 2 Spinreact, Barcelona, Spain
35P03
Presence of a Common Haplotype in the Turkish VWD
Patients
Berber E 1 , Dagdemir A 2 , Pehlevan F 2 , Akin M 1 , Kavakli K 1 ,
Caglayan S 3
1 Ege University, 2 Halic University, and 3 Bogazici University,
Istanbul, Turkey
35P04
Von Willebrand Disease Prophylaxis Network
Abshire T1 , Bowen J2 , Berntorp E3 1 2 BloodCenter of Wisconsin, Milwaukee, WI, U.S.A., Rho,
Inc., Chapel Hill, NC, U.S.A., 3Centre for Thrombosis and
Haemostasis, Malmö University Hospital, Lund University,
Malmö, Sweden
35P05
Prospective Validation of a Modified von Willebrand Score
in Children
Bidlingmaier C1 , Olivieri M1 , Budde U2 , Kurnik K1 1Children’s University Hospital Munich, Germany,
2Coagulation Laboratory Hamburg, Germany
35P06
Focus On Gynecological & Obstetrics Procedures In
Women with von Willebrand Disease (VWD): Data From A
French Clinical Postmarketing Survey Of A High-Purity von
Willebrand Factor Concentrate with a Low Factor VIII
Content
Borel-Derlon A1 , Goudemand J2 , Boyer-Neumann C3 , Sié
P4 , Bertrand M5 , Post
Marketing Study Group6 , Henriet C7 , Bridey F7 ,
Chatelanaz C7 1Haemophilia Centre, University Hospital Centre, Caen,
2Haemophilia Centre, University Hospital Centre, Lille,
3Haematology Laboratory, A-Béclère Hospital, Clamart,
4Haemophilia Centre, University Hospital Centre, Toulouse,
5Haemophilia Centre, University Hospital Centre, Besançon,
6 7 French HTC, LFB, LES ULIS, France

Index of Poster Presenters cont’d
35P07
Type 2N (Normandy) von Willebrand Disease (VWD) – A
Report of 3 Cases Misdiagnosed as Hemophilia A
Carcao M1 , Stain A2 , Lillicrap D3 , Leggo J3 , Blanchette V1 1 2 Division of Haematology/Oncology and Dept. of Nursing,
Hospital For Sick Children, Toronto, ON, Canada, 3Dept. of
Pathology and Molecular Medicine, Queen’s University,
Kingston, ON, Canada
35P08
Correlation of Three Functional Assays for von Willebrand
Factor Activity Determination
Chen Y1,2 , Tsai W1,2 , Hu S1 , Cheng S1,3 , Chao T1,2 1 2 Hemophilia Care & Research Center, Division
Hematology/Oncology, Department of Internal Medicine,
3Department of Pediatric, Tri-Service General Hospital,
National Defense Medical Center, Taipei, Taiwan
35P09
Impact of von Willebrand Disease on Health Related Quality
of Life in a Pediatric Population
De Wee E1 , Fijnvandraat K2 , De Goede-Bolder A3 , Mauser-
Bunschoten E4 , Van der Bom J5 , Leebeek F1 1Hematology, Erasmus University Medical Center Rotterdam,
the Netherlands, 2Pediatric Hematology, Emma Children’s
Hospital AMC, Amsterdam, the Netherlands, 3Pediatrics, Erasmus MC, Sophia Children’s Hospital, Rotterdam, the
Netherlands, 4Van Creveldkliniek and Hematology, University
Medical Center Utrecht, the Netherlands, 5Department of
Clinical Epidemiology, Leiden University Medical Center, the
Netherlands
35P10
Acquired von Willebrand Syndrome in Monoclonal
Gammopathies
Djunic I1 , Elezovic I1 , Tomin D1 , Antic D1 , Ilic V2 , Milosevic-
Jovcic N2 1Institute of Haematology, Clinical Center Of Serbia,
Belgrade, Serbia, 2Institute for Medical Research, Belgrade,
Serbia
35P11
Clinical Use of Haemate-P in Inherited von Willebrand
Disease: A Patient with Type 3 VWD and Recurrent
Menometrorrhagia
Dolatkhah R, Asvadi Kermani I, Sanaat Z, Seifi S
Heamtology and Oncology Research Centre, Tabriz University
of Medical Sciences, Shahid Ghazi Hospital, Tabriz, Iran
35P12
Chronic Oral Anticoagulation in Patients with Inherited
Bleeding Disorders
Cruz E, Morais S, Campos M, Pinho N, Moreira L, Miranda M
Hematology Unit, Santo António Hospital, Porto, Portugal
35P13
Pregnancy in Type 3 von Willebrand Disease
Morais S, Cruz E, Pereira M, Campos M
Hematology Unit, Santo António Hospital, Porto, Portugal
35P14
Frequency of Discrepant VWF:RCo/VWF:Ag Ratios and
Thrombocytopenia in a Cohort of Children with Type 2b von
Willebrand Disease
Frontroth J, Hepner M, Pieroni G, Annetta E, Castañón M,
Bonduel M
Hospital De Pediatria Prof Dr Juan P Garrahan, Buenos Aires,
Argentina
35P15
Methodology of Ristocetin-Induced Platelet-Aggregation
(Ripa) Mixing Studies in Type 2b von Willebrand Disease
Frontroth J, Hepner M, Pieroni G, Annetta E, Castañón M,
Bonduel M
Hospital De Pediatria Prof Dr Juan P Garrahan, Buenos Aires,
Argentina
35P16
Use of Haemoctin for Bleeding Episodes in Type 3 von
Willebrand Disease
Gouider E, Zahra K, Zorgan M, Balkis M
Hemophilia Treatment Centre Aziza Othmana Hospital, Tunis,
Tunisia
35P17
Long-term Prophylactic Treatment of Juvenile von Willebrand
Type 2 and 3 Patients with Two Different von Willebrand
Factor Concentrates – a Two-Center Cohort Study
Halimeh S1 , Krümpel A2 , Rott H1 , Manner D2 , Mesters R3 ,
Nowak-Göttl U2 1 2 MVZ Laboratory Duisburg GmbH, Germany, University
Hospital Muenster, Germany Dep. of Pediatrics, 3University Hospital Muenster, Germany
35P18
Treatment of a Patient with Type 3 von Willebrand Disease
and Alloantibody against von Willebrand Factor
Halimeh S1 , Faeser B1 , Budde U2 , Laws H3 , Rott H1 1MVZ Laboratory Duisburg GmbH, Germany,
2 3 AescuLaboratory Hamburg, Germany, University Hospital
Duesseldorf, Germany
89
Posters, Tuesday and Wednesday

Posters, Tuesday and Wednesday
Index of Poster Presenters cont’d
35P19
Comparison of Several Automated VWF:RCo Assays for
Monitoring of Patients Treated with VWF/FVIII Concentrates:
Improved Performance with a New Modified Method
Stadler M2 , Hillarp A1 , Janisch S2 , Zapfl C2 , Haderer C2 ,
Schwartz B3 1 2 Malmö University Hospital, Malmö, Sweden, Octapharma
PPGmbH, Vienna, Austria, 3Octapharma U.S.A., Inc.,
Lafayette Hill, PA, U.S.A.
35P20
Improved Performance Characteristics of the von Willebrand
Factor Ristocetin Cofactor Activity Assay (VWF:RCo) Using
a Novel Automated Assay Protocol
Hillarp A1 , Stadler M2 , Haderer C2 , Weinberger J2 , Kessler
C3 , Roemisch J2 1 2 Malmö University Hospital, Malmö, Sweden, Octapharma
PPGbmH, Vienna, Austria, 3Georgetown University Hospital,
Washington, DC, U.S.A.
35P21
Does the von Willebrand Factor (VWF) Triplet Structure Affect
VWF Function?
Fuchs B, Solecka B, Kroening M, Kannicht C
Octapharma R&D, Molecular Biochemistry Berlin, Berlin,
Germany
35P22
Efficiency of Prophylaxis in Patient with Type 3 von Willebrand
Syndrome and Recurrent Gastrointestinal Bleeding
Krause M1 , Eckardt V2 , Pillitteri D1 , Scholz T1 , Kirchmaier C1 1 2 Haemostaseology and Gastroenterology, Department of
Internal Medicine,
Deutsche Klinik für Diagnostik, Hessen, Germany
35P23
Use of FVW/FVIII Concentrates for Hysterectomy in VWD
Patient
Lavalle E1 , Ucar L1 , Citrín E2 Sanatorio Americano, Montevideo, Uruguay
35P24
Treatment of von Willebrand disease by “Immunate”
Likhacheva E, Kopylov K, Plyushch O, Severova T
Hematological Research Centre RAMS, Moscow, Russia
35P25
Enhanced VWF-GPIb Binding is Associated with a Reduced
Thrombogenic Response in Mice with Type 2B von
Willebrand Disease
Golder M, Pruss C, Hegadorn C, Mewburn J, Sponagle K,
Lillicrap D
Dept. Pathology & Molecular Medicine, Queen’s University,
Kingston, ON, Canada
90
35P26
Correlation between Clinical Data, Laboratory Results and
Adverse Reactions after Administration of Desmopressin
(DDAVP)
Miesbach W 1 , Dueck O 1 , Krekeler S 1 , Schuettrumpf J 1 , Alesci
S 1 , Großmann R 2
1 University Hospital Frankfurt, Germany, 2 Gemeinschaftspraxis
Laborärzte Schweinfurt, Germany
35P27
Retrospective Analysis of the Clinical Efficacy and Safety of
Humate® P in Patients Treated with Humate® P for More
Than 5 Years
Miesbach W, Asmelash G, Müller S, Haferland I, Krekeler S,
Alesci S
University Hospital Frankfurt, Germany
35P28
The Psychosocial Issues Which Impact Children in NM who
have von Willebrand Disease
Halona M, Montoya R, Mathew P
Ted R.Montoya Hemophilia Program, Albuquerque, NM,
U.S.A.
35P29
Clinical Situation in Patients with von Willebrand Disease in
Combination with a Newly Developed Disease-Specific
Quality of Life Questionnaire (Wilqol) for Germany
Moorthi C1 , Bade A1 , von Mackensen S2 , Overberg D1 ,
Auerswald G1 1 2 Prof. Hess Children´s Hospital, Bremen, Germany, Institute
and Polyclinics of Medical Psychology, University Medical
Centre Hamburg-Eppendorf, Hamburg, Germany
35P30
Preliminary Study of VWF Clearance Analysing the VWF
Propeptide
Moret A, Cabrera N, Cid A, Haya S, Abad-Franch L, Aznar J
Unidad de Hemostasia y Trombosis, Hospital Universitario
La Fe, Valencia, Spain
35P31
Plasma ADAMTS13 Activities in Non-Human Primates and
Rabbits Do Not Change Upon Administration of
Recombinant VWF
Varadi K, Rottensteiner H, Weber A, Gritsch H, Turecek PL,
Muchitsch E-M
Baxter Innovations GmbH, Vienna, Austria

Index of Poster Presenters cont’d
35P32
Experience with a VWF/FVIII Concentrate in Surgeries in
Patients with von Willebrand Disease – Results from a
German Prospective Post-Licensure Surveillance
Scharrer I1 , Dörner T2 , Kadar J3 , Nowak-Göttl U4 , v Depka
M5 , Feddern J6 1 2 University Clinic, Mainz, Germany, Charite, Berlin, Germany
3Practice for Transfusion Medicine, Cologne, Germany,
4 5 University Clinic, Münster, Germany, Werlhof Clinic, Hanover,
Germany, 6Octapharma, Langenfeld, Germany
35P33
Latest Interim Results from a German Prospective Post-
Marketing Surveillance of Treatment of von Willebrand
Disease with a New Generation VWF/FVIII Concentrate
Alesci S1 , Halimeh S2 , Kadar J3 , Nowak-Göttl U4 , Scharrer I5 ,
v. Depka M6 , Feddern J7 for the SET study group
1 2 University Clinic, Frankfurt, Germany, MVZ, Duisburg,
Germany, 3Practice for Transfusion Medicine, Köln, Germany,
4 5 University Clinic, Münster, Germany, University Clinic, Mainz,
Germany, 6Werlhof Clinic, Hannover, Germany, 7Octapharma, Langenfeld, Germany
35P34
1 + 1 = 3: A Family’s Experience of VWD
Porter-Bishop L
Haemophilia Foundation of New Zealand, Canterbury, New
Zealand
35P35
Comparative Immunogenicity Assessment of Recombinant
and Highly Purified Plasma-Derived Human von Willebrand
Factor in Balb/C Mice
Reipert B, Ahmad RU, Horling FM, Matthiessesn P, Turecek
PL, Schwarz H-P and
van Helden P
Baxter BioScience, Vienna, Austria
35P36
Secondary Prophylaxis in Type III von Willebrand Disease:
First Case in a Pediatric Patient
Rodriguez I, Boggia B, Ferrari S, Raffo C, Mezzano R, Lemos F
Centro Hospitalario Pereira Rossell, Montevideo, Uruguay
35P37
Evaluation of VWF Concentrate Activity Assays Employing
Collagen Types I and III
Stadler M, Janisch S, Zapfl C, Roemisch J
Octapharma PPGmbH, Vienna, Austria
35P38
Comparison of Plasma-Derived and Recombinant von
Willebrand Factor by Atomic Force Microscopy
Seyfried BK 1 , Friedbacher G 1 , Schwarz HP 2 , Ehrlich HJ 2 ,
Turecek PL 2 , Rottensteiner H 2
1 Vienna University of Technology, and 2 Baxter Innovations
GmbH, Vienna, Austria
35P39
In Vitro and In Vivo Cleavage of Human Recombinant VWF
(rVWF) By ADAMTS13
Varadi K, Vejda S, Schreiner J, Gritsch H, Muchitsch E-M,
Rottensteiner H
Baxter Innovations GmbH, Vienna, Austria
35P40
Comparing the Pharmacokinetic Properties of Wilate® and
Humate-P® in Subjects with Inherited von Willebrand Disease
(VWD) - A Prospective, Randomised, Crossover Study
Schwartz B1 , Powell J2 , Kessler C3 , Schindel F4 1 2 Octapharma U.S.A. Inc, Hoboken, NJ, U.S.A., University of
California, Davis, Sacramento, U.S.A., 3Georgetown University
Hospital, Washington, DC, U.S.A., 4Accovion Biostatistics,
Marburg, Germany
35P41
Evaluation of Clinical Hemostatic Efficacy of Wilate Utilizing
Subjective vs. Objective Criteria - A Way to Improve Accuracy
and Comparability of Results in VWD Trials
Kessler C1 , Schwartz B2 , Knaub S3 , Walter O3 , Schindel F4 ,
Hegener O3 1Georgetown University Hospital, Washington, DC, U.S.A.,
2 3 Octapharma U.S.A. Inc, Hoboken, NJ, U.S.A., Octapharma
AG, Lachen, Switzerland, 4Accovion Biostatistics, Marburg,
Germany
35P42
Clinical Features and Types of von Willebrand Disease in
Karachi, Pakistan
Borhany M, Shamsi T, Naz A, Farzana T, Ansari S, Nadeem M
Thrombosis and Haemostasis Unit of National Institute of
Blood Disease & Bone Marrow Transplantation, Karachi,
Pakistan
35P43
Effectiveness of DDAVP (Minirin Parenteral) in Subjects with
von Willebrand Disease (VWD) Type 1 and 2a
Siegmund B, Richter H, Pollmann H
Institute for Thrombosis and Hemostasis, Muenster, Germany
91
Posters, Tuesday and Wednesday

Posters, Tuesday and Wednesday
Index of Poster Presenters cont’d
35P44
Therapeutic Algorithm for Patients with Acquired von
Willebrand Syndrome and Monoclonal Gammopathy
Staritz P1 , Krause M2 , Zimmermann R1 , Huth-Kühne A1 1SRH Kurpfalzkrankenhaus, Hemophilia Care Center,
Heidelberg, Germany 2Deutsche Klinik für Diagnostik,
Fachbereich Hämostaseologie, Wiesbaden, Germany
35P45
Review of 5 Cases with an Acquired von Willebrand
Syndrome
Suzuki T, Amano K, Otaki M, Tsujikawa A, Inaba H,
Fukutake K
Dept. of Laboratory Medicine, Tokyo Medical University,
Tokyo, Japan
35P46
Functional Characterization of a Recombinant von Willebrand
Factor (VWF) Drug Candidate
Schrenk G, Rottensteiner H, Varadi K, Ehrlich HJ, Schwarz
HP, Turecek P
Baxter Innovations GmbH, Vienna, Austria
35P47
Structural Characterization of Recombinant Human von
Willebrand Factor (rVWF) Produced on Large Scale
Graninger M, Foettinger-Vacha A, Kaliwoda M, Purtscher M,
Mitterer A, Turecek P
Baxter Innovations GmbH, Vienna, Austria
35P48
Interaction Studies of Recombinant VWF (rVWF) and
Recombinant FVIII (rFVIII) in Solution
Schrenk G, Rottensteiner H, Turecek P, Ehrlich HJ, Schwarz
H-P, Varadi K
Baxter Innovations GmbH, Vienna, Austria
35P49
The Kinetics of Recombinant VWF Cleavage by Human
ADAMTS13 is Similar to that of Plasma-Derived VWF
Rottensteiner H, Vejda S, Schreiner J, Gritsch H, Turecek PL,
Varadi K
Baxter Innovations GmbH, Vienna, Austria
35P50
Acquired von Willebrand Syndrome Associated with a
Monoclonal Gammopathy: Experience of a Single-Centre
Registry in 36 Patients
Voisin S1 , Hamidou M2 , Lefrançois A3 , Sigaud M3 , Mahé B4 ,
Trossaërt M3 1 2 Laboratoire Hématologie Hôpital Toulouse France, Service
de Médecine Interne Hôpital Nantes France, 3Laboratoire Hématologie Hôpital Nantes France, 4Service d’Hématologie
Clinique Hôpital Nantes France
92
35P51
Successful Management of Cardiac Surgery with
Cardiopulmonary Bypass in an Acquired von Willebrand
Disease Patient
Volot F 1 , Dutrillaux F 1 , Bouchot O 2 , Leguy v 3 , De Maistre E 1 ,
Lorenzini J 1
1 Bocage Service Hématologie, 2 Cardiovascular Surgery and
3 Medicine, CRTH- CHU, Dijon, France
35P52
C1272f: A Novel Type 2a von Willebrand Disease Mutation
in A1 Domain
Woods A1 , Sanchez-Luceros A1, 2 , Kempfer A1 , Powazniak
Y3 , Calderazzo Pereyra J1 , Blanco A2 1National Council of Scientific and Technological Research
(CONICET), 2Hematological Research Institute, National
Academy of Medicine, 3SECYT, Buenos Aires, Argentina
35P53
Major Hemorrhage Related to Surgery in Patients with Type
2a von Willebrand Disease
Woods A1 , Meschengieser S2 , Sanchez-Luceros A1, 2 , Blanco
A2 , Kempfer A1 , Lazzari M1, 2
1National Council of Scientific and Technological Research
(CONICET), 2Hematological Research Institute, National
Academy of Medicine, Buenos Aires, Argentina
35P54
Alloantibodies in Type 3 VWD: Report of Two Cases and
Review of the Literature
Yaish H, Rodgers G
Primary Children Medical Center, University of Utah, Salt
Lake City, UT, U.S.A.
35P55
Northern Pakistan Experience of Severe von Willebrand
Disease
Zafar T1, 2 , Rizwi F1 , Winter M3 1Islamabad Medical & Dental College, Islamabad, Pakistan,
2 Pakistan Haemophilia Patients Welfare Society, Islamabad,
Pakistan, 3Kent Haemophilia Treatment Centre, Canterbury,
Kent, U.K.